

## Medically important snakes and snakebite envenoming in Iran

Dehghani, Rouhollah; Monzavi, Seyed Mostafa; Mehrpour, Omid; Shirazi, Farshad M.; Hassanian-Moghaddam, Hossein; Keyler, Daniel E.; Wüster, Wolfgang; Westerström, Alexander; Warrell, David A.

### Toxicon

DOI:

<https://doi.org/10.1016/j.toxicon.2023.107149>

Published: 23/05/2023

Peer reviewed version

[Cyswllt i'r cyhoeddiad / Link to publication](#)

*Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):*

Dehghani, R., Monzavi, S. M., Mehrpour, O., Shirazi, F. M., Hassanian-Moghaddam, H., Keyler, D. E., Wüster, W., Westerström, A., & Warrell, D. A. (2023). Medically important snakes and snakebite envenoming in Iran. *Toxicon*, 230, Article 107149. <https://doi.org/10.1016/j.toxicon.2023.107149>

#### Hawliau Cyffredinol / General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

#### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# Journal Pre-proof

Medically important snakes and snakebite envenoming in Iran

Ruhollah Dehghani, Seyed Mostafa Monzavi, Omid Mehrpour, Farshad M. Shirazi, Hossein Hassanian-Moghaddam, Daniel E. Keyler, Wolfgang Wüster, Alexander Westerström, David A. Warrell



PII: S0041-0101(23)00135-6

DOI: <https://doi.org/10.1016/j.toxicon.2023.107149>

Reference: TOXCON 107149

To appear in: *Toxicon*

Received Date: 28 March 2023

Revised Date: 1 May 2023

Accepted Date: 2 May 2023

Please cite this article as: Dehghani, R., Monzavi, S.M., Mehrpour, O., Shirazi, F.M., Hassanian-Moghaddam, H., Keyler, D.E., Wüster, W., Westerström, A., Warrell, D.A., Medically important snakes and snakebite envenoming in Iran, *Toxicon* (2023), doi: <https://doi.org/10.1016/j.toxicon.2023.107149>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier Ltd.

**Author contributions:**

Conceptualization (R.D., O.M., D.A.W.); Methodology (S.M.M., O.M.); Investigation (S.M.M., R.D., H.H.M., W.W., A.W., F.M.S.); Validation (S.M.M., D.A.W., D.E.K., W.W., A.W.); Visualization (S.M.M., R.D.); Data curation (S.M.M., O.M.); Formal analysis (S.M.M., D.A.W., O.M.); Writing - original draft (All authors); Writing - review & editing (All authors); Supervision (D.A.W., O.M.)


Journal Pre-proof

**A Critical Review on: Medically Important Snakes and Snakebite Envenoming in Iran**

**1 Updated checklist and taxonomy of medically important snakes**

Non-front-fanged { Colubridae: 13 species  
Lamprophidae: 4 species


Front-fanged { Viperidae: 16 species  
Elapidae: 14 species



**2 Updated geographical distribution of medically important snakes**




**3 Review of venom studies & venomics of medically important snakes**



**4 Description of species-specific clinical features of envenoming**

Puncture marks Swelling & ecchymosis Nausea

local Bleeding systemic Respiratory distress Ptosis



**5 Review of Iranian antivenoms**

F(ab')<sub>2</sub> Immunoglobulins

Snake Antivenin Polyvalent (Egsene)

Each ml neutralizes more Than 50 I.D.Us venoms of: Viperidae: Viper albicomuta Echis carinatus Pseudocerastes persicus Agkistrodon halys Najm raji Ophiura


Razi vaccine & serum Research Institute www.rzi.ac.ir rzi06@yahoo.com Made in U.S.A. Iran



**6 Training and updated guidelines for medical management**

Updating clinical practice guidelines Medical personnel training

Public education Improved medical care & patient outcomes



Journal Pre-proof

## 1                   **Medically important snakes and snakebite envenoming in Iran**

2  
3   Ruhollah Dehghani<sup>1,2\*</sup>, Seyed Mostafa Monzavi<sup>3,4\*</sup>, Omid Mehrpour<sup>5,6✉</sup>, Farshad M. Shirazi<sup>7</sup>,  
4   Hossein Hassanian-Moghaddam<sup>4,8</sup>, Daniel E. Keyler<sup>9</sup>, Wolfgang Wüster<sup>10</sup>, Alexander  
5   Westerström<sup>11</sup>, David A. Warrell<sup>12</sup>

6  
7   <sup>1</sup> Department of Environmental Health, Kashan University of Medical Sciences, Kashan, Iran

8   <sup>2</sup> Social Determinants of Health Research Center, Kashan University of Medical Sciences, Kashan, Iran

9   <sup>3</sup> Medical Toxicology Center, Mashhad University of Medical Sciences, Mashhad, Iran

10   <sup>4</sup> Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran Iran

11   <sup>5</sup> Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand, Iran

12   <sup>6</sup> Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO, USA

13   <sup>7</sup> Arizona Poison and Drug Information Center, University of Arizona, Tucson, AZ, USA.

14   <sup>8</sup> Department of Clinical Toxicology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences,  
15   Tehran, Iran

16   <sup>9</sup> Department of Experimental & Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA

17   <sup>10</sup> Molecular Ecology and Evolution at Bangor, School of Natural Sciences, Bangor University, Bangor, UK

18   <sup>11</sup> National Museum of Natural History, Sofia, Bulgaria

19   <sup>12</sup> Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

20  
21   \* These authors contributed equally to this work.

22  
23   ✉ **Correspondence to:** Omid Mehrpour; MD. Medical Toxicology and Drug Abuse Research Center, Birjand  
24   University of Medical Sciences, Birjand, Iran, AND Rocky Mountain Poison and Drug Center, Denver Health  
25   and Hospital Authority, Denver, CO, USA.

26   **E-mail:** [omid.mehrpour@yahoo.com.au](mailto:omid.mehrpour@yahoo.com.au), [omid.mehrpour@cuanschutzu.edu](mailto:omid.mehrpour@cuanschutzu.edu)

27   **Manuscript type:** Review Article (Systematic Review)

28   **Running title:** Medically Important Snakes of Iran

29 **ABSTRACT**

30 Snakebite is a common health condition in Iran with a diverse snake fauna, especially in tropical  
31 southern and mountainous western areas of the country with plethora of snake species. The list  
32 of medically important snakes, circumstances and effects of their bite, and necessary medical  
33 care require critical appraisal and should be updated regularly. This study aims to review and  
34 map the distributions of medically important snake species of Iran, re-evaluate their taxonomy,  
35 review their venomics, describe the clinical effects of envenoming, and discuss medical  
36 management and treatment, including the use of antivenom. Nearly 350 published articles and  
37 26 textbooks with information on venomous and mildly venomous snake species and snakebites  
38 of Iran, were reviewed, many in Persian (Farsi) language, making them relatively inaccessible to  
39 an international readership. This has resulted in a revised updated list of Iran's medically  
40 important snake species, with taxonomic revisions of some, compilation of their morphological  
41 features, remapping of their geographical distributions, and description of species-specific  
42 clinical effects of envenoming. Moreover, the antivenom manufactured in Iran is discussed,  
43 together with treatment protocols that have been developed for the hospital management of  
44 envenomed patients.

45 **Keywords:** Iran; Elapidae; Hydrophiini; Viperidae; Snakebites; Antivenoms

46 **1. INTRODUCTION**

47 Paradoxically, snake [ma:r in Persian (Farsi) language] has epitomized both “vivification/  
48 vitality/agility/well-being/productivity” and “annihilation/cunning/treason” in Persian culture  
49 and literature (Afshari & Monzavi, 2016b; Rasmi, 2016). “Bimar”, Persian for “patient”, is a word  
50 compounded of “bi (= without)” and “mar”; denoting a living entity that has lost its vitality/well-  
51 being (bimar = without well-being) (Afshari & Monzavi, 2016b). Rooted in old Persian, and  
52 perhaps through mutual understanding and cultural exchange, these concepts may have  
53 contributed to an ancient Greek symbol, the “Rod of Asclepius”, a serpent-entwined staff,  
54 representing health and healing. In addition, in historical remains and architecture of Persian  
55 territory, the snake is depicted with reverence, as signifying life, fertility, and blessings conferred  
56 on nature and the environment (Kazemi Shishavan & Maleki, 2018; Rasmi, 2016; Taheri, 2015).

57 Iran (literally means the land of Aryan people) covers an area of 1,648,195 square kilometers,  
58 bordering Armenia, Azerbaijan, and Turkmenistan in the north, Afghanistan and Pakistan in the  
59 east, and Iraq and Turkey in the west, and associated maritime boundaries with Kuwait, Iraq,  
60 Saudi Arabia, Bahrain, Oman, Qatar, and the United Arab Emirates across the Persian Gulf and  
61 the Sea (or Gulf) of Oman (also known as Sea of Makran) (**Fig. 1**). Iran is separated from the arid  
62 lowland areas of Iraq by the high Zagros Mountains, more than 4,000 m in altitude, and from the  
63 Caucasus and Turkmenistan's arid sandy deserts in the north and northeast, by the higher Alborz  
64 Mountains, at more than 5,500 m. The country's 31 provinces have widely varying climates (**Fig.**  
65 **1**). Average annual rainfall is rarely more than 40 mm in some parts of central and southern Iran,  
66 but exceeds 600 mm in some western and northern regions. The faunal diversity of Iran is  
67 influenced by its geographical position interconnecting the Palearctic, Ethiopian and Oriental  
68 regions (Dehghani et al., 2014b; Hosseinzadeh et al., 2014; Jowkar et al., 2016). Iran's vast  
69 biological diversity and tropical/subtropical, and semi-arid climate, have provided an ideal  
70 habitat, in which many species of snakes and other reptiles have evolved. This has exposed  
71 Iranians to the potential health-related dangers of encounters with these creatures throughout  
72 history. Ancient Indo-Iranian (Aryan) healers and physicians practiced various and sometimes  
73 strange methods of treating snakebites victims, although some of them, contemporary with  
74 Thritha or Trita (the earliest known Aryan physician and producer of antidotes and remedies, in  
75 about 3000 BCE) (Ambartsumian, 2001; Dadashi Arani & Mastali Parsa, 2020; Jayne, 1919;  
76 Nayernouri, 2015), were said to have had a good knowledge of antidotal remedies for snakebites  
77 (Kaviani Pooya, 2010; Najmabadi, 1992; Saameie, 2020). More recently, the world-renowned  
78 Iranian physicians, Zakaria Razi (Abu Bakr al-Razi or Rhazes, 854-932 A.D.) and Ibn Sina (Avicenna,  
79 980-1037 A.D.), advanced the knowledge on snakebites and envenoming management. At a time  
80 when the "snake stone" was one of the foundations of traditional snakebite treatment, Razi was  
81 among the few who questioned its usefulness. Through careful observation and scrutiny, he  
82 ultimately discredited its effectiveness (A'alam, 2000; Pymm, 2017). He used pressure bandaging

83 above the bite site and a kind of snakebite antidote (*Teriaq-e Afa'ei*) to treat the patients and he  
84 believed that the internal temperature of the patient should be increased using grape wine or  
85 naked lady lily (Rezaei-Orimi et al., 2022). Avicenna in his monumental masterpiece, *The Canon*  
86 *of Medicine*, provided classified diagnostic descriptions of bites of different venomous animals.  
87 He listed 30 different snakes and ranked them according to 3 classes based on lethality to  
88 humans. His therapeutic directives were based mainly on preventing venom's entering the  
89 bloodstream, i.e., by washing the wound, incision of the bite site and amputation of the bitten  
90 limb (for severe cases), and on the use of various herbal remedies depending on the snake species  
91 involved (Rezaei-Orimi et al., 2019).

92 Modern ophiology in Iran owes an enormous debt to the late Professor Mahmoud Latifi (1929-  
93 2005), a renowned herpetologist, who devoted his life to gathering information about the  
94 snakes of Iran (**Fig. 2**). Following 24 years of painstaking expeditions (1959 to 1983) across the  
95 whole country, Latifi and his team collected 62 species from 28 genera and 8 families of  
96 venomous and non-venomous snakes. These were the basis of research articles and, notably,  
97 his classic textbook, "Snakes of Iran", originally published in 1985 in Persian by the Iranian  
98 Department of Environment (IDE) (Latifi, 1985), and later translated into English through the  
99 support of the National Museum of Natural History, Smithsonian Institution and the Society for  
100 the Study of Amphibians and Reptiles (Latifi, 1991). The naming of *Montivipera latifii*, an  
101 endemic species of viper from the Lar valley in Mount Damavand, was fitting recognition of his  
102 endeavors. Latifi also pioneered antivenom production in Iran at the Razi Vaccine and Serum  
103 Research Institute in Karaj, supplying the country and the Middle East region for over 50 years.  
104 This program depended on the help of a network of snake catchers who brought snakes  
105 captured throughout Iran to the institute (**Fig. 2**). Another major contribution was the late Dr.  
106 Reza Farzanpay's (1934-2018) book "Ophiology" on the morphological characteristics of Iran's  
107 snakes [published in Persian, 1990] (Farzanpay, 1990). Dr. Farzanpay was best known for his  
108 work on scorpions and scorpion antivenoms at the Razi Institute. Zoological studies and  
109 conservation of wildlife, including snakes, in Iran are also indebted to the late Eskandar Firouz  
110 (1926-2020), a pioneering environmentalist and conservationist, who was the founding director  
111 of the IDE and a cofounder of the Convention on Wetlands of International Importance, also  
112 known as the Ramsar Convention (1971). In 1977, he was elected president of the International  
113 Union for Conservation of Nature and Natural Resources (IUCN). His book "The Complete Fauna  
114 of Iran" (2005) is an essential reference for anyone interested in the vertebrate fauna of Asia  
115 and the Middle East (Firouz, 2005) (**Fig. 2**).

116 Worldwide, the survival of snakes is threatened by human intrusion into their environment,  
117 global climatic change, and excessive collecting, for commercial reasons such as the sale of their  
118 body parts for food and medicines, venoms and skin (Almasieh et al., 2019; Ansari, 2020;  
119 Dehghani et al., 2014a; Jowkar et al., 2016; Reading et al., 2010; Yousefi et al., 2019). This is why



120 so many snake species are now in the IUCN's red list of threatened species (Betts et al., 2020).  
121 Therefore, accurate and up-to-date information about the geographical distribution and  
122 preferred habitats of different snake species is needed to conserve them and their ecosystems,  
123 and to make the human inhabitants of these regions aware of the risk of venomous snakebites  
124 (Yousefi et al., 2020). Determination of precise geographical distributions of venomous snake  
125 species is also important for developing preventive interventions to reduce human-snake  
126 encounters, and to improve medical services to make antivenom and other medical resources  
127 more readily available (Warrell, 2016). The list of medically-important snakes of Iran has not been  
128 critically reevaluated since the publication of Latifi's book in 1985 (Latifi, 1991, 1985). The  
129 present study has reviewed all relevant publications concerning the geographical distribution,  
130 morphology, taxonomy, venom composition, clinical effects of envenoming, and clinical  
131 significance of Iran's medically important snakes (i.e., front-fanged venomous, and non-front-  
132 fanged mildly-venomous snakes, both potentially dangerous to human health). Locally developed  
133 protocols for medical management of envenomed patients are also assessed in the light of  
134 international advances in clinical toxinology.

135 **2. METHODS**

136 A systematic review was performed using keywords including, "SNAKE", "SNAKEBITE",  
137 "ENVENOMING", "ENVENOMATION", "ANTIVENOM" and "IRAN"; as well as "species names" of  
138 snakes currently known to be part of herpetofauna of Iran, based on two reliable resources (Latifi,  
139 1991, 1985; Safaei-Mahroo et al., 2015). Articles and scientific documents available up to the end  
140 of 2022 were explored in peer-reviewed biological and biomedical journals, as well as eminent  
141 indexing databases including Web of Science, PubMed, Scopus and Google Scholar. In addition,  
142 articles in Persian were retrieved from Iranian online repositories of scientific literature including  
143 the Scientific Information Database (SID) and IranDoc. Original studies of clinical findings of  
144 envenoming or LD<sub>50</sub> studies of venom of snake species occurring in Iran, including studies not  
145 performed by Iranian scientists or those carried out in adjacent or neighboring countries, were  
146 also reviewed and reliable data extracted. A total of 2897 articles were identified, and after  
147 removal of 797 duplicates, the abstracts of the remaining titles were evaluated; and accordingly,  
148 1768 irrelevant documents and those not meeting the required criteria were removed. Within  
149 the study objectives, 347 documents (including 186 studies from Iran and 161 articles about  
150 publications involving Iran's snake species occurring in other geographic regions) were finally  
151 determined to be eligible for review and were subjected to deeper scrutiny and analyses (**Fig. 3**).  
152 Ten Iranian clinical and environmental toxicology textbooks and compendia on Iranian  
153 herpetofauna, as well as sixteen international toxicology and toxinology textbooks were also  
154 reviewed for relevant information on Iranian snakes and snakebites (Afshari & Monzavi, 2016a;  
155 Balali-Mood & Shariat, 1999; Dehghani, 2010; Farzanpay, 1990; Firouz, 2005; Latifi, 1991, 1985;  
156 Mozaffari et al., 2016; Nabipour, 2012; Rajabizadeh, 2018; Zare Mirakabadi & Teymurzadeh,  
157 2009). An Iranian website focusing on ecological information including Iran's wilderness deserts  
158 (<https://www.irandeserts.com>), which is directed by an expert team of scientists and interested  
159 volunteers, was accessed to retrieve relevant photos and information on the geographical  
160 biotopes of Iranian snakes. The <http://reptile-database.reptarium.cz/>,  
161 <https://www.iucnredlist.org> and <https://www.inaturalist.org> databases were also accessed to  
162 find relevant photos, taxonomic information and global conservation status of the Iranian snake  
163 species. Reports and guidelines endorsed by the World Health Organization (WHO), available on  
164 the WHO website ([www.who.int/snakebites/resources](http://www.who.int/snakebites/resources)), were also reviewed. Following  
165 consensus of all authors, retrieved materials that were deemed authentic were further  
166 interpreted, and compiled with tables, representative images of medically important snakes of  
167 Iran and their geographical distributions in regionalized distribution maps along with their global  
168 conservation status (based on IUCN).

### 169 3. RESULTS

#### 170 3.1. Checklist of Iranian medically important snakes

171 Snakebite is not uncommon in Iran, at least for some Iranians who live and work in regions  
172 inhabited by a plethora of snake species, such as the tropical southern and mountainous western  
173 areas of the country. Various species of snakes and snakebites are reported, from islands in the  
174 Persian Gulf in the South, to the northernmost regions of the country (Afshari & Monzavi, 2016b;  
175 Dehghani, 2010; Nabipour, 2012). A total of 89 species have been identified, of which 30 are  
176 venomous, seventeen are mildly-venomous (non-front-fanged species) and the remainder are  
177 considered non-venomous (Dehghani, 2010; Dehghani et al., 2014c; Ebrahimi et al., 2018;  
178 Farzanpay, 1990; Fathinia et al., 2011; Firouz, 2005; Gholamifard, 2011; Hosseinian Yousefkhani  
179 et al., 2014; Latifi, 1991, 1985; Latifi et al., 1966; Malekoutian et al., 2018; Moradi et al., 2013;  
180 Mozaffari et al., 2016; Nabipour, 2012; Nasrabadi et al., 2016; Rajabizadeh, 2013, 2018; Ramezani  
181 et al., 2011; Rastegar-Pouyani et al., 2008; Safaei-Mahroo et al., 2015; Shaykhi Ilanloo et al., 2015;  
182 Soleimanfallah et al., 2018; Zare Mirakabadi & Teymzadeh, 2009). While some species are  
183 widely distributed throughout the country, others are restricted to limited geographic regions  
184 (**Supplementary material - Table 1S**). Potential factors influencing the distribution of Iran's  
185 common venomous snakes include rainfall seasonality, alterations in habitat suitability, and  
186 vegetation properties (Yousefi et al., 2015; Yousefi et al., 2020). Some species have shown  
187 morphological adaptations to specific geographical locations (Fathinia & Rastegar-Pouyani, 2010;  
188 Gholamifard, 2011; Gholamifard & Esmaeili, 2010; Moradi et al., 2014; Navidpour et al., 2019;  
189 Rajabizadeh et al., 2012; Rastegar-Pouyani et al., 2008; Safaei-Mahroo et al., 2015;  
190 Todehdehghan et al., 2019; Yousefi et al., 2015).

191 In this study, at the family and subfamily levels, we followed the classification of Pyron et al.  
192 (Pyron et al., 2013). Accordingly, the functionally venomous snake species of Iran are grouped in  
193 the families Colubridae (subfamily Colubrinae), Lamprophiidae (subfamily Psammophiinae),  
194 Elapidae and Viperidae (subfamilies Crotalinae and Viperinae). While older works have frequently  
195 recognized subfamilies within the Elapidae (especially the subfamily Hydrophiinae for the marine  
196 elapids), recent studies (Figueroa et al., 2016; Pyron et al., 2013; Wallach et al., 2017; Zaher et  
197 al., 2019) have not supported this arrangement. Therefore, the subfamilies within the Elapidae  
198 are not recognized in this manuscript.

##### 199 3.1.1. *Non-front-fanged snakes*

200 For humans, bites by the majority of opisthoglyphous (non-front-fanged or rear-fanged) snakes  
201 are mainly mildly or non-venomous, and are rarely severe, even though these snakes possess  
202 venoms containing components that are often highly toxic to their natural prey (Weinstein et al.,  
203 2023b; Weinstein et al., 2013). This is largely due to the fact that the venom-delivering fangs are  
204 at the back of the maxilla with lack of venom storage reservoir, and the venom glands lack

205 powerful compressor muscles (Modahl & Mackessy, 2019; Modahl et al., 2016; Saviola et al.,  
206 2014). Hence, except in a few documented cases, this precludes the injection of venom under  
207 high pressure and in quantities in sufficient to cause envenoming in humans, unlike the front-  
208 fanged (proteroglyphous and solenoglyphous) vipers and elapids (Araujo et al., 2018; Brandehoff  
209 et al., 2019; Dehghani et al., 2012; Weinstein et al., 2014). However, outside Iran, bites by a few  
210 opisthoglyphous species (e.g., *Dispholidus typus*, *Rhabdophis* spp., and *Thelotornis* spp.) can  
211 result in envenoming as dangerous as from front-fanged venomous snakes (Dashevsky et al.,  
212 2018; Junqueira-de-Azevedo et al., 2016; Weinstein et al., 2013). The mildly venomous non-front-  
213 fanged snakes of Iran belong to two families - Colubridae and Lamprophiidae (**Supplementary  
214 material - Table 1SA & Table 2S**). Their venoms contain proteins that are structurally convergent  
215 with those of front-fanged venomous snakes (Xie et al., 2022).

#### 216 **3.1.1.1. Colubridae**

217 Over 40 colubrid species have been recorded in Iran, the majority of which are considered non-  
218 venomous, or whose bites are largely unstudied (Dehghani et al., 2014c; Dehghani et al., 2016a;  
219 Rastegar-Pouyani et al., 2008; Safaei-Mahroo et al., 2015). Among these, thirteen species in four  
220 genera (*Boiga*, *Hemorrhois*, *Platyceps* and *Telescopus*) are considered mildly venomous  
221 (Dehghani et al., 2016a; Moradi et al., 2021; Rastegar-Pouyani et al., 2008; Safaei-Mahroo et al.,  
222 2015; Schaetti et al., 2012). *Boiga* and *Telescopus* species in Iran are functionally venomous,  
223 whereas symptomatic envenoming after bites by *Hemorrhois* and *Platyceps* species has not been  
224 adequately documented.

225 The black-headed cat snake (*Boiga trigonata melanocephala*) occurs exclusively in eastern Iran,  
226 whereas *Hemorrhois*, *Platyceps* and *Telescopus* species collectively inhabit most regions of the  
227 country, although their diversity is greatest in the western third of the country, and lowest in the  
228 deserts of the center (Moshtaghi et al., 2018; Safaei-Mahroo et al., 2015). The recent discovery  
229 of the black-headed tiger snake (*Telescopus nigriceps*) in the southwest of Iran, close to the Iraq  
230 border, has increased the number of *Telescopus* species in Iran to five (**Table 1S**) (Nilson &  
231 Rastegar-Pouyani, 2013; Rastegar-Pouyani et al., 2008; Safaei-Mahroo et al., 2015). The type  
232 specimen of *Platyceps rhodorachis* was from Persia (De Filippi, 1865). *P. rhodorachis* and *T.*  
233 *rhinopoma* have also been recorded on some southern islands of Iran (Latifi, 1991), i.e., *P.*  
234 *rhodorachis* on Kharg (or Khark), Kish, Qeshm, Hengam and Hormoz Islands; and *T. rhinopoma* on  
235 Kharg Island.

#### 236 **3.1.1.2. Lamprophiidae**

237 The four species of Iranian Lamprophiidae are members of the subfamily Psammophiinae in the  
238 genera *Psammophis* and *Malpolon* (**Table 2S**). Snakes in the closely-related Lamprophiidae and  
239 Elapidae families are sometimes referred to jointly as the superfamily Elapoidea (Kelly et al.,  
240 2009), but Elapoidea have now been shown to be paraphyletic. *Psammophis lineolatus*,

241 *Psammophis schokari*, *Malpolon insignitus fuscus* and *Malpolon moilensis* occur in Iran. In the  
 242 Persian Gulf, *P. schokari* is recorded from Kharg and Qeshm Islands, and *M. moilensis* from Kharg  
 243 Island (Latifi, 1991). Iran has been the easternmost global distribution of the genus *Malpolon*  
 244 (Safaei-Mahroo et al., 2016).

### 245 **3.1.2. Front-fanged venomous snakes**

246 Iran's front-fanged venomous snakes belong to two families, Elapidae (terrestrial and marine  
 247 elapids) and Viperidae [Crotalinae (pit vipers) and Viperinae (true/Old World vipers)], which  
 248 altogether include 30 species (**Tables 1SB & 3S**) (Gholamifard et al., 2012; Rastegar-Pouyani et  
 249 al., 2008; Rezaie-Atagholipour et al., 2016; Safaei-Mahroo et al., 2015). The truly endemic  
 250 venomous species of Iran are *Macrovipera razii*, *Montivipera latifii*, *Montivipera kuhrangica*, and  
 251 *Bungarus persicus* (Abtin et al., 2014; Bok et al., 2017; Fathinia et al., 2016; Gholamifard, 2011;  
 252 Oraie, 2020; Oraie et al., 2018; Rajabizadeh et al., 2011a; Rajabizadeh et al., 2012).

#### 253 **3.1.2.1. Elapidae**

254 In Iran, 14 elapid species in 4 genera have been recorded, characterized by their proteroglyphous  
 255 fangs and circular pupils (**Table 1SB & 3S**) (Firouz, 2005; Latifi, 1985; Rastegar-Pouyani et al.,  
 256 2008; Shoorabi et al., 2017). Among the terrestrial elapids, the most widely distributed species are  
 257 the Central Asian/Oxus/Caspian Cobra (*N. oxiana*) (Shoorabi et al., 2017), and the Eastern black  
 258 desert or Morgan's Cobra (*Walterinnesia morgani*) (Nilson & Rastegar-Pouyani, 2007). The  
 259 Iranian/Persian krait (*Bungarus persicus*), a relatively recent addition to the list of Iranian  
 260 Elapidae, is restricted to the southeastern part of the country (Abtin et al., 2014; Rajabizadeh, 2018).  
 261 It is the westernmost geographically distributed member of the genus *Bungarus* (Abtin et al.,  
 262 2014).

263 **Bungarus:** *B. persicus* was discovered approximately 100 kilometers west of the Pakistan border,  
 264 north of Sarbaz in Iran's Sistan and Baluchistan province (Abtin et al., 2014). It is distinguished  
 265 from its closest relative *B. sindanus* by a unique small loreal scale or loreal black spot and higher  
 266 numbers of ventral and subcaudal scales. Recently, there were two other reports from  
 267 Bashagard, Hormozgan province (Shahi et al., 2022). There has also been a report of likely  
 268 specimen collected in Ras Jiwani in Pakistan's Baluchistan region, just across the Pakistan-Iran  
 269 borders, which was perhaps misidentified as *B. caeruleus* (Shockley, 1949).

270 **Naja:** *N. oxiana* is distributed in northeastern and possibly eastern Iran, Afghanistan,  
 271 northwestern India (Jammu and Kashmir, and Himachal Pradesh), northern and western  
 272 Pakistan, southern Turkmenistan, southwestern Tajikistan and southern Uzbekistan (Kazemi et  
 273 al., 2021a; Kazemi et al., 2021b; Yousefi et al., 2020).

274 **Walterinnesia:** *W. morgani* has been reported from northern, western and southern parts of  
 275 Iran, and, elsewhere, in Iraq, southeastern Turkey (Urfa), Syria, Saudi Arabia, and Kuwait  
 276 (Gholamifard & Rastegar-Pouyani, 2012; Nilson & Rastegar-Pouyani, 2007).

277 **Hydrophis:** Marine elapids are represented in the Persian Gulf and the Sea of Oman by 11 species  
 278 in the monophyletic clade Hydrophiini (viviparous sea snakes) (Gillett et al., 2014; Heydari Sereshk &  
 279 Riyahi Bakhtiari, 2014; Lillywhite et al., 2014; Mirtschin et al., 2018; Nabipour, 2012; Rezaie-  
 280 Atagholipour et al., 2016; Rezaie-Atagholipour et al., 2012a; Rezaie-Atagholipour et al., 2012b;  
 281 Sanders et al., 2013). The most recent addition to Iran's list of sea snakes is Günther's or Cantor's  
 282 narrow-headed sea snake (*Hydrophis cantoris*) (Rezaie-Atagholipour et al., 2016). *H. cantoris*, *H.*  
 283 *viperinus* and *H. cyanocinctus* live in deep waters and are occasionally caught in fishing nets.  
 284 Although rarely seen, they are not in danger of extinction. The beaked sea-snake (*H. schistosus*)  
 285 has a very potent venom, making it perhaps the deadliest snake of Iran (**Tables 1S, 3S**). Elsewhere,  
 286 it has been proven to be the most medically important sea-snake species (Mirtschin et al., 2018).  
 287 The yellow-bellied sea-snake (*H. platurus*) is a pelagic species (inhabiting the open ocean) which  
 288 floats, feeds, and, remarkably, drinks fresh rain water after storms on the sea surface (Gillett et  
 289 al., 2014; Lillywhite et al., 2014). Stokes's sea-snake (*H. stokesii*) has been recorded in the Makran  
 290 coast of Baluchistan in Pakistan, contiguous with Iran's Makran coast of Baluchistan, making it  
 291 highly probable that this species also occurs in Iran's coastal waters (Rastegar-Pouyani et al.,  
 292 2008). Despite their prodigious numbers, all species of sea-snakes are threatened by rapidly-  
 293 increasing water pollution, fishing activities and marine vessel traffic (Heydari Sereshk & Riyahi  
 294 Bakhtiari, 2014; Rezaie-Atagholipour et al., 2012a; Rezaie-Atagholipour et al., 2012b; Yaghmour  
 295 et al., 2022).

### 296 **3.1.2.2. Viperidae**

297 The 16 Viperidae species (belonging to eight genera and two subfamilies) recorded in Iran (**Table**  
 298 **1S & 3S**) are characterized by vertically elliptical pupils, marked flattened triangular (wedge-  
 299 shaped) head, and retractable solenoglyphous fangs (**Fig. 4**). The most widely distributed species  
 300 are the Sindh or Sochurek's Saw-scaled viper (*Echis carinatus sochureki*), Blunt-nosed or  
 301 Levantine Viper (*Macrovipera lebetina*), and Persian Horned Viper (*Pseudocerastes persicus*)  
 302 (Dehghani et al., 2014b; Fathinia & Rastegar-Pouyani, 2010; Moradi et al., 2014; Rastegar-  
 303 Pouyani et al., 2008; Safaei-Mahroo et al., 2015). These species are responsible for the majority  
 304 of human snakebite envenomings in Iran (Dehghani et al., 2014b; Dehghani et al., 2012; Monzavi  
 305 et al., 2019a; Monzavi et al., 2019b).

306 **Cerastes:** The Arabian or Desert Horned Viper (*Cerastes gasperettii*) occurs in southwestern Iran,  
 307 inhabiting arid areas around oases in Khuzestan (Carné et al., 2020; Spawls & Branch, 1995). It  
 308 has also been seen on Tahmadu (Jabrin) Island in the Persian Gulf (Latifi, 1991). Based on  
 309 morphological observations, Werner et al. proposed that *C. gasperettii* be divided into two

310 subspecies (i.e., *C. g. gasperettii* and *C. g. mendelssohni*). However, a recent molecular  
311 phylogenetic analysis has questioned this subspecific division (Carné et al., 2020).

312 ***Echis***: Despite studies suggesting that two distinct taxa of *Echis* occur in Iran, *E. multisquamatus*  
313 Cherlin, 1981 and *E. carinatus sochureki* Stemmler, 1969 (Bagherian & Kami, 2008; Cherlin, 1981;  
314 Cherlin, 1990), they have been synonymized based on more recent evidence of molecular  
315 phylogeny and clinal variation in morphology (Arnold et al., 2009; Navidpour et al., 2019; Pook et  
316 al., 2009). Hence, only one *Echis* taxon, i.e., *E. carinatus sochureki*, is recognized in Iran. The  
317 species is widely distributed in the country, except in the northwest parts. It also occurs on Kharg,  
318 Shif, Lavan, Kish, Qeshm, Greater Tunb and Hormoz Islands in the Persian Gulf (Latifi, 1991).

319 ***Eristicophis***: MacMahon's Desert Viper or Leaf-nosed Viper (*Eristicophis macmahonii*) is an  
320 uncommon monotypic species native to the dry loose sandy desert regions in the extreme east  
321 of Iran (e.g., Tasouki) that share borders with Afghanistan and Pakistan (**Tables 1S, 3S**). It was  
322 first described by Alcock, Finn, Maynard and McMahan in 1896 close to the Iran border in  
323 Pakistan (Amirchah, Zeh, Drana Koh and Robot I. between 760 and 1,360 m altitude (Alcock et  
324 al., 1896), and in Iran by Guibé (Guibé, 1957) as "*Pseudocerastes latirostris*" from "Taraki 120  
325 km after Zabol on the way to Zahedan" near to the Afghanistan border, and by Latifi (Latifi,  
326 1991), who examined one specimen from Kerman and a few others from the Iran-Pakistan  
327 border (Latifi, 1991). Sindaco shows a record from near Zahak (Sindaco et al., 2013) and Joger  
328 (Joger, 1984) shows two records from the Zahak "bulge" but does not specify a source. Based  
329 on Papenfuss et al.'s assessment, this species also occurs near Jiroft, Kerman province  
330 (Papenfuss et al., 2021). It is a small irritable viper, characterized by two butterfly-shaped  
331 laterally projecting naso-rostral scales, which help prevent sand entering its nostrils, especially  
332 when the animal burrows down into the sand concealing itself to ambush prey.

333 ***Gloydius***: The Caucasian Pit Viper (*Gloydius caucasicus*) is Iran's only pit viper. Recently it was  
334 elevated from being a subspecies of *G. halys* to full species rank (Asadi et al., 2019; Shi et al.,  
335 2016). It inhabits a range of environments in the Hyrcanian broad-leaved forest of the Alborz  
336 range, in northeastern to northwestern Iran, and in southeast Azerbaijan, ranging in altitude from  
337 30 to 3000 m above sea level (Ghelichy Salakh et al., 2020; Khani et al., 2017). It is the most  
338 westerly species of Crotalinae in the Palearctic (Asadi et al., 2019; Ghelichy Salakh et al., 2019;  
339 Shi et al., 2016). This species has been regularly collected by the Razi Institute for antivenom  
340 production since 1924 (Asadi et al., 2019).

341 ***Macrovipera***: The Blunt-nosed or Levantine Viper (*Macrovipera lebetina*) is widely distributed  
342 from Turkey and Cyprus east to Kashmir. In Iran, two sub-species are recognized, *M. lebetina*  
343 *obtusata* in the northwest and *M. l. cernovi* (Cernov's Viper) in the northeast (Stümpel & Joger,  
344 2009; Stümpel et al., 2016). Recently, a second species of potential medical importance, Razi's  
345 viper (*Macrovipera razii*), has been identified in the Zagros Mountains of central and southern  
346 Iran, distinguished from *M. lebetina* by mitochondrial Cytb gene sequence phylogeny and

347 morphology (Oraie, 2020; Oraie et al., 2018). Compared to *M. lebetina*, *M. razii* has higher ventral  
348 scale counts, elongated anterior chin-shields, and lower numbers of canthal and inter-  
349 supraocular scales.

350 **Montivipera:** The three closely-related species of the *Montivipera raddei* complex in Iran  
351 comprise *M. raddei*, *M. latifii*, and *M. kuhrangica* (Behrooz et al., 2018; Fakharmanesh et al.,  
352 2014; McDiarmid et al., 1999; Rajabizadeh, 2013; Stümpel et al., 2016; Yousefi et al., 2015).  
353 Through molecular analyses (on the basis of nuclear and mitochondrial genes), the sub-specific  
354 status of *M. raddei kurdistanica* and *M. raddei albicornuta* was not supported, implying that they  
355 should be collapsed into *M. raddei* (Stümpel et al., 2016). Phylogenetic evaluations also  
356 suggested that *M. latifii* is a separate evolutionary lineage from the closely-related Armenian,  
357 Caucasus or Radde's Viper (*M. raddei*). This was confirmed by the distinctive ecological  
358 adaptation of *M. latifii* to alpine habitats in the Alborz Mountains, where it can remain active  
359 despite the cold climate (Stümpel et al., 2016; Yousefi et al., 2015). Although regarded by some  
360 as diverging populations of the same species (Rastegar-Pouyani et al., 2014), using mitochondrial  
361 gene assay, phylogenetic and phylogeographic analyses, it has been shown that *M. latifii* and *M.*  
362 *kuhrangica* represent two monophyletic clades (Behrooz et al., 2018). Latifi's Viper (*M. latifii*), an  
363 endemic species, possesses a venom more potent than the venoms of other Iranian Viperidae  
364 except *E. c. sochureki* and *M. raddei* (Table 1) (Archundia et al., 2011; Latifi, 1984; Weinstein &  
365 Minton, 1984). Several species of the *raddei* complex, especially *M. latifii*, are rare and listed as  
366 "threatened" in the IUCN's red list (Ahmadi et al., 2019; Yousefi et al., 2015) with *M. latifii* classed  
367 as "endangered". This latter species has been subject to irrational killings, and its distribution is  
368 restricted to the Lar Valley, central Alborz region (Asadi et al., 2016; Behrooz et al., 2015;  
369 Rajabizadeh et al., 2012). The Kuhrang mountain viper (*M. kuhrangica*) is another endemic  
370 *Montivipera* that is restricted to the Central Zagros region and is rarely observed (Rajabizadeh et  
371 al., 2011a). The occurrence of Wagner's or ocellate mountain viper (*M. wagneri*) in Iran is  
372 uncertain. Although Nilson and Andrén reported a type locality of the species in the "vicinity of  
373 Lake Urmia" in northwestern Iran (Nilson & Andrén, 1984), it has not been reliably observed in  
374 the country since then (Kumlutas et al., 2015; Rastegar-Pouyani et al., 2008), although recent  
375 explorations have demonstrated a wide range for *M. wagneri* in eastern Turkey towards its  
376 border with northwestern Iran (Mebert et al., 2020).

377 **Pseudocerastes:** The horns of "false horned vipers" (*Pseudocerastes*) are composed of numerous  
378 small supraocular scales, rather than the single supraocular scales of the genus *Cerastes* (Bok et  
379 al., 2017; Fathinia et al., 2014). The Persian horned viper (*Pseudocerastes persicus*) is perhaps the  
380 most widely distributed viper species in the Middle East, from Northern Iraq to Pakistan with  
381 isolated populations in mountains of the South-East Arabian Peninsula (Sindaco et al., 2013).  
382 Field's horned viper (*P. fieldi*) is separated from *P. persicus* in its geographical range by the Zagros  
383 Mountains, and, although formerly classified as a sub-species, is now recognized as a separate



384 species, based both on morphological features and differences in venom composition (Bdolah,  
385 1986; Dehghani et al., 2014c; Gholamifard & Esmaeili, 2010). *P. persicus* has uniformly keeled  
386 scales and a longer tail than *P. fieldi*. The southern localities for *P. fieldi* in Iran need to be  
387 confirmed (Sindaco et al., 2013), while it is likely that the Fars record from a decade ago  
388 (Gholamifard & Esmaeili, 2010), was based on a misidentified *P. persicus*. In general, controversy  
389 has remained, and while some scientists do not recognize *P. fieldi* from Iran and suggest that all  
390 *P. fieldi* records from Iran were perhaps *P. persicus* (Fathinia et al., 2018; Safaei-Mahroo et al.,  
391 2015), others have reported the occurrence of *P. fieldi* in western and central Iran (Dehghani et  
392 al., 2014c; Mozaffari et al., 2016). The spider-tailed horned viper (*Pseudocerastes urarachnoides*),  
393 occurs in the west of Iran, and is also reported from the extreme East of Iraq (Al-Sheikhly et al.,  
394 2019; Al-Sheikhly et al., 2020; Fathinia et al., 2020). It has an extraordinary bristle-brush-like  
395 appendage on the tip of its tail (**Table 1S**). It was first collected during an American museum  
396 expedition in 1968, but neither the integrity of its solpugid/solifugid (camel spider)-like caudal  
397 appendage, a lure that attracts prey such as small birds and lizards, nor its specific status were  
398 appreciated until 2006 (Bostanchi et al., 2006; del Marmol et al., 2016; Fathinia et al., 2009;  
399 Fathinia et al., 2016).

400 **Vipera:** The Alburzi or Armenian steppe viper (*Vipera eriwanensis*) is distributed over northwest  
401 Iran, northeast Turkey and Transcaucasia (Rajabizadeh et al., 2011b), and is in danger of  
402 extinction (Tuniyev et al., 2009a). It was formerly considered a subspecies of the *V. ursinii*  
403 complex (Rajabizadeh et al., 2011b). Höggren et al. recognized *V. eriwanensis* as a distinct species  
404 (Höggren et al., 1993), a status supported by a more recent study (Zinenko et al., 2015). Ebner's  
405 viper (*V. ebneri*) has been reported from the central Alborz and the northernmost Zagros  
406 mountains. It was previously regarded as a sub-species of *V. eriwanensis* (Kukushkin et al., 2012;  
407 Rajabizadeh et al., 2011b; Rastegar-Pouyani et al., 2008), but species status was supported by  
408 Zinenko et al. (Zinenko et al., 2015). The zoogeographic status of the Transcaucasian sand viper  
409 (*Vipera ammodytes transcaucasiana*), has remained controversial (Mülder, 2017; Stümpel &  
410 Joger, 2009; Tok & Kumluç, 1996). While it has been reported from extreme northwestern Iran,  
411 these reports seem unreliable, and its presence in the country has not been rigorously  
412 established (Mülder, 2017; Safaei-Mahroo et al., 2015; Tuniyev et al., 2009b). Elsewhere, it occurs  
413 in northern Turkey, Georgia, and northwest Azerbaijan (Mülder, 2017). Some herpetologists  
414 consider it a sub-species of *V. ammodytes*, whereas others accord it the status of a full species  
415 (Nilson et al., 1999).

### 416 **3.2. A brief review of studies on the venoms of some Iranian snakes**

417 Experimental studies of Iranian snake venoms date from Latifi's original studies on venom yield  
418 and lethal potency (Latifi, 1984), to more recent cytotoxic assays, and the application of  
419 proteomics or venomics (Ghezellou et al., 2021; Ghezellou et al., 2019). Lethal doses (LD<sub>50</sub>) of the  
420 venoms of some common Iranian snakes of medical importance are presented in **Table 1**.

<b>Table 1.</b> Lethal doses (LD <sub>50</sub> ) of Iran's medically important snakes (Studies on mouse using crude venom)				
<b>Species/Subspecies</b>	<b>Route of injection</b>	<b>Reporting format</b>	<b>Result (mg/kg)</b>	<b>Reference</b>
<i>Cerastes gasperettii</i>	i.p.	Median	0.98	(Al-Sadoon et al., 2016)
	i.p.	Median	1.32	(Zaeri et al., 2021a)
<i>Echis carinatus sochureki</i>	i.p.	Median	1.68	(Ghezellou et al., 2021)
	i.v.	Mean ± SD	0.25 ± 0.06	(Latifi, 1984)
	i.v.	Median (Range)	0.26 (0.2-0.32)	(Latifi & Tabatabai, 1989)
	i.v.	Median (95% CI)	0.55 (0.44-0.69)	(Salmanizadeh et al., 2013)
	i.v.	Median	0.57	(Nasri Nasrabadi et al., 2022)
<i>Gloydius caucasicus (halys)</i>	i.p.	Median	1.45	(Fathi et al., 2022)
	i.v.	Mean ± SD	0.69 ± 0.04	(Latifi, 1984)
	i.p.	Median	0.84-0.92	(Rasoulinasab et al., 2020)
<i>Hydrophis cantoris</i>	s.c.	Median	0.5	(Reid, 1956)
<i>Hydrophis curtus</i>	i.v.	Median	0.7	(Alam & Qasim, 1993)
	i.p.	Median	0.12	(Carey & Wright, 1960)
	i.v.	Median (95% CI)	0.2 (0.18-0.24)	(Tan et al., 2018)
<i>Hydrophis cyanocinctus</i>	i.v.	Median	0.6	(Alam & Qasim, 1993)
	i.p.	Median	0.8	(Ali et al., 1999a)
	i.v.	Median (95% CI)	0.29 (0.26-0.32)	(Baxter & Gallichio, 1976)
	s.c.	Median (95% CI)	0.49 (0.44-0.56)	
	i.v.	Median	0.13	(Calvete et al., 2012)
	i.p.	Median	0.17	
<i>Hydrophis gracilis</i>	s.c.	Median (95% CI)	0.51 (0.44-0.59)	(Baxter & Gallichio, 1976)
<i>Hydrophis ornatus</i>	i.m.	Median	0.16	(Tamiya & Puffer, 1974)
	i.v.	Median	2.2	(Tu, 1974)
<i>Hydrophis platurus</i>	i.p.	Median (95% CI)	0.12 (0.08-0.18)	(Lomonte et al., 2014)
	i.v.	Median (95% CI)	0.2 (0.04-0.32)	
<i>Hydrophis schistosus</i>	i.v.	Median (95% CI)	0.1 (0.08-0.11)	(Baxter & Gallichio, 1976)
	s.c.	Median (95% CI)	0.12 (0.1-0.14)	
	s.c.	Median (95% CI)	0.16 (0.15-0.19)	(Broad et al., 1979)
	i.v.	Median (95% CI)	0.07 (0.05-0.09)	(Tan et al., 2015)
	i.v.	Median	0.14-0.21	(Tu, 1974)
<i>Hydrophis spiralis</i>	i.v.	Median	0.4	(Alam & Qasim, 1993)
	i.p.	Median	0.58	(Carey & Wright, 1960)
<i>Hydrophis stokesii</i>	i.v.	Median (95% CI)	0.17 (0.15-0.2)	(Baxter & Gallichio, 1976)
	s.c.	Median (95% CI)	0.28 (0.24-0.31)	
<i>Hydrophis viperinus</i>	i.v.	Median	4.5	(Tu, 1974)
<i>Macrovipera lebetina cernovi</i>	i.v.	Median (95% CI)	0.88 (0.65-1.2)	(Archundia et al., 2011)
	i.v.	Median (95% CI)	0.99 (0.92-1.0)	(Garcia-Arredondo et al., 2019)
<i>Macrovipera lebetina obtusa</i>	i.v.	Median (95% CI)	1.51 (1.32-1.72)	(Archundia et al., 2011)
	i.v.	Median	0.9	(Elfiky et al., 2022)
	i.p.	Range	2.5-2.8	(Eskafi et al., 2021)
	i.p.	Median	3.87	(Fathi et al., 2022)

<b>Table 1.</b> Lethal doses (LD <sub>50</sub> ) of Iran's medically important snakes (Studies on mouse using crude venom)				
<b>Species/Subspecies</b>	<b>Route of injection</b>	<b>Reporting format</b>	<b>Result (mg/kg)</b>	<b>Reference</b>
	i.v.	Median (95% CI)	0.82 (0.79-0.85)	(Garcia-Arredondo et al., 2019)
	i.v.	Mean ± SD	0.92 ± 0.07	(Kurtovic et al., 2014)
	i.v.	Mean ± SD	0.32 ± 0.07	(Latifi, 1984)
	i.p.	Median (95% CI)	1.75 (0.95-2.75)	(Pla et al., 2020)
	s.c.	Median	3.0	(Schöttler, 1938)
<i>Malpolon insignitus (monspessulanus)</i>	i.v.	Median	6.5	(Rosenberg et al., 1985)
<i>Montivipera latifii</i>	i.v.	Median	0.4	(Archundia et al., 2011)
	i.p.	Median	0.84	(Fathi et al., 2022)
	i.v.	Median (95% CI)	0.28 (0.24-0.31)	(Garcia-Arredondo et al., 2019)
	i.v.	Mean ± SD	0.28 ± 0.04	(Latifi, 1984)
	i.v.	Median (95% CI)	0.35 (0.31-0.42)	(Weinstein & Minton, 1984)
	i.p.	Median (95% CI)	2.07 (1.73-2.47)	
	s.c.	Median (95% CI)	4.61 (3.82-5.55)	
<i>Montivipera raddei</i>	i.v.	Median (95% CI)	0.19 (0.19-0.2)	(Archundia et al., 2011)
	i.p.	Range	1.63-2.05	(Fathi et al., 2022)
	i.v.	Median (95% CI)	0.2 (0.16-0.23)	(Garcia-Arredondo et al., 2019)
	i.v.	Mean ± SD	0.46 ± 0.03	(Kurtovic et al., 2014)
	i.v.	Mean ± SD	0.36 ± 0.05	(Latifi, 1984)
<i>Naja oxiana</i>	i.v.	Median	0.56	(Kazemi-Lomedasht et al., 2019)
	i.v.	Mean ± SD	0.42 ± 0.05	(Latifi, 1984)
	i.v.	Median	0.49	(Latifi & Tabatabai, 1989)
	s.c.	Median	0.45	(Minton, 1967)
<i>Pseudocerastes fieldi</i>	i.v.	Median	0.25	(Batzri-Izraeli & Bdolah, 1982)
	i.v.	Median	1.06	(Elfiky et al., 2022)
	i.p.	Median	1.0	(Gitter et al., 1962)
<i>Pseudocerastes persicus</i>	i.v.	Mean ± SD	0.81 ± 0.14	(Latifi, 1984)
	i.v.	Median	1.1	(Madani et al., 2018)
<i>Vipera ammodytes transcaucasiana</i>	i.v.	Median (95% CI)	0.4 (0.35-0.31)	(Garcia-Arredondo et al., 2019)
<i>Vipera eriwanensis</i>	i.v.	Mean ± SD	1.09 ± 0.03	(Latifi, 1984)
<i>Walterinnesia morgani</i>	i.p.	Median (95% CI)	0.66 (0.13-3.37)	(Calvete et al., 2021)
Pooled venom ( <i>N. oxiana</i> , <i>C. gasperettii</i> , <i>E. c sochureki</i> , <i>M. l. obtusa</i> , <i>G. caucasicus</i> , and <i>M. raddei</i> )*	i.p.	Median	0.57	(Kadkhodazadeh et al., 2020)

\* The six common snakes of medical importance in Iran

**Abbreviations:** i.p. = intraperitoneal, i.v. = intravenous, s.c. = subcutaneous, LD50 = 50% lethal dose

421 The LD<sub>50</sub> values summarized in **Table 1**, indicate that some Hydrophiini have the most potent  
422 venoms among Iranian venomous snakes. *H. schistosus* has the most lethal venom, followed  
423 closely by *H. platurus*, *H. curtus* and *H. cyanocinctus*. Among Iranian terrestrial species, *M. raddei*  
424 has the most lethal venom, closely followed by *M. latifii* and *E. c. sochureki*.

425 **3.2.1. Colubridae and Lamprophiidae:** Despite advances in 'omics' profiling of venoms, the  
426 venoms of non-front-fanged snakes remain largely unexplored (Modahl et al., 2016). However, a  
427 combination of transcriptomic, proteomic and genomic studies has revealed that some non-  
428 front-fanged snake venoms contain many protein families similar to those found in Viperidae and  
429 Elapidae, such as three-finger toxins (3FTxs), snake venom metalloproteinases (SVMPs),  
430 phospholipases A<sub>2</sub> (PLA<sub>2</sub>), serine proteases, hyaluronidases, L-amino acid oxidases (LAOs), C-type  
431 lectins (CTLs) and Cysteine-Rich Secretory Proteins (CRiSPs) (Junqueira-de-Azevedo et al., 2016;  
432 Modahl et al., 2016). These venoms are highly toxic to diapsid (birds and reptiles) prey, but are  
433 usually less potent and typically produce weaker, negligible, or no neurotoxic effects in mammals  
434 (Dashevsky et al., 2018). Clinically, bites by most non-front-fanged species pose lower risks to  
435 humans compared with vipers and elapids, as discussed earlier.

436 Iranian non-front-fanged snake genera, whose venoms are rich in 3FTxs, include *Boiga* and  
437 *Psammophis* (Modahl & Mackessy, 2019; Sunagar et al., 2013). *Platyceps rhodorachis* venom is  
438 also rich in 3FTxs, as analyzed with liquid chromatography and mass spectrometry (Fry et al.,  
439 2003). Likewise, *Telescopus* species venoms contain 3FTx (such as denmotoxin and irditoxin) but  
440 in lower yields (Dashevsky et al., 2018; Junqueira-de-Azevedo et al., 2016; Lumsden et al., 2004;  
441 Modahl & Mackessy, 2019). *Hemorrhhis* species venoms may contain anticoagulant toxins (Ana  
442 Maria, 2021) and venoms of some *Boiga* species such as *B. irregularis* contain serine proteases,  
443 with known fibrinolytic activity (Mackessy, 2002). Venoms of *Malpolon* species are  
444 potentially dangerous because of their pro-hemorrhagic fraction (intravenous LD<sub>50</sub> = 1 mg/kg),  
445 but coagulopathy has never been reported in human victims (Rosenberg et al., 1992).

446 **3.2.2. Elapidae and Viperidae:** Venoms of Iranian elapids are usually rich in 3FTxs, whereas those  
447 of Iranian vipers are usually rich in SVMPs (Ghezellou et al., 2021; Modahl et al., 2016; Mohebbi  
448 et al., 2016; Monzavi et al., 2019a). The composition, and pharmacological and  
449 pathophysiological properties of venoms of some species are described as follows:

450 ***Bungarus sp.:*** There is no published report of *B. persicus* venom or clinical effects of envenoming.  
451 However, the venoms of closely-related species such as *B. sindanus* and *B. caeruleus*, which are  
452 notorious for their neurotoxic effects, are rich in 3FTxs (including  $\alpha$ -bungarotoxin) and PLA<sub>2</sub>s  
453 (including  $\beta$ -bungarotoxins) and also contain SVMPs, LAOs, acetylcholinesterase, CRiSPs and  
454 Kunitz-type serine protease inhibitors (Oh et al., 2019; Patra et al., 2019; Sunagar et al., 2021).

455 ***Cerastes gasperettii:*** The major components of *C. gasperettii* venom are SVMPs, serine  
456 proteases, PLA<sub>2</sub>, CTLs, disintegrins, CRiSPs, and LAOs (Al-Sadoon et al., 2016; Zaeri et al., 2021a).

457 In mice, the venom can cause severe hepatic inflammation and necrosis, glomerular  
458 degeneration and coagulative necrosis of the kidney, lung congestion, testicular tissue  
459 degeneration, myonecrosis, hemodynamic disturbances (reduction in mean arterial pressure  
460 and bradycardia), and hemorrhage (Al-Sadoon et al., 2013a; Al-Sadoon et al., 2013b; Al-Sadoon  
461 et al., 2014; Al-Sadoon et al., 2016; Bassam, 1995; Zaeri et al., 2021a).

462 ***Echis carinatus sochureki***: Its venom is rich in SVMPs, and also contains serine proteases, PLA<sub>2</sub>s,  
463 LAOs, CTLs, disintegrins, CRiSPs, hyaluronidase, and growth factors (Casewell et al., 2009). The  
464 venom possesses pro-coagulant properties such as prothrombin activation (Babaie et al.,  
465 2013a; Mehdizadeh Kashani et al., 2012; Nasri Nasrabadi et al., 2022; Salmanizadeh et al.,  
466 2013), and anticoagulant activities (Amrollahi Byoki & Zare Mirakabadi, 2013; Babaie et al.,  
467 2013b; Ghezellou et al., 2021; Latifi & Tabatabai, 1989; Mehdizadeh Kashani et al., 2012; Nasri  
468 Nasrabadi et al., 2022), such as fibrinogenolytic (Kamyab et al., 2017) and anti-platelet effects  
469 (Babaie et al., 2013b; Mehdizadeh Kashani et al., 2012). Animal and *in vitro* experiments  
470 revealed that the venom can also induce hemodynamic instability, acute tubular necrosis,  
471 interstitial pulmonary inflammation, neurotoxicity and myotoxicity (Barfaraz & Harvey, 1994;  
472 Harvey et al., 1994; Zaeri et al., 2021b). In addition, it has *in vitro* cytotoxic effects (Balali  
473 Bahadorani & Zare Mirakabadi, 2016; Zare Mirakabadi & Horrieh, 2020).

474 ***Eristicophis macmahonii***: Venom of a specimen from Nushki, Baluchistan in Pakistan, consisted  
475 of SVMPs, kallikrein serine proteases, LAOs and PLA<sub>2</sub>, disintegrins, lectins, CRiSPs and vascular  
476 endothelial growth factor (VEGF) (Ali et al., 2015). The venom inhibits platelet aggregation and  
477 causes edema in mice (Ali et al., 1999b). Its venom is also procoagulant (Op den Brouw et al.,  
478 2021a), fibrinogenolytic (Op den Brouw et al., 2021b), and has anti-cancer activities (Op den  
479 Brouw et al., 2021a; Op den Brouw et al., 2021b).

480 ***Gloydus caucasicus***: Its venom has pro-hemorrhagic, necrotizing, and edematogenic activities,  
481 and contains a non-protease anticoagulant factor (Ghorbanpur et al., 2010), and pro-coagulant  
482 effects (Rasoulinasab et al., 2020), attributable to a serine protease (Ghorbanpur et al., 2009). *In*  
483 *vitro*, the venom has shown anti-cancer effects on colon cancer cells (Salmanzadeh Zehkesh &  
484 Mohammadpour Donighi, 2021)

485 ***Hydrophis spp.***: The venoms of Iranian *Hydrophis* are rich in 3FTxs (> 50%), and neuromyotoxic  
486 PLA<sub>2</sub>s, explaining their lethal potency. Other components include SVMPs, LAOs and CRiSPs in  
487 very low quantities. (Calvete et al., 2012; Mohebbi et al., 2016). Venoms are powerfully anti-  
488 bacterial *in vitro* (Abtahi et al., 2014).

489 ***Macrovipera lebetina***: Venom of both *M. l. obtusa* and *M. l. cernovi* contain enzymes, such as  
490 PLA<sub>2</sub> and hyaluronidase, explaining local tissue damage, and pro-coagulant factor V and X  
491 activators (Amoozegari et al., 2016; Amoozegari et al., 2013; Ghezellou et al., 2022; Igci &  
492 Demiralp, 2012; Sanz et al., 2008; Shanaki Bavarsad et al., 2009), linked to coagulopathy.

493 Experimental evidence showed a PLA<sub>2</sub> vasodilator component responsible for hemodynamic  
494 instability and circulatory failure (Fatehi-Hassanabad & Fatehi, 2004). Proteomic studies  
495 revealed a serine protease that can lead to coagulopathy and platelet aggregation (i.e., a  
496 unique short disintegrin known as obtustatin, dimeric disintegrin, CTLs and LAO), and Zn<sup>2+</sup>-  
497 SVMs that can damage the vascular endothelium (Amoozgari et al., 2020; Bazaa et al., 2005;  
498 Ghezellou et al., 2022; Hamza et al., 2010; Pla et al., 2020; Sanz et al., 2008). The venom also  
499 contains large amounts of bradykinin-potentiating peptides (BPPs), C-type natriuretic peptides  
500 (C-NAP) and possibly nitric oxide or nitric oxide-like compounds contributing to hypotensive  
501 effects (Bazaa et al., 2005; Fatehi-Hassanabad & Fatehi, 2004; Pla et al., 2020; Sanz et al., 2008),  
502 and VEGF-like molecules (svVEGF) that cause increased capillary permeability (Bazaa et al.,  
503 2005). The venom has shown *in vitro* fibrinolytic activity (Amoozgari et al., 2020; Hamza et al.,  
504 2010), cytotoxicity (Esmaili Jahromi et al., 2016; Kakanj et al., 2015; Oghalaie et al., 2017), and  
505 considerable affinity to mimic epitopes of human alpha 1 neuronal nicotinic acetylcholine  
506 receptors (Chowdhury et al., 2022), and in animal models has caused cardiovascular collapse  
507 and neuromuscular blockade (Fatehi-Hassanabad & Fatehi, 2004).

508 ***Montivipera latifii***: Its venom contains a pro-coagulant serine protease isoform (Taherian et al.,  
509 2016), and can cause pro-hemorrhagic and necrotizing effects (Weinstein & Minton, 1984). It  
510 can damage the lipid bilayer of erythrocyte membrane causing hemolysis (Ghulikyan et al.,  
511 2016; Kirakosyan et al., 2016). It also has anti-cancer and anti-bacterial effects *in vitro*  
512 (Moridikia et al., 2018).

513 ***Montivipera raddei***: Proteomics of Armenian *M. raddei* venom revealed toxins similar to those  
514 of *M. l. obtusa* venom, such as dimeric disintegrin, CRiSPs, PLA<sub>2</sub>, serine protease, CTL, LAO,  
515 svVEGF, Zn<sup>2+</sup>-dependent SVMs, BPPs and C-NAP (Sanz et al., 2008). An isoform of the serine  
516 protease has shown to possess procoagulant activity (Taherian et al., 2016). The venom also  
517 contains an anti-coagulant Kunitz-type serine protease inhibitor (Sanz et al., 2008). Anti-  
518 proliferative and cytotoxic effects of the venom have been observed *in vitro* (Amirian et al.,  
519 2022; Malekara et al., 2020).

520 ***Montivipera wagneri***: Its venom is potently anticoagulant by inhibiting factor Xa (Chowdhury et  
521 al., 2021) and has anti-cancer properties *in vitro* (Nalbantsoy et al., 2016).

522 ***Naja oxiana***: Its venom contains post-synaptic 3FTxs, such as a long neurotoxin (Nasiripour et  
523 al., 2008; Samianifard et al., 2021; Talebzadeh-Farooji et al., 2004), cardiotoxins (Angaji et al.,  
524 2016; Gasanov et al., 2015), and cytotoxins that can cause local tissue inflammation, necrosis,  
525 hemolysis and inhibition of platelet aggregation (Derakhshani et al., 2020; Esmaili et al., 2021;  
526 Gasanov et al., 2014; Gasanov et al., 2015). Coagulopathic properties of *N. oxiana* venom  
527 (Mitel'man, 1966), have never been detected clinically. The venom also exhibits anti-plasmodial  
528 (Hajjaliani et al., 2020), anti-leishmanial (Fallahi et al., 2020; Sharifi et al., 2021), anti-bacterial

529 (Talebi Mehrdar, 2020; Talebi Mehrdar et al., 2017), anti-rabies (Farzad et al., 2020), and anti-  
 530 cancer activities (Barati & Davoudi, 2017; Derakhshani et al., 2020; Ebrahim et al., 2015;  
 531 Ebrahim et al., 2016; Javani Jouni et al., 2022; Sinaei et al., 2022).

532 ***Pseudocerastes fieldi***: Its venom is unusual in lacking the metalloproteinase hemorrhagin,  
 533 procoagulant and LAO activities that are typical of most Viperidae, but it possesses CRiSPs, serine  
 534 proteases, Kunitz peptide, lectin, VEGF, and a heterodimeric PLA<sub>2</sub> complex with pre-synaptic  
 535 neurotoxic activity in experimental models (Ali et al., 2015; Bdolah, 1986; Francis et al., 1995;  
 536 Gitter et al., 1962; Op den Brouw et al., 2021a; Op den Brouw et al., 2021b; Tsai et al., 1983).  
 537 Some venom fractions can inhibit platelet aggregation, and have fibrinogenolytic and hemolytic  
 538 activities (Batzri-Izraeli & Bdolah, 1982; Mehdizadeh Kashani et al., 2012; Op den Brouw et al.,  
 539 2021b).

540 ***Pseudocerastes persicus***: Its venom contains SVMPs, kallikrein and CRiSPs, acidic and basic PLA<sub>2</sub>  
 541 enzymes, lectin toxins, VEGF, nerve growth factor (Ali et al., 2015; Op den Brouw et al., 2021b),  
 542 a natriuretic peptide (Amininasab et al., 2004; Elmi et al., 2006) and Kunitz-type proteins  
 543 (Banijamali et al., 2019; Op den Brouw et al., 2021b). Unlike *P. fieldi* venom, the venom of *P.*  
 544 *persicus* has prohemorrhagic and LAO activities (Bdolah, 1986). The venom also has  
 545 fibrinogenolytic, cytotoxic, antibacterial and anti-cancer effects (Ghezellou et al., 2021;  
 546 Nodooshan et al., 2021; Op den Brouw et al., 2021b; Shahbazi et al., 2019; Zargan et al., 2022).

547 ***Pseudocerastes urarachnoides***: Its venom contains SVMPs, serine proteases, LAOs, PLA<sub>2</sub> and  
 548 lectin isoforms, and causes strong procoagulant, fibrinogenolytic and cytotoxic effects (Op den  
 549 Brouw et al., 2021a; Op den Brouw et al., 2021b). The procoagulant activity of the venom is  
 550 attributed to prothrombin and factor X activation (Op den Brouw et al., 2021a).

551 ***Vipera ammodytes transcaucasiana***: Its venom contains PLA<sub>2</sub>s (including a potentially-  
 552 neurotoxic Vipoxin homologue), SVMPs, serine proteases, LAOs, CRiSPs, CTLs, VEGF, a disintegrin  
 553 and a phosphodiesterase (Hempel et al., 2018). The venom has shown anticoagulant (Chowdhury  
 554 et al., 2021), cytotoxic and anti-cancer activities (Celen et al., 2018).

555 ***Walterinnesia morgani***: No studies of Iranian *W. morgani* venom have been published, but, the  
 556 composition of venom from a Turkish specimen has been characterized using mass  
 557 spectrometry (Calvete et al., 2021). It consists of 3FTxs, PLA<sub>2</sub>s, CRiSPs, and Kunitz-type serine  
 558 proteinase inhibitor, with a low content of class PIII SVMPs, LAO, endonuclease,  
 559 phosphodiesterase, VEGF and acetylcholinesterase (Calvete et al., 2021). A procoagulant factor  
 560 X activator (probably a serine protease) has been identified in the venom of the closely-related  
 561 *W. aegyptia* (Khan & Al-Saleh, 2015).

### 562 3.3. Snakebites in Iran

#### 563 3.3.1. Epidemiology

564 According to available statistics released from the Iranian Ministry of Health (2002-2011)  
565 (Dehghani et al., 2014a; Dehghani et al., 2014b), there are 5,000-7,000 snakebite  
566 envenomings/year or 6.3-8.8/100,000 population/year, which falls within the very wide WHO  
567 guesstimates of 210-11,079/year or 0.3-47.2/100,000/year in Iran (Kasturiratne et al., 2008).  
568 Snakebite in Iran results in 3-12 snakebite deaths/year or 0.003-0.01 snakebite deaths/100,000  
569 population/year, compared to WHO estimates of 6-13.2 snakebite deaths/year, or 0.01-  
570 0.02/100,000/year (Dehghani et al., 2014a; Dehghani et al., 2014b; Kasturiratne et al., 2008;  
571 Monzavi et al., 2014). These estimates for Iran are lower than worldwide estimated average  
572 incidences of 25.7-40 snakebite envenomings/100,000 population/year; and 1.2-2 snakebite  
573 deaths/100,000 population/year (Gutierrez et al., 2017), which is surprising considering the  
574 country's extensive desert and rural areas, and possessing a rich and diverse venomous snake  
575 fauna. A low mortality might be explained by the high priority accorded to snakebite as a  
576 toxicological emergency and the access to toxicology trained physicians in the Iranian healthcare  
577 system, together with the provision of antivenom, as part of an essential pharmaceutical  
578 stockpile (IFDA, 2021), even in remote and less developed areas of the country. Urbanization may  
579 have reduced the number of snakebite encounters (rural areas are inhabited by < 25% of total  
580 population). However, under-reporting might be concealing the real magnitude of the snakebite  
581 problem in Iran. In India, for example, a well-designed community-based survey revealed 25-fold  
582 higher snakebite mortalities than a government figure based on returns from health facilities  
583 (Suraweera et al., 2020). In Iran, the problem of under-reporting may be partly addressed by the  
584 introduction of a standardized national minimum dataset registry for poisoning (Banaye  
585 Yazdipour et al., 2020).

586 Hospital-based epidemiological studies have shown that only approximately 0.5-1% of acute  
587 poisoning cases admitted to emergency departments of tertiary hospitals in Iran are due to  
588 snakebites (Afshari et al., 2004; Alavi & Alavi, 2008; Rasouli et al., 2011; Shadnia et al., 2007).  
589 Using species-distribution models and considering the habitat preferences of the 4 most common  
590 medically-important venomous snakes, the northeast of Iran was predicted to have the highest  
591 snakebite risk (Yousefi et al., 2020). However, most snakebites are reported from the middle and  
592 southern provinces of Iran (Alavi & Alavi, 2008; Alinejad et al., 2017; Dehghani et al., 2014a;  
593 Dehghani et al., 2014b; Hafezi et al., 2018; Jalali et al., 2012; Kassiri et al., 2019; Sagheb et al.,  
594 2011b; Soleimani et al., 2021), partly because of their warmer climate (Ebrahimi et al., 2018),  
595 which affords more favorable snake thermoregulation and that prolongs the snakes' active  
596 seasons. In Iran, most snakebites occur during the warm months of the year, when outdoor  
597 agricultural and leisure activities increase (Dehghani et al., 2022; Khosravani et al., 2018; Monzavi  
598 et al., 2019b; Oghabian et al., 2022). More than 70% of snakebites occur in rural areas of Iran  
599 (Dehghani et al., 2014b; Dehghani et al., 2014c; Dehghani et al., 2016c; Ebrahimi et al., 2018;  
600 Eslamian et al., 2016; Monzavi et al., 2019b; Moradiasl et al., 2018; Nejadrahim et al., 2019), and,  
601 as in other parts of the world, young adult men are most commonly affected (Dadpour et al.,



602 2012; Dehghani et al., 2014a; Dehghani et al., 2014b; Ebrahimi et al., 2018; Eslamian et al., 2016;  
603 Farzaneh et al., 2017; Khadem-Rezaiyan et al., 2018; Monzavi et al., 2019b; Nejadrahim et al.,  
604 2019; Oghabian et al., 2022; Soleimani et al., 2021). The economic burden caused by snakebite  
605 has been estimated to be less than 0.001% of the Iran's gross domestic product (Mashhadi et al.,  
606 2017; Patikorn et al., 2022).

### 607 **3.3.2. Clinical features of snakebite**

608 Many clinico-epidemiological studies of snakebite have been reported from Iran, nonetheless,  
609 in very few of them the species of snake responsible was reported. As a result, clinical  
610 envenoming syndromes attributed to Iranian snakes, have not been verified in most cases. One  
611 reason might be polyvalent antivenoms produced by Razi Vaccine and Serum Research  
612 Institute, and Padra Serum Alborz company, both covering the common local species of  
613 greatest medical importance and being available in tertiary referral hospitals throughout the  
614 country (Abouyannis et al., 2021; Dehghani et al., 2014a; Dehghani et al., 2014b; Monzavi et al.,  
615 2014), have made species diagnosis less important. Another reason is that the species of snake  
616 responsible is not among the essential data that should be recorded in the medical forms of  
617 snakebite patients in Iran. To identify the species of snake responsible, immunodiagnostic  
618 methods can be used, but only in Australia snake venom diagnostic/detection kits (SVDK/VDK)  
619 are commercially available for clinical use despite some problems in interpreting their results  
620 (Dhananjaya et al., 2015; Johnston et al., 2017). Elsewhere, confirmation of species identity  
621 relies on competent identification of the snake brought with the patient, or of photographs  
622 captured at the scene of the bite. Alternatively, its identity might be inferred from by observing  
623 the evolving clinical signs of envenoming, using a syndromic algorithm (Bawaskar & Bawaskar,  
624 2019; Monzavi et al., 2014). However, for optimal medical management of an envenomed  
625 snakebite patient, it is important to know which species was responsible, so that likely  
626 complications can be anticipated, prevented or managed. There are, however, a few clinical  
627 reports from Iran based on expertly identified snakes (Dadpour et al., 2012; Hassanian-  
628 Moghaddam et al., 2022; Kazemi et al., 2021c; Kazemi et al., 2023b; Monzavi et al., 2019a;  
629 Monzavi et al., 2019b; Monzavi et al., 2015). This information has been augmented by  
630 published accounts of snake envenoming in other countries caused by the same species  
631 occurring in Iran (see below).

#### 632 **3.3.2.1. Dry bites**

633 Bites by venomous snakes, with evidence that fangs have pierced the skin, do not always result  
634 in envenoming. An average of at least 20% of venomous snake strikes (globally and in Iran) fail to  
635 cause local or systemic envenoming (i.e., no systemic effects with no or very limited local effects),  
636 so called "dry bites" (Afshari & Monzavi, 2016b; Gold et al., 2002; Lavonas et al., 2011; Mehta &  
637 Sashindran, 2002; Monzavi et al., 2019b; Monzavi et al., 2015; Naik, 2017; Riley et al., 2011). The

638 highest rate of dry bites by venomous snakes, up to 80%, has been reported following some  
639 Oceanian Elapidae and sea-snake strikes (Naik, 2017). Bites by mildly-venomous non-front-  
640 fanged snakes, due to position of fangs and lack of a high-pressure venom delivery apparatus,  
641 more often result in dry bites, as reported in studies from central and northeast Iran (Dehghani  
642 et al., 2014c; Monzavi et al., 2019b). Only 1-20% of bites by colubrids result in envenoming  
643 (Minton, 1990). Dry bites may be wrongly inferred, if victims failed to see the animal involved, or  
644 mistook a non-venomous snake or snake-like animal, such as a legless lizard for a venomous  
645 snake (Bazi et al., 2019), or suffered a painful penetrating injury from thorns, splinters, or other  
646 sharp objects. Since there is usually a delay between the bite and appearance of signs and  
647 symptoms of envenoming, "dry bites" should not be diagnosed too hastily. Following viper and  
648 cobra bites, local pain and swelling usually appear within 1-2 hours, but systemic effects of viper  
649 envenoming may be delayed for some hours. Bites by kraits and sea-snakes may not cause local  
650 envenoming, and systemic envenoming may not become evident until 12 hours or more after  
651 the bite (Gold et al., 2002; Monzavi et al., 2014; Riley et al., 2011). The initial absence of  
652 symptoms in an apparently-well patient can be deceptive, persuading clinicians to discharge the  
653 patient prematurely. A wise precaution is a statutory observation period of 24 hours for all  
654 suspected snakebite patients.

### 655 **3.3.2.2. Clinical effects of envenoming (Clinical syndromes)**

656 In the acute phase following a venomous snakebite, there are sets of clinical manifestations,  
657 "envenoming syndromes", that may suggest a genus or species diagnosis (Ariaratnam et al., 2009;  
658 Blaylock, 2014; Warrell, 2016). **Table 2** summarizes the common local and systemic effects of  
659 snakebite envenoming in Iran. Most bites by venomous snakes and a few by mildly-venomous  
660 non-front-fanged snakes cause local effects, while some elapids, particularly kraits and sea-  
661 snakes, may cause minimal or no local effects during the early hours after the bite (Mehta &  
662 Sashindran, 2002; Monzavi et al., 2014; Riley et al., 2011). Local and systemic effects and their  
663 severity differ depending on the species responsible, the amount of venom injected, and its  
664 depth of injection, and the composition of the venom (Lavonas et al., 2011; Monzavi et al., 2014;  
665 Riley et al., 2011). Punctures made by paired fangs or teeth may be visible at the bite site,  
666 suggesting snakebite, but bites by rodents, fish, large spiders, lizards or inanimate sharp objects  
667 such as thorns and splinters, as well as incisions made intentionally at the bite site may cause  
668 confusion (Bazi et al., 2019; Lavonas et al., 2011; Mehta & Sashindran, 2002; Monzavi et al., 2014;  
669 Riley et al., 2011; Zamani et al., 2016).

670 Systemic effects of Viperidae envenoming often include shock and hemostatic disturbances,  
671 while envenoming by Elapidae usually causes neurotoxic effects manifesting typically with  
672 descending flaccid paralysis (Afshari & Monzavi, 2016b; Dadpour et al., 2012; Isbister et al., 2013;  
673 Lavonas et al., 2011; Monzavi et al., 2014; Riley et al., 2011; Warrell, 2010; White, 2005), and in  
674 the case of *Hydrophiini* envenoming, generalized rhabdomyolysis (Mehta & Sashindran, 2002;

675 Nabipour, 2012; Nabipour et al., 2015). However, these descriptions cannot be generalized to all  
 676 snakebite cases in all regions. For example, envenoming by Oceanian (or Australasian) elapids,  
 677 some North American rattlesnakes, or European *V. a. ammodytes*, may induce both hemostatic  
 678 disturbances and neurotoxic effects (Di Nicola et al., 2021; Farstad et al., 1997; Isbister et al., 2013;  
 679 Karabuva et al., 2016; Logonder et al., 2008; Massey et al., 2012; White, 2005). Moreover,  
 680 presumption of clinical effects following bites by a species based on its venom components may  
 681 not be sensible. As for example, venom of *P. fieldi* contains potentially neurotoxic components (Ali  
 682 et al., 2015), but there are no clinical reports of neurotoxic human envenoming by this species.

<b>Table 2.</b> Common clinical features of snakebite envenoming in Iran		
<b>Venom effects</b>	<b>Description</b>	<b>Plausible offending snake – (sub)Family</b>
<b>Local</b>		
Fang marks	Presence of one or two puncture marks suggests a bite by a venomous snake	Venomous snakes*
Tooth marks <sup>¶</sup>	Numerous small shallow puncture wounds arranged in an arc	Non-venomous and mildly venomous snakes
Pain <sup>†</sup>	Burning, bursting or throbbing pain localized to the bite site and sometimes radiating up the limb	Venomous snakes especially Viperidae, mildly venomous snakes
Local lymphadenopathy/ lymphadenitis <sup>†</sup>	Painful, tender swelling of local lymph nodes draining the bite site	Venomous snakes
Local swelling <sup>†</sup>	Swelling around the bite site that may extend rapidly and involve the entire limb and/or areas of adjoining trunk	Venomous snakes especially Viperidae
Local cutaneous damage <sup>†</sup>	Erythema, local ecchymosis, blister/bulla formation and sometimes local necrosis may appear over hours to few days following the bite	Venomous snakes especially Viperidae
Local myonecrosis	Necrosis of local muscles adjacent to the bite site	Venomous snakes
Compartment syndrome	It is a potential, but in practice very rare, manifestation in envenomed tissue that is contained in a tight fascial compartment including the pulp space of digits, anterior forearm or anterior tibia	Viperidae
<b>Systemic</b>		
Parasympathetic excitation	Uncontrollable vomiting, fasciculations, congested conjunctivae, gooseflesh, sweating, sialorrhea, lacrimation, respiratory tract secretions, cramping abdominal pain, diarrhea	Venomous snakes (especially Elapidae)
Neurotoxic effects <sup>#</sup>	Descending flaccid paralysis (starting with bilateral ptosis and external ophthalmoplegia with diplopia and blurred vision), bulbar palsy, respiratory paralysis (paralysis of intercostal muscles and diaphragm), fasciculations, limb paralysis	Elapidae
Myotoxic effects <sup>§</sup>	Myalgia, myopathy, marked increase in serum creatine kinase, muscle stiffness, necrosis of muscle fibers, systemic rhabdomyolysis (occasionally), cardiac dysrhythmia, abnormal echocardiogram, trismus, myoglobinuria, generalized trunk pain	Elapidae (particularly sea-snakes)
Vasculotoxic and hemotoxic effects <sup>#</sup>	Spontaneous bleeding, thrombocytopenia, coagulopathy (consumption coagulopathy), microangiopathic hemolysis/thrombotic microangiopathy (schistocytes), local or spontaneous systemic hemorrhage, diffuse cutaneous ecchymosis,	Viperidae

	gingival bleeding, epistaxis, hematemesis, melaena/blood in feces, hemoptysis, intracranial hemorrhage, hematuria, uterine bleeding	
Shock	Severe hypotension, hypovolemia, myocardial depression and elevated levels of troponins	Venomous snakes
<p>* Bites by mildly venomous snakes (e.g., Iranian colubrids) may also produce fang marks.</p> <p><sup>¶</sup> Some elapid bites may produce this pattern.</p> <p><sup>†</sup> Bites by elapids, especially kraits and sea-snakes, may be painless and without swelling or other local effects. Bites by mildly venomous snakes may produce erythema, blister formation, lymphadenopathy and limited local swelling without (or with limited) progression.</p> <p><sup>§</sup> Although rare, in bites by some vipers may also be seen.</p> <p><sup>#</sup> Bites by mildly venomous snakes very rarely may also produce neurotoxic effects and limited bleeding from the bite site.</p>		

### 683 3.3.2.3. Species-specific descriptions of snakebite envenoming

684 Species-specific descriptions of envenoming following bites by the medically important snakes of  
 685 Iran provided in this section are based on reports of cases, in which the snake responsible for the  
 686 bite was competently identified using the methods described above, either in Iran, in neighboring  
 687 countries or other countries inhabited by the species same as those occurring in Iran:

688 **Colubridae and Lamprophiidae:** Although the venoms of some colubrid and lamprophiid species  
 689 contain toxic components similar to those of vipers and elapids, bites by these non-front-fanged  
 690 species usually do not result in envenoming in humans. Reports of lethargy and respiratory  
 691 difficulty following these bites are unlikely to be neurotoxic in origin. In general, the bites of  
 692 opisthoglyphous species rarely cause systemic effects; and local effects such as swelling, pain,  
 693 blister formation, erythema/ecchymosis and bleeding from fang punctures are the most common  
 694 clinical features (Araujo et al., 2018; Dehghani et al., 2014c; Dehghani et al., 2012; Weinstein et  
 695 al., 2014). Systemic effects include cranial nerve palsy, coagulopathy and thrombocytopenia  
 696 (Brandehoff et al., 2019; Kuch & Mebs, 2002; Pommier & de Haro, 2007; Weinstein et al., 2023a).

697 Bites by *Boiga trigonata melanocephala* have not been reported, but in Sri Lanka, bites by the  
 698 closely-related *B. t. trigonata* caused no systemic nor significant local envenoming (Ariaratnam  
 699 et al., 2009). A case bitten by a large male *Hemorrhoids ravergeri* developed rapidly progressive  
 700 swelling, that spread from bitten fingers to involve the whole hand, 10-15 minutes after the  
 701 bite. There was also dizziness, and pain in axillary lymph nodes. Symptoms persisted for 3 days  
 702 (Darevsky, 1969). Mamonov reviewed Darevsky's case and another case reported by Ishunin  
 703 (Ishunin, 1950), in which there was profuse bleeding of the bite wound, pain, swelling and  
 704 bluish and reddish discoloration of the hand, which began to resolve 30 hours later, but it took  
 705 10 days to recover completely; and also reported a similar case of his own (Mamonov, 1977).  
 706 Pain, transient bleeding and edema quickly spreading from the bite site to affect entire limb  
 707 (10-15 min after bite) were also reported by Kazemi et al. in three cases of bites by *H. ravergeri*  
 708 and *H. nummifer* in central and western Iran (Kazemi et al., 2023a). Kocourek reported pain and  
 709 local swelling in the arm (Kocourek, 1990), and Schweiger reported burning sensation, severe

710 local swelling in the hand, and severe bleeding from puncture marks after bites by *H. ravergeri*  
711 (Schweiger, 1991), the symptoms of both cases resolved a day later. A bite by *H. nummifer*  
712 produced similar symptoms (Weinstein et al., 2023b). Branch reported only mild symptoms  
713 from a bite by *P. rhodorachis* from Saudi Arabia (Branch, 1982), less severe than those of a bite  
714 by this species in Israel, which caused immediate erythema, lymphangitis, swelling and  
715 numbness of the bitten hand, and generalized irritation (Perry, 1988). In southern Saudi Arabia,  
716 Malik described five confirmed bites by *P. rhodorachis*, all of which produced local pain and  
717 tenderness, with local swelling and redness in three, elevated serum creatine kinase in two,  
718 and blistering with lymphadenitis, and leukocytosis in one (Malik, 1995). An anecdotal report of  
719 "moderate systemic paralysis of the skeletal muscles and breathing difficulty following *P.*  
720 *rhodorachis* bite, which resolved spontaneously after 7 hours" (Fry et al., 2003), is discounted as  
721 being medically unsubstantiated. Multiple bites by a presumed *P. najadum* in Greece, initially  
722 caused local swelling, diffuse myalgia, and axial muscle stiffness, which progressed to areflexic  
723 quadriplegia 3 months after the bite. The patient died from a progressive segmental  
724 neuropathy about 6 months after the incident (Chroni et al., 2005). The authors suggested that  
725 auto-immune damage to neural antigens provoked by *P. najadum* venom toxins might have  
726 been responsible, but causation was not confirmed (Weinstein et al., 2023a). In Nakhchivan  
727 Autonomous Republic, Azerbaijan, a 35-year-old farmer was bitten on his index finger by a  
728 *Telescopus fallax iberus*, and shortly afterwards, developed hypotension, a hemorrhagic blister  
729 on the bitten finger, and pain and swelling extending to the dorsum of the hand. These  
730 symptoms resolved after 3 days (Sultanov, 1966). No bites by *T. rhinopoma*, *T. nigriceps*, or *T.*  
731 *tessellatus* have been reported so far.

732 A bite by Moila's Snake (*Malpolon moilensis*) caused only local swelling and numbness of the  
733 bitten digit (Perry, 1988), while bites by the Eastern Montpellier Snake (*M. insignitus*) are said to  
734 have caused only local symptoms such as swelling, paresthesia, stiffness of the affected limb and  
735 lymphangitis, which resolved within 48 hours (Jimenez-Cazalla, 2012). Similarly, a bite by *M.*  
736 *insignitus* was reported from central Iran causing only mild local symptoms (Dehghani et al.,  
737 2014c). In France, a bite by the closely-related Montpellier Snake (*Malpolon monspessulanus*)  
738 caused self-limiting local effects, but some hours later, the patient developed blurred vision,  
739 nystagmus, partial oculomotor paralysis with ptosis and complete paralysis of accommodation.  
740 These neurological symptoms took 6 days to resolve completely (Pommier & de Haro, 2007).  
741 Among 60 reported cases of *M. monspessulanus* bites in Spain, most (50 cases, 83%) were  
742 asymptomatic, while nine had local envenoming, and only one developed neurologic symptoms  
743 (ptosis, dysphagia, mild dyspnea, difficulty in speaking and loss of reflexes and paresthesia in the  
744 bitten limb) in addition to severe swelling. Laboratory tests were normal (Gonzales, 1978). A bite  
745 by the Schokari Sand Racer, *Psammophis schokari*, was reported from central Iran (Dehghani et  
746 al., 2014c), with only local erythema. In Oman, a bite by *P. schokari* caused mild local swelling,  
747 erythema, and pruritus of the bitten finger followed by protracted morbidity (Ineich et al., 2020).

748 A review of other *Psammophis* bites suggested nothing more than mechanical injury by teeth and  
749 fangs (Ineich et al., 2020). No bites by *P. lineolatus* have been reported so far.

750 ***Bungarus persicus***: No bite by the Persian krait (*Bungarus persicus*) has yet been reported.  
751 However, in the northern region of Sarbaz, in Iran's Sistan and Baluchistan province, where this  
752 species was discovered, it is well known locally under the name "Siah Mar" (black snake) and it is  
753 greatly feared (Abtin et al., 2014). There can be no doubt about the potential danger of  
754 envenoming. Features typical of bites by other *Bungarus* species, such as the closely-related  
755 Sindh krait (*B. sindanus*) and common krait (*B. caeruleus*), include the risk of painless nocturnal  
756 bites inflicted on people sleeping on the ground, minimal or absent symptoms of local  
757 envenoming, and evolution of abdominal pain, myalgia, autonomic disturbances and descending  
758 paralysis, sometimes after a delay of several hours (Kularatne, 2002; Pillai et al., 2012; Theakston  
759 et al., 1990).

760 ***Cerastes gasperettii***: While there is no report from Iran, a bite by a *Cerastes* in Qatar caused  
761 progressive local swelling, consumptive coagulopathy, and cardiotoxic effects (right bundle  
762 branch block, bradycardia, chest pain, electrocardiographic ST segment abnormalities, with  
763 cardiac troponin elevation) (Razok et al., 2020). However, the authors' attribution to *C. cerastes*  
764 (Razok et al., 2020), is impossible on geographical grounds and the snake must have been *C.*  
765 *gasperettii*. In two patients bitten by imported specimens of the closely-related *C. cerastes* in  
766 Europe, there were extensive swelling and life-threatening systemic envenoming, characterized  
767 by systemic hemorrhage, coagulopathy, increased fibrinolysis, thrombocytopenia, micro-  
768 angiopathic hemolytic anemia and acute kidney injury (AKI) (Schneemann et al., 2004).

769 ***Echis carinatus sochureki***: In a series of confirmed cases of bites by this species in northeast Iran,  
770 extensive local edema (55.6%), ecchymoses (48.1%), elevated serum creatine kinase (44.4%),  
771 coagulopathy (40.7%), thrombocytopenia (33.3%), lymphadenopathy (29.6%), nausea/vomiting  
772 (25.9%), blister formation (11.1%), and local necrosis (25.9%) were documented (Monzavi et al.,  
773 2019b). There have also been reports of local and systemic bleeding (epistaxis and gingival  
774 bleeding) (Monzavi et al., 2019a; Monzavi et al., 2019b) (Fig. 5). AKI has been reported in a case  
775 in southern Iran (Sagheb et al., 2011a). *E. c. sochureki* venom contains procoagulants, platelet-  
776 activating toxins, and hemorrhagins that are responsible for consumption coagulopathy,  
777 thrombocytopenia, vascular endothelial damage and microangiopathic hemolysis leading to local  
778 and occasionally serious systemic bleeding (Afshari & Monzavi, 2016b; Babaie et al., 2013a;  
779 Balali-Mood & Shariat, 1999; Monzavi et al., 2019b; Salmanzadeh et al., 2013; Warrell, 1995;  
780 Warrell, 2016). Outside Iran, among 117 proven cases of *E. c. sochureki* envenoming in Jammu,  
781 Northern India, all developed coagulopathy, 68% had evident bleeding and the rest had defective  
782 coagulation (Bhat, 1974). Hemorrhages were in the form of local bleeding from the bite wound,  
783 hematuria, hemoptysis, gingival bleeding, hematemesis, epistaxis, rectal and subarachnoid  
784 hemorrhage. Other symptoms included fever, vomiting, upper abdominal pain, leukocytosis,

785 blisters, regional lymphadenitis and shock (Bhat, 1974). In another report from the Thar Desert  
786 region of Rajasthan, India, all the victims developed coagulopathy, the majority had local swelling  
787 (92%), and vomiting (92%), two-thirds had local or systemic bleeding (i.e., from bite site,  
788 hematuria, hemoptysis, gingival bleeding, hematemesis, melena and intracranial hemorrhage),  
789 25% developed local blistering, and 16.7% necrosis (Kochar et al., 2007). Mortality rates in *E. c.*  
790 *sochureki* victims treated with antivenom have been very low (Bhat, 1974; Kochar et al., 2007;  
791 Monzavi et al., 2019b), but in untreated cases, fatalities are common and may be delayed for  
792 several days after the bite (Bhat, 1974; Minton, 1966).

793 ***Eristicophis macmahonii***: There has been no report of bites in Iran. Five cases were described  
794 from Baluchistan in Pakistan (Shaw, 1925). Two died several hours after the bite, having  
795 developed local swelling, abdominal pain and distension. One of them was weak and feverish,  
796 and complained of thirst, but was unable to swallow. She would not raise her eyelids, suggesting  
797 the possibility of neurotoxicity. The other victim developed marked local swelling, signs of  
798 bleeding, and died after becoming comatose. In two other cases, there was extensive local  
799 swelling which persisted for 3 days. Local ulceration developed in one of them (Shaw, 1925). In  
800 another report from western Asia, the life of a patient was seriously endangered after an  
801 *Eristicophis* bite in spite of treatment with antivenom (Mertens, 1965). In Belgium, a man  
802 previously envenomed by four other species, was bitten on one finger by his pet *E. macmahonii*,  
803 rapidly become nauseated, developed a rash, collapsed, and become transiently unconscious  
804 (Van den Enden & Bottieau, 2005). The affected limb became tender and swollen, with axillary  
805 lymphadenopathy and an ecchymosis. He felt weak and breathless with a dry mouth and bilateral  
806 eyelid swelling (angioedema). His symptoms resolved with corticosteroids and antihistamines  
807 suggesting anaphylaxis caused by hypersensitization by his previous envenomings. Laboratory  
808 investigations, including tests of blood coagulation, were normal and the only features directly  
809 attributable to envenoming were the local effects (Van den Enden & Bottieau, 2005). Two bites  
810 by pet *E. macmahonii* in Switzerland caused local swelling, and in one, minimal coagulopathy  
811 (Fuchs et al., 2022).

812 ***Gloydius caucasicus***: Envenoming can cause local swelling and necrosis (Latifi, 1991, 1985). Since  
813 the venom contains a procoagulant serine protease and anticoagulant factor (Ghorbanpur et al.,  
814 2010; Ghorbanpur et al., 2009), bleeding and coagulopathy are to be expected. In Ýolöten in  
815 south-eastern Turkmenistan, a 5-year-old boy bitten by *G. caucasicus* bled from the bite wound  
816 on the foot. Swelling spread up to the shin, while severe anemia ( $2.9 \times 10^6$  red blood cells/mm<sup>3</sup>)  
817 and lymphocytosis emerged. He recovered and was discharged after 8 days of hospitalization  
818 despite highly irregular treatment with wound incision, application of a tourniquet and local  
819 novocain infiltration (Tushiev, 1963). In Germany, a snake-keeper who was bitten by a closely-  
820 related species, *Gloydius halys*, developed incoagulable blood, afibrinogenaemia, elevated  
821 plasma fibrin(ogen) degradation products, thrombocytopenia and mildly reduced plasminogen

822 concentrations within two hours after the bite. At the bite site, he developed serosanguineous  
823 blisters and necrosis requiring debridement. Hemorrhagic signs included oral mucosal bleeding  
824 and frank hematuria. He was given two doses of antivenom 9 and 16 hours after the bite. Blood  
825 clotting returned to normal within 48 hours (Meissner et al., 1989).

826 ***Hydrophis spp.***: No sea-snake bites have been reported from Iran or other Middle-Eastern  
827 countries, but symptoms produced by the same species that occur in Iranian waters have been  
828 described from other regions (Warrell, 2016; Warrell, 1994). Bites are usually painless with  
829 minimal or no local swelling. Early systemic symptoms include headache, a thick feeling of the  
830 tongue, thirst, sweating, and vomiting followed by neurotoxicity and generalized rhabdomyolysis  
831 in cases of envenoming by many species (Mehta & Sashindran, 2002; Nabipour, 2012; Warrell,  
832 2016; Warrell, 1994). Myotoxic symptoms include generalized muscle aching, stiffness, and  
833 tenderness that becomes noticeable 30 minutes to over 3 hours after the bite. Trismus is  
834 common, and passive stretching of the muscles is painful. Later, there is progressive flaccid  
835 paralysis starting with ptosis, as in other neurotoxic envenomings. The patient remains conscious  
836 until respiratory muscle paralysis results in respiratory failure. Myoglobinemia and myoglobinuria  
837 become evident 3-8 hours after the bite. Myoglobin and potassium released from damaged  
838 skeletal muscles may cause AKI, whereas hyperkalemia developing within 6 to 12 hours of the  
839 bite may precipitate diastolic cardiac arrest (Nabipour, 2012; Reid, 1961; Sitprija, 2006; Warrell,  
840 2016; Warrell, 1994).

841 ***Macrovipera lebetina***: Local pain and swelling, thirst, nausea, vomiting and sometimes  
842 diarrhea, are early symptoms of envenoming. Swelling may extend to involve the whole bitten  
843 limb, and trunk, with bruising, lymphangitic markings, regional lymphadenitis, and  
844 serosanguinous blistering that preceded necrosis (Balali-Mood & Shariat, 1999; Dadpour et al.,  
845 2012; Kazemi et al., 2021c; Monzavi et al., 2019b) (**Fig. 6**). Latifi illustrated extensive swelling,  
846 ecchymoses, and digital necrosis with residual deformity in two victims of bites by this species  
847 (Latifi, 1991, 1985). Consumption coagulopathy and thrombotic microangiopathy may develop  
848 in cases of more severe envenoming, making the victims susceptible to spontaneous local and  
849 systemic bleeding from mucous membranes, subconjunctival and retinal hemorrhages, and  
850 melena or blood in the feces (Dadpour et al., 2012; Monzavi et al., 2019a; Monzavi et al.,  
851 2019b). Anemia is associated with hemolysis and thrombocytopenia (Monzavi et al., 2019b),  
852 consistent with microangiopathic hemolysis, and there is neutrophilic leukocytosis. Delayed  
853 severe thrombocytopenia, poorly responsive to antivenom, may also occur (Abukamar et al.,  
854 2022). Body temperature may be elevated even in the absence of infection and large increases  
855 in serum creatine kinase levels (>1000 IU/L) suggest rhabdomyolysis (Monzavi et al., 2019b).  
856 AKI and oliguria may develop but this does not appear to be common. In cases of *M. lebetina*  
857 envenoming reported from Azerbaijan, Cyprus, Israel, India, Iraq and Jordan; trembling, rigors,  
858 dizziness, reduced consciousness, subarachnoid hemorrhage, massive ecchymoses,



859 hemodynamic instability progressing to shock with tachycardia and cold sweats were also  
860 noted (Abu Baker et al., 2022; Amr et al., 2020; Sultanov, 1983). The largest published  
861 experience of *M. l. obtusa* bites (1,122 cases between 2009 and 2020) is from Azerbaijan  
862 (Efendiev, 2021). This species is known locally as “gyurza”. In this report, the diagnosis was  
863 based on the clinical picture of envenoming and detection of venom in patients’ blood by  
864 spectrofluorimetry. Severe cases had local swelling and bruising, involving the entire bitten limb  
865 and beyond, especially when a tourniquet had been applied. Case-fatality was 1.9%,  
866 attributable to septicemia, consumption coagulopathy, shock, hepatic and renal toxicity, and  
867 hemolytic anemia. Various antivenoms were used, including Sanofi-Pasteur (probably  
868 “Favirept”, now discontinued) that proved the safest and most effective, polyvalent  
869 “Antigyurza, antiefa, anticobra” produced in Uzbekistan that caused many adverse reactions,  
870 and “Antigadyuka” from a Russian manufacturer that was wholly ineffective (Efendiev, 2021).  
871 The only report of *M. l. cernovi* envenoming is from Ýölöten in south-eastern Turkmenistan  
872 (Tushiev, 1963). A 33-year-old male snake catcher was admitted 3 days after the bite with  
873 severe weakness, persistent vomiting, severe radiating pain, swelling and bruising in the bitten  
874 limb, thirst, chest tightness, shortness of breath, weak pulse, fever (39°C) and leukocytosis  
875 (13,100 white blood cells/ $\mu$ l). He was treated with two doses of “antigyurza” antivenom, began  
876 to improve after the fifth day, and was discharged on the 15<sup>th</sup> day (Tushiev, 1963).

877 ***Montivipera latifii***: Bites are rare, as this snake is mainly restricted to a highly-protected  
878 national park in Iran. In the only report of a confirmed case of *M. latifii* envenoming, a teen-age  
879 girl who was bitten on her face, rapidly developed swelling of the head, neck and oropharynx  
880 (Hassanian-Moghaddam et al., 2022). Antivenom therapy was delayed, due to a misleading  
881 history of hymenoptera sting from the parents, and thus she developed acute upper airway  
882 obstruction, respiratory distress, hypoxia, loss of consciousness and cerebral edema. There was  
883 an extensive local ecchymosis, but no evidence of coagulopathy. She died several days later  
884 from complications of hypoxic brain damage and nosocomial septicemia secondary to hospital-  
885 acquired pneumonia (Hassanian-Moghaddam et al., 2022).

886 ***Montivipera raddei***: Serious local effects and hemostatic disturbances are expected following  
887 envenoming by this species (Darevsky, 1966; Ettling et al., 2012; Nejadrahim et al., 2019). Latifi  
888 illustrates extensive blistering after a bite by this species (Latifi, 1991, 1985). In Armenia, during  
889 1951-3, there were human fatalities, including two 14-year-old children bitten on their legs, and  
890 an adult man bitten on the shoulder who died within 12 hours of the bite (Darevsky, 1966). Also  
891 in Armenia, a 51-year-old man who was bitten on a finger and thumb developed intense  
892 burning and throbbing pain that radiated up the arm to his shoulder, dizziness, profuse  
893 sweating and blistering (Ettling et al., 2012). After admission, the patient was treated  
894 conservatively with a variety of unconventional medications, but no antivenom was given. At 24  
895 hours, there was swelling and ecchymoses of the right side of his body, which increased,

896 together with myalgia, arthralgia and severe local pain. The patient survived despite lack of  
897 antivenom therapy. His pain persisted for several weeks, and at 6<sup>th</sup> week, necrotic tissue was  
898 debrided from the thumb (Ettling et al., 2012).

899 ***Naja oxiana***: Despite this species' wide distribution in Asia, there are very few reliable  
900 published reports about envenoming. According to Latifi (Latifi, 1991, 1985), weakness,  
901 drowsiness, and paralysis of the throat, usually develop within one hour and progress rapidly to  
902 respiratory distress and possible cardiac arrest. He considered that these symptoms might be  
903 delayed for up to 10 hours by applying a tourniquet (this first-aid method currently is not  
904 recommended). Local pain and swelling are said to be uncommon and mild, although local  
905 blistering and superficial necrosis are described after bites by other Asian cobras (Afshari &  
906 Monzavi, 2016a; Warrell, 2016). Neurotoxic envenoming usually starts with bilateral ptosis and  
907 external ophthalmoplegia and descends involving muscles innervated by the cranial then  
908 thoracic nerves eventually causing life-threatening bulbar and respiratory muscle paralysis. In  
909 northeast Iran, a 4-year-old child died after developing respiratory muscle paralysis and  
910 cyanosis, 30 minutes after being bitten by a *N. oxiana* (Balali-Mood & Shariat, 1999). Also in  
911 Iran (same region), a 39-year-old man bitten on the finger by *N. oxiana* presented with bilateral  
912 ptosis, mydriasis, sluggish pupillary light reflex and sialorrhoea 30 minutes after the bite. After an  
913 hour, he developed difficulty in breathing from respiratory muscle paralysis, requiring  
914 intubation and mechanical ventilation. The patient was treated with an initial dose of 100 mL of  
915 Razi antivenom (hexavalent), followed by three 50 mL doses at 6-hour intervals. He was  
916 extubated 48 hours later (Rajabi et al., 2022). In Russia, a 28-year-old snake-keeper, bitten on  
917 his index finger by a captive *N. oxiana* from Turkmenistan, 147 cm in total length, developed  
918 increasing weakness in his legs 15 minutes later, a feeling of constriction in the throat, difficulty  
919 breathing, and hypotension with frequent extrasystoles (Kudriavtsev, 1983). After 20-25  
920 minutes, there was complete paralysis of the lower extremities, respiratory arrest and coma.  
921 However, intravenous and local subcutaneous injection of "anticobra" antivenom resulted in  
922 rapid restoration of respiration and consciousness. He also suffered persisting periods of  
923 hypotension, multiple extrasystoles, vomiting and chills and showed marked mydriasis. There  
924 was swelling of the entire bitten arm with local tissue necrosis at the bite site. He recovered  
925 gradually over 5 days (Kudriavtsev, 1983). Barkagan described two patients bitten by *N. oxiana*  
926 in Tajikistan, who suffered progressive paralysis involving respiratory muscles and also  
927 dysphagia, loss of tendon reflexes, disturbances of superficial and deep sensitivity, dysarthria,  
928 aphonia and other disturbances of speech (Barkagan, 1964). In Turkmenistan, *N. oxiana* bite  
929 victims experienced local slight burning sensation, redness and swelling, followed after 30  
930 minutes by "irresistible drowsiness", impairment of consciousness and lower limb weakness  
931 (Talyzin, 1963). Hypersalivation, paralysis of the tongue and larynx, generalized paralysis and  
932 respiratory failure may develop, leading to death in 2-7 h after the bite in untreated cases  
933 (Talyzin, 1963).

934 ***Pseudocerastes fieldi***: Although the venom of this species is neurotoxic in small mammals, the  
935 very few human bite victims documented in Middle Eastern countries developed only local  
936 symptoms and all survived (Amr et al., 2020; Kochva, 1990).

937 ***Pseudocerastes persicus***: The most common clinical manifestations of envenoming are localized  
938 pain and swelling, associated with local tissue necrosis. Passing through the superficial lymphatic  
939 vessels, the venom causes lymphangitis, swelling, ulceration, and superficial thromboses that  
940 slowly spread (Afshari & Monzavi, 2016b; Balali-Mood & Shariat, 1999). Consistent with the  
941 known venom composition of *P. persicus* (Mehdizadeh Kashani et al., 2012), consumption  
942 coagulopathy and thrombocytopenia have been reported following envenoming (Afshari &  
943 Monzavi, 2016b; Balali-Mood & Shariat, 1999; Heiner et al., 2013). A herpetologist bitten by an  
944 identified *P. persicus* in Kerman Province, Iran, developed local pain and swelling, bleeding from  
945 the bite site, mild non-specific symptoms, increased serum creatine kinase and minimal  
946 laboratory evidence of coagulopathy (Kazemi et al., 2023). Four days after a reported bite by this  
947 species in Pakistan, a young Makrani boy appeared very weak and jaundiced but seemed to be  
948 recovering (Minton, 1966).

949 ***Vipera ammodytes transcaucasiana***: There have been no reports of bites by *V. a.*  
950 *transcaucasiana*. However, vomiting, diarrhea, thrombocytopenia, AKI, hypokalemia,  
951 proteinuria, elevated liver enzymes, hemolytic anemia, petechiae, hematoma, hematuria,  
952 thrombocytopenia, severe coagulopathy, and rarely neurotoxic symptoms (expressed as  
953 transient paresis of the bitten limb) have been reported from bites by the closely-related *V. a.*  
954 *ammodytes* (Liapis et al., 2019; Marinov et al., 2010; Nikolić et al., 2021).

955 ***Walterinnesia morgani***: In Iraq, close to the western border of Iran, a man bitten on his leg by a  
956 “large black snake”, assumed to be *W. morgani*, was reported to have developed respiratory  
957 distress and generalized limb weakness along with mild edema, erythema, and numbness around  
958 the bite site. During recovery, he experienced diplopia without objective evidence of external  
959 ophthalmoplegia but made a complete recovery (Lauer et al., 2011). Also in Iraq, Corkill described  
960 three fatalities within 6-10 h of suspected bites by this species (Corkill, 1939, 1932). Clinical  
961 features included local swelling, vomiting, collapse and paralysis (Corkill, 1939, 1932).  
962 Envenoming by the closely-related Egyptian or Western Black Desert Cobra (*W. aegyptia*) has  
963 been reported to cause local pain and swelling, fever, nausea, vomiting, diaphoresis, generalized  
964 weakness, involuntary movements, respiratory distress, loss of consciousness, and peripheral  
965 neutrophilic leukocytosis (Abu Baker et al., 2022; Lifshitz et al., 2003; Yayon et al., 1988).

### 966 **3.3.3. Secondary complications of snakebite envenoming**

967 The etiology of the often poly-microbial wound infections and cellulitis in snake-bitten patients  
968 reflects the varied, unusual, and distinctive bacterial flora of snakes’ oral cavities (Dehghani et  
969 al., 2020; Dehghani et al., 2016b; Sadeghi et al., 2021). However, many snake venoms possess

970 anti-bacterial activity. In a Brazilian study, bacterial contamination was very uncommon in  
971 venom of recently-captured snakes (Garcia-Lima & Laure, 1987). Another source of secondary  
972 bacterial or, rarely, fungal infection following snakebite is the use of non-sterile incisions at the  
973 bite site (Afshari & Monzavi, 2016b; Dehghani, 2010; Dehghani et al., 2016b; Dehghani et al.,  
974 2015).

975 Many of the systemic manifestations of envenoming arise from direct venom toxicity, but they  
976 may sometimes result indirectly through other mechanisms. For example, AKI may be caused by  
977 direct nephrotoxicity of snake venom, or it may result from profound or prolonged hypotension  
978 due to massive hemorrhage, hypovolemia, anaphylaxis or vasoactive venom toxins, or from  
979 “pigment nephropathy” in cases of rhabdomyolysis or hemolysis (Sitprija, 2006). Renal damage  
980 is usually transient and responsive to short-term hemodialysis without the complication of  
981 chronic renal failure (Elkabbaj et al., 2012; Rahmani et al., 2022; Valenta et al., 2010). In Iran,  
982 complications, such as pancreatitis, subarachnoid hemorrhage, compartment syndrome,  
983 ischemic contracture, and digital necrosis requiring amputation, have also been reported  
984 following snakebite envenoming (Dehghani et al., 2014b; Eslamian et al., 2016; Farzan et al.,  
985 2003; Nejadrahim et al., 2019; Sagheb et al., 2011a, 2011b; Zamani et al., 2016). In a rare case of  
986 envenoming by *E. c. sochureki* in southern Iran, the victim developed AKI and necrotizing  
987 pancreatitis (Sagheb et al., 2011a). AKI and pancreatitis, and posterior reversible encephalopathy  
988 syndrome, have also been reported following *C. cerastes* envenoming (Ibrahim et al., 2017;  
989 Valenta et al., 2010).

990 In addition to organic symptoms, snakebite victims may experience psychiatric symptoms and  
991 mental health problems such as visual hallucinations, and acute and chronic post-traumatic  
992 stress disorders (Khosrojerdi & Amini, 2013; Mehrpour et al., 2018).

### 993 **3.4. Medical management of snakebite envenoming in Iran**

994 Snakebite envenoming is a medical emergency. If intervention is delayed, irreversible sequelae  
995 and even death may ensue (Hassanian-Moghaddam et al., 2022; Monzavi et al., 2014). In fact,  
996 traditional therapeutic measures in rural areas, misleading self-reported history by the victims or  
997 relatives, and inadequate inspection of the bite wound and initial misdiagnosis by the clinicians,  
998 are the major contributory factors that delay appropriate medical interventions. In rural areas of  
999 Iran, traditional treatments include aggressive wound incision/pricks, suction, tight tourniquets  
1000 above the bite site, and local application of various herbal medicines (e.g., mullein, dandelion,  
1001 onion, turmeric, etc.) (Afshari & Monzavi, 2016b; Astaraki et al., 2020; Balali-Mood & Shariat,  
1002 1999; Besharat et al., 2008).

1003 The most effective and the only specific treatment to prevent, halt and reverse venom effects is  
1004 specific antivenom (Gutierrez, 2018; Warrell, 2016). *E. c. sochureki*, *M. lebetina*, *M. raddei*, *G.*  
1005 *caucasicus*, *P. persicus* and *N. oxiana* have long been considered the species of greatest medical

1006 importance in Iran (Afshari & Monzavi, 2016b; Balali-Mood & Shariat, 1999; Latifi, 1985). That is  
1007 why Iranian antivenoms were designed specifically to target the venoms of these species. Razi™  
1008 Polyvalent Antivenin (Razi Vaccine & Serum Research Institute, Tehran, Iran) has been  
1009 commercially available for over five decades (Latifi, 1984). The antivenom is an equine-derived  
1010 F(ab')<sub>2</sub> immunoglobulin, that is produced in two formulations: (1) pentavalent, capable of  
1011 neutralizing the venom of 5 common medically important snakes in Iran including *E. carinatus*,  
1012 *M. lebetina*, *M. raddei (albicornuta)*, *G. caucasicus (halys)* and *P. persicus*, and (2) hexavalent,  
1013 with the addition of neutralizing *N. oxiana* venom (Latifi, 1984; Monzavi et al., 2019a; Monzavi  
1014 et al., 2014; Theakston & Warrell, 1991). The hexavalent formulation is distributed only in  
1015 northeastern regions of Iran, where *N. oxiana* is reported. The effectiveness of this antivenom  
1016 has been predicted, based on both *in vitro* and *in vivo* studies, but no formal clinical trial has been  
1017 carried out (Akbari et al., 2010; Heiner et al., 2013; Latifi, 1984; Monzavi et al., 2019a). For this  
1018 antivenom, the average time needed to achieve a “therapeutic response” or “initial control”  
1019 (judged by the reversal of systemic effects, or arrest of progression of local effects when there  
1020 are no systemic effects) was approximately 2 (range 1-9) hours in viper envenomed victims in  
1021 northeastern Iran after treatment with a median of 10 ampoules (100 mL, two doses of 50  
1022 ml/hour) (Monzavi et al., 2019b). In southern parts of the country, higher doses (10-20 ampoules)  
1023 are usually administered (Rahmani et al., 2014), because different criteria for clinical response  
1024 are considered (their criteria generally differ from the consensus definition of initial control  
1025 according to widely-accepted guidelines and textbooks) (Lavonas et al., 2011; Monzavi et al.,  
1026 2014; Riley et al., 2011; Warrell, 2016). The frequency and severity of early adverse reactions  
1027 following treatment with this antivenom are reported to be low (4.5-6%) with few or no late  
1028 reactions, but detection of all adverse events requires close monitoring of patients for at least 4  
1029 hours after antivenom treatment and follow-up for the next 4 weeks (Mohammad Alizadeh et  
1030 al., 2016; Monzavi et al., 2019a; Monzavi et al., 2015). Recently, a new Iranian company (Padra  
1031 Serum Alborz, Karaj, Iran) has started manufacturing snake antivenoms, i.e., SnaFab5®  
1032 (pentavalent) and SnaFab6® (hexavalent), to expand antivenom production capacity and  
1033 availability for Iran and neighboring countries (Abouyannis et al., 2021; Kazemi et al., 2023b).  
1034 Both brands (Razi™ and SnaFab®) have been listed in the WHO database of antivenoms (World  
1035 Health Organization, 2021), and share similar composition and formulation. However, to  
1036 separate IgG, ammonium sulfate is used for Razi™, whereas caprylic acid is employed for SnaFab®  
1037 production. Razi institute plans to produce a monovalent antivenom for *N. oxiana* (Akbari et al.,  
1038 2010). In Iran, other suggested innovations have included raising antivenoms in chicken egg yolks  
1039 (Zolfagharian & Dounighi, 2015), and development of recombinant antibodies against Iranian  
1040 venomous snakes using phage-display technology (Eskafi et al., 2021; Kadkhodazadeh et al.,  
1041 2020; Nazari et al., 2020), and species-specific human recombinant Fab antivenom (Kazemi-  
1042 Lomedasht et al., 2019; Motedayen et al., 2018). Novel drug delivery methods to enhance  
1043 antivenom efficacy have also been explored (Alirahimi et al., 2018; Shahidi Bonjar, 2014).

1044 Venom-induced hemostatic disorders and shock are usually reversible with prompt and  
1045 appropriate antivenom therapy. However, death due to envenoming may occur in the first few  
1046 hours after elapid bites, due to neurotoxic bulbar and/or respiratory paralysis (Angaji et al., 2016;  
1047 Gasanov et al., 2015; Lewis & Gutmann, 2004). Post-synaptic neurotoxicity following cobra  
1048 envenoming is fairly responsive to antivenom therapy; whereas, presynaptic neurotoxicity of sea-  
1049 snakes and kraits is poorly reversible, once established, since the PLA<sub>2</sub> neurotoxins permanently  
1050 damage targeted nerve terminals at neuromuscular junctions (NMJs). Hence, in all cases of  
1051 neurotoxic envenoming, airway management and assisted ventilation should be considered to  
1052 keep the patient alive until the antivenom takes effect or venom effects wear off.  
1053 Anticholinesterases given with atropine may also be helpful first-aid for postsynaptic neurotoxic  
1054 effects. Since the appearance of effects of pre-synaptic neurotoxins may be delayed, snakebite  
1055 victims, even those with only limited local signs, should be observed carefully, especially during  
1056 the first 24 hours after admission to the hospital (Afshari & Monzavi, 2016b; Monzavi et al., 2014;  
1057 Riley et al., 2011; Warrell, 2016).

1058 Optimal medical management of a snakebite envenomed patient requires a comprehensive  
1059 approach rather than antivenom therapy alone. Region-specific guidelines or protocols are  
1060 advocated for this purpose, as medical system infrastructure, antivenom availability, and locally-  
1061 important snake species vary in each country or geographical region (Chippaux & Goyffon, 1998;  
1062 Lavonas et al., 2011; Monzavi et al., 2014). In Iran, a group of medical toxicologists has developed  
1063 a nationally unified protocol for hospital management of snakebite (Monzavi et al., 2014). This  
1064 protocol comprises: (1) a severity grading scale for initial assessment of the clinical condition, (2)  
1065 a schematic algorithm that indicates a logical sequence of diagnostic and therapeutic measures  
1066 with suggested antivenom dosing, and (3) recommended supportive and adjunctive treatments  
1067 when necessary (Monzavi et al., 2014).

1068 In clinical practice, this protocol has reduced antivenom usage, compared to a locally-practiced  
1069 anecdotal recommendation for antivenom dosing (Monzavi et al., 2015). The protocol also  
1070 reduced the healthcare costs and length of hospital stay (Monzavi et al., 2015). Nonetheless, the  
1071 minimum recommended starting dose of antivenom in the new protocol (5 ampoules = 50 mL)  
1072 (Monzavi et al., 2014; Monzavi et al., 2015), is still 2.5 times higher than the dosage (2 ampoules  
1073 = 20 mL) recommended in the package insert of the Razi™ Antivenin (RVSRI, 2021). This is  
1074 because the optimal starting dose of antivenom has not been established by formal clinical trials  
1075 in Iran (as in many other parts of the world), and that the US guidelines, as a standard practice,  
1076 has been adopted instead (Lavonas et al., 2011; Monzavi et al., 2014; Riley et al., 2011).

1077 As mentioned, some clinicians in southern parts of the country consider their own antivenom  
1078 dosing and use their own definition of clinical response, which results in administration of higher  
1079 starting (10 ampoules) and maintenance doses of antivenom. Therefore, to establish rational  
1080 antivenom dosing, a multi-center blinded randomized dose-finding clinical trial may be required,

1081 in which the envenoming species is identified, to compare the manufacturer's recommended  
1082 dose of 20-ml with 50-ml and 100-ml doses.

1083 In addition to antivenom therapy, supportive measures are essential for critically ill snakebite  
1084 patients (Monzavi et al., 2014): (1) assisted ventilation for respiratory muscle paralysis; (2)  
1085 intravenous fluid replacement with or without vasopressor drugs for hypotension and shock; (3)  
1086 airway support for bites in the head and neck region with a risk of airway obstruction; (4) blood  
1087 products to accelerate restoration of hemostasis in response to specific antivenom in patients  
1088 with severe, spontaneous bleeding (e.g., gastro-intestinal bleeding) causing hemodynamic  
1089 instability; (5) protection of kidneys from pigment nephropathy caused by myoglobinuria in cases  
1090 of severe myotoxicity/rhabdomyolysis, or hemolysis; (6) use of anticholinesterases, such as  
1091 neostigmine or edrophonium chloride, along with atropine to reverse NMJ blockade by post-  
1092 synaptic neurotoxins in cases of cobra bite envenoming; (7) treatment of secondary bacterial bite  
1093 wound infections. Despite all the evidence and guidelines discouraging early wound incision and  
1094 fasciotomy for patients with extensive swelling of the bitten limb (Darracq et al., 2015; Greene  
1095 et al., 2021; Monzavi et al., 2014; Warrell, 2016), these outdated practices persist in some parts  
1096 of Iran, increasing the risk of complications such as bleeding, secondary nosocomial infections,  
1097 prolonged hospital admission and residual deformities (Kazemi et al., 2021c). Whether or not  
1098 anti-inflammatory treatments may help alleviate the local effects of envenoming is an  
1099 unanswered question. Results of a recent study in Isfahan that compared single with multiple  
1100 doses of anti-inflammatory treatments (histamine H1 and H2 blockers and hydrocortisone)  
1101 suggested some benefit of multiple doses (Dorooshi et al., 2021). However, the results were  
1102 inconclusive because the study was retrospective, non-randomized, unblinded, did not  
1103 distinguish envenoming by different species, the two groups were not similar before treatment,  
1104 and many patients had negligible symptoms.

1105 Sea-snake bite envenoming in Iran is rare. Local sailors and fishermen are aware to avoid sea-  
1106 snakes and release them untouched from the fishing nets. It should be noted that victims of sea-  
1107 snake bite envenoming are at risk, because local and systemic effects may be absent during the  
1108 first few hours after the bite, no specific antivenom is available in the country, and  
1109 anticholinesterases are unlikely to be effective in sea-snake bite venom-induced neurotoxicity  
1110 (Nabipour et al., 2015; Warrell, 2016). In the absence of a specific antivenom for sea-snake bite  
1111 envenoming, medical management is based on supportive measures for controlling the  
1112 neurotoxic and myotoxic effects that may include airway support, assisted ventilation, and  
1113 prevention of myoglobinuria-induced AKI (Monzavi et al., 2014; Nabipour et al., 2015). An  
1114 algorithm for the early-stage management of marine envenomings in Iran has been proposed,  
1115 but it addresses only primary care measures (Nabipour et al., 2015).

1116

## 1117 4. DISCUSSION & CONCLUSIONS

### 1118 4.1. Review of Iran's venomous snake fauna

1119 In this review of medically important snakes of Iran, 17 species of mildly-venomous non-front-  
1120 fanged Colubridae and Lamprophiidae, and 30 species of venomous snakes, including 15  
1121 Viperinae, 1 Crotalinae, and 14 Elapidae are discussed. Occurrence of these species, and their  
1122 population densities vary across Iran with climate and other environmental characteristics  
1123 (Dehghani, 2010; Dehghani et al., 2014b; Farzanpay, 1990; Firouz, 2005; Latifi, 1991, 1985;  
1124 Rastegar-Pouyani et al., 2008; Safaei-Mahroo et al., 2015). Among these, three new species,  
1125 endemic to Iran, were first described within the last 15 years. We have critically reviewed  
1126 recent taxonomic revisions to produce an updated checklist with some new additions (e.g., *M.*  
1127 *razii*, and *H. cantoris*), some former sub-species have been raised to species status (e.g.,  
1128 *Platyceps ladacensis*, *P. fieldi*, *G. caucasicus*, *V. ebneri*), and some sub-species have been  
1129 subsumed (e.g., *E. c. multisquamatus*, *M. r. kurdistanica* and *M. r. albicornuta*). Morphological  
1130 features are described and illustrated and the country-wide geographical distributions of  
1131 medically-important species are updated and mapped (**Supplementary File**). However, further  
1132 taxonomic and zoogeographic revisions are anticipated. Freitas et al. have emphasized that  
1133 taxonomic status (species/sub-species) is important for understanding biodiversity, and for  
1134 mobilizing efforts and allocating resources to develop conservation strategies (Freitas et al.,  
1135 2020). In their review of Eurasian vipers, they questioned the species status of the following  
1136 taxa, based on genetic divergence, and suggested more appropriate status within other  
1137 species/species complexes: (1) *M. kuhrangica* and *M. latifii* show only 2% genetic divergence  
1138 from *M. raddei*; (2) *M. wagneri* is part of the *M. bornmuelleri* group; (3) *V. erivanensis* and *V.*  
1139 *ebneri* show close genetic affinity suggesting sub-specific status within the *V. renardi* group  
1140 (Freitas et al., 2020).

1141 The occurrence of some species in Iran should be clarified. Despite some studies reporting or  
1142 proposing presence of *M. wagneri* and *V. a. transcaucasiana* in Iran, their presence has not  
1143 been supported with solid evidence, and hence needs further scrutiny. There are also questions  
1144 over the occurrence of *P. fieldi* in Iran. Besides, *H. stokesii* has been recorded in the Makran  
1145 coast of Pakistan, and it likely (but not definitely) occurs alongside this coast of Iran (Rastegar-  
1146 Pouyani et al., 2008). Unless the statuses of these species are fully elucidated, the presence of  
1147 these species in Iran should be considered as doubtful (questionable).

### 1148 4.2. Importance of species identification of venomous snakes

1149 Knowledge of the geographic range distribution of the different medically-important species  
1150 will help hospital staff to interpret early symptoms of envenoming by the local species in their  
1151 area, and to prepare patients and medical staff for the likely evolution and complications of  
1152 envenoming (Amr et al., 2020; Warrell, 2016). In this way, treatment of envenoming by each  
1153 species can be optimized. In Iran, as elsewhere in the world, there is a great need to design  
1154 prospective studies to establish the clinical features (phenotype or syndrome) resulting from



1155 envenoming by each species, to form a sounder basis for diagnostic and therapeutic algorithms.  
1156 Clinical toxicologists and emergency medicine clinicians should be strongly encouraged to  
1157 establish and enter into the patients' medical records the identity of the biting species,  
1158 especially when the responsible snake is brought to the hospital (Bawaskar & Bawaskar, 2019;  
1159 Monzavi et al., 2019a). Alternatively, smart-phone images, taken at the location where the bite  
1160 occurred, are increasingly available and can easily be sent electronically to a regional or  
1161 national reference center/herpetologist for identification. When getting an expert opinion is  
1162 not feasible, perhaps, a recent effort to devise state-of-the-art machine learning algorithms in  
1163 Iran, which helps generating cellphone applications for snake image identification with  
1164 reasonable accuracy and reliability can be seen as a solution (Rajabizadeh & Rezaghi, 2021). Far  
1165 less convincing is recognition by the bite victim of colored pictures or museum specimens of  
1166 local species, or the use of local snake names. Future clinical research on snakebite in Iran will  
1167 be greatly assisted if species identification can be confirmed using immunodiagnostic methods,  
1168 especially in those snakebite cases where the responsible snake is not available for  
1169 examination.

#### 1170 *4.3. Venomous snake conservation and community education*

1171 Where natural and human environments interface, lack of public education has contributed to  
1172 ignorance about the biological and ecological value of snakes, predisposing them to the danger  
1173 of unnecessary human predation. On the other hand, the risk of snakebite envenoming  
1174 depends on the extent to which human settlements and agricultural activities encroach upon  
1175 areas with habitats supporting higher population densities of venomous snake species.  
1176 Enhancing the level of public awareness and knowledge would appreciably reduce the number  
1177 of adverse snakebite events and increase public support for the conservation of snakes in  
1178 nature (Mashhadi et al., 2017; Warrell, 2016). Snakes play an integral role in maintaining  
1179 ecological equilibrium and controlling rodent- and bat-related zoonoses of human and  
1180 veterinary public health importance, such as plague, leptospirosis, hantavirus, coronavirus and  
1181 arenavirus diseases. Studies have revealed some snake venom toxins of potential value in  
1182 designing new treatments for human diseases such as hypertension, thrombophilia, diabetes  
1183 mellitus, malignancy, infections and intractable pain, and providing useful diagnostic laboratory  
1184 reagents (Ali et al., 1999b; Chan et al., 2016; Op den Brouw et al., 2021b). This is an additional  
1185 argument for conserving venomous snakes. Data on geographical distribution of snakes are  
1186 crucial for determining regions important for the conservation of species in danger of extinction  
1187 and preserving their habitat. Given the diverse biogeographic status of Iran, a collaborative  
1188 approach for the sustainable management of Iranian herpetofauna has been recommended to  
1189 be made between Iranian governmental institutions and NGOs, and international agencies  
1190 (Jowkar et al., 2016; Rastegar-Pouyani et al., 2015).

#### 1191 *4.4. Clinical features of envenoming and management protocols*

1192 In this paper, we have provided species-specific descriptions of the clinical features of  
1193 envenoming by the medically important snakes of Iran according to available literature. In  
1194 addition, we discussed the improvements made in the medical management of snakebite  
1195 victims in Iran, by rationalizing antivenom dosage and through appropriate use of supportive  
1196 measures according to a recently-developed comprehensive protocol. The use of this protocol  
1197 is more cost-effective and abandons long-practiced unsubstantiated treatments, while it  
1198 provides step-by-step instructions for clinicians (Monzavi et al., 2015). Although the antivenoms  
1199 in Iran are polyvalent, covering the most common venomous species, it is highly likely that the  
1200 antivenom dosage requirements differ between species as well as with different levels of  
1201 severity of envenoming. Therefore, formal dose-finding clinical trials are necessary, so that  
1202 antivenom can be used more effectively, and in view of its economic cost and dose-related risk  
1203 of adverse reactions, excessive dosage can be avoided.

#### 1204 *4.5. Provision of antivenoms and medical staff training*

1205 Medical facilities, especially those in areas where snakebites are relatively common, should be  
1206 provided with vital medications, such as adequate stocks of antivenom, especially during the  
1207 warm seasons (Mondal et al., 2012; Monzavi et al., 2019b). In each geographical region, one of  
1208 the main challenges affecting the treatment of snakebite victims has been the training of  
1209 medical staff to recognize signs and symptoms of envenoming and to understand the  
1210 distinction of the bites by non-venomous species from the bites by venomous species. Medical  
1211 staff should receive training in snakebite management, including criteria for transferring  
1212 severely-envenomed patients to higher levels of medical care when necessary (Warrell, 2016).  
1213 Community education must also be prioritized along with medical staff training, that in case of  
1214 a venomous snakebite, the victim should be transported quickly and passively to medical care,  
1215 without delay for traditional treatments.

1216 **DECLARATIONS**

1217 **Ethical clearance:** No experimentation with human subjects was involved in this review.

1218 **Conflict of interest:** The authors declare that they have no known competing financial interests  
1219 or personal relationships that could have appeared to influence the work reported in this  
1220 paper.

1221 **Funding and support:** This research did not receive any specific grant from funding agencies in  
1222 the public, commercial, or not-for-profit sectors.

1223 **Acknowledgements:** We are grateful to Professor Mark O'Shea, University of Wolverhampton,  
1224 UK, for his collation of records of venomous snakes on Persian Gulf islands. Some of the  
1225 graphical elements used in the graphical abstract were created using BioRender.com and  
1226 mindthegraph.com. The graphical abstract elements produced via mindthegraph.com, are  
1227 made available freely by the website under a free culture Creative Commons license (CC BY-SA  
1228 4.0).

1229 **Author contributions:** Conceptualization (R.D., O.M., D.A.W.); Methodology (S.M.M., O.M.);  
1230 Investigation (S.M.M., R.D., H.H.M., W.W., A.W., F.M.S.); Validation (S.M.M., D.A.W., D.E.K.,  
1231 W.W., A.W.); Visualization (S.M.M., R.D.); Data curation (S.M.M., O.M.); Formal analysis  
1232 (S.M.M., D.A.W., O.M.); Writing - original draft (All authors); Writing - review & editing (All  
1233 authors); Supervision (D.A.W., O.M.)

1234 **FIGURE LEGENDS**

1235 **Fig. 1.** Map of the geographic location of Iran and neighboring countries, and Iran's provinces

1236 **Fig. 2.** Iran's pioneers in herpetology and snakebite, and textbooks of ophiology and natural  
 1237 conservation. **A**, Professor Mahmoud Latifi; **B**, Professor Reza Farzanpay; **C**, Engineer Eskandar  
 1238 Firouz; **D**. A group photo in the garden of the Razi Institute, Iran, Left to right: Professor Claus  
 1239 Andrén, Professor Mahmoud Latifi, Professor Göran Nilson, Professor Reza Farzanpay; **E**, The  
 1240 Snake Sultan, a nomadic Bakhtiari tribe snake catcher for the Razi Institute in the Zagros  
 1241 Mountains of eastern Iran, with *Pseudocerastes persicus*; **F**, A group photo at the Fifth  
 1242 symposium of International Society of Toxinology in Irazú Hotel, Costa Rica, 1976, Left to right:  
 1243 Professor Findlay E. Russell, Professor William B. Elliott, Professor Akira Ohsaka, Professor David  
 1244 Chapman, Professor Mahmoud Latifi, Professor Roger Bolaños, Professor H. Alistair Reid,  
 1245 Professor Yoshio Sawai, Professor Gastão Rosenfeld. **G**, *Snakes of Iran* (Persian version) by M.  
 1246 Latifi, **H**, *Snakes of Iran* (English translated version), **I**, *Ophiology* (in Persian) by R. Farzanpay; **J**,  
 1247 *The complete fauna of Iran* (in English) by E. Firouz.

1248 **Fig. 3.** Flow diagram of literature search

1249 **Fig. 4.** Cardinal characteristics of Viperidae. **A**, Vertically elliptical pupil; **B**, Solenoglyph  
 1250 dentition showing tubular (canaliculated) fangs of *Pseudocerastes persicus* - a viper with a wide  
 1251 geographic distribution in Iran.

1252 \* Figures are from R. Dehghani's personal archive and require permission for reproduction.

1253 **Fig. 5.** Symptoms observed following a facial bite that resulted from severe *Echis carinatus*  
 1254 envenoming in northeast Iran (with permission). **A & B**, The patient was unable to open her eyes  
 1255 due to extensive edema. Ecchymosis and blister formation were also present. Arrows show the  
 1256 bite site (fang marks). The edge of edema was marked on the victim's face with a blue line. The  
 1257 patient developed thrombocytopenia and consumption coagulopathy; **C**, The patient on the 4<sup>th</sup>  
 1258 day post-bite, after administration of 24 vials of snake antivenom (Razi Antivenin), and other  
 1259 supportive treatments. The edema and ecchymoses were considerably reduced compared to the  
 1260 day of admission and she could open her left eye (of note, by the 7<sup>th</sup> day post-bite, the edema on  
 1261 the right side subsided and she could open her right eye, as well).

1262 \* Figures are taken with permission from the patient and legal guardians. The figures are from  
 1263 S. M. Monzavi's personal archive and require permission for reproduction.

1264 **Fig. 6. A & B**, Edema, blister formation, and local necrosis following Viperidae snakebite in  
 1265 northeast Iran attributed to *Macrovipera lebetina obtusa* bite. The right upper limb of the patient  
 1266 is massively swollen; **C**, Rapidly developing swelling and necrosis in a toe attributed to  
 1267 *Macrovipera lebetina obtusa* bite

1268 \* Figures are from S. M. Monzavi's personal archive and require permission for reproduction.

1269 **TABLES**1270 **Table 1.** Lethal doses (LD<sub>50</sub>) of Iran's medically important snakes1271 **Table 2.** Common snakebite envenoming features in Iran

1272

1273

1274 **SUPPLEMENTARY FILE:**1275 **Table 1S.** Photographs, conservation status and distribution of Iran's medically important  
1276 snakes1277 **Table 2S.** Taxonomy and morphologic features of the mildly-venomous (non-front-fanged)  
1278 snakes of Iran1279 **Table 3S.** Taxonomy and morphological features of the venomous snakes of Iran

## 1280 REFERENCES

- 1281 A'alam, A. M. (2000). Antivenom. [In Persian]. In *Encyclopedia of the Islamic World*. Tehran, Iran:  
1282 Encyclopedia Islamica Foundation.
- 1283 Abouyannis, M., Aggarwal, D., Laloo, D. G., Casewell, N. R., Hamaluba, M., & Esmail, H., 2021. Clinical  
1284 outcomes and outcome measurement tools reported in randomised controlled trials of  
1285 treatment for snakebite envenoming: A systematic review. *PLoS Negl Trop Dis*. 15, e0009589.
- 1286 Abtahi, B., Mosafer Khorjistan, S., Ghezellou, P., Aliahmadi, A., Ranaei Siadat, S. O., Kazemi, S. M., . . .  
1287 Fathinia, B., 2014. Effects of Iranian Snakes Venom True Sea and Terrestrial Snakes on Some  
1288 Bacterial Cultures. *J Persian Gulf (Marine Sci)*. 5, 27-36.
- 1289 Abtin, E., Nilson, G., Mobaraki, A., Hosseini, A. A., & Dehgannejhad, M., 2014. A New Species of Krait,  
1290 *Bungarus* (Reptilia, Elapidae, Bungarinae) and the First Record of That Genus in Iran. *Russ J*  
1291 *Herpetol*. 21, 243-250.
- 1292 Abu Baker, M. A., Al-Saraireh, M., Amr, Z., Amr, S. S., & Warrell, D. A., 2022. Snakebites in Jordan: A  
1293 clinical and epidemiological study. *Toxicon*. 208, 18-30.
- 1294 Abukamar, A., Abudalo, R., Odat, M., Al-Sarayreh, M., Issa, M. B., & Momanie, A., 2022. Arabian  
1295 Levantine viper bite induces thrombocytopenia - a case report. *J Med Life*. 15, 867-870.
- 1296 Afshari, R., Majdzadeh, R., & Balali-Mood, M., 2004. Pattern of acute poisonings in Mashhad, Iran 1993-  
1297 2000. *J Toxicol Clin Toxicol*. 42, 965-975.
- 1298 Afshari, R., & Monzavi, S. M. (2016a). *Afshari's Clinical Toxicology and Poisoning Emergency Care. [In*  
1299 *Persian & English]* (3rd ed.). Mashhad, Iran: Mashhad University of Medical Sciences Publication.
- 1300 Afshari, R., & Monzavi, S. M. (2016b). Venomous animals and arthropods envenomation. [In Persian]. In:  
1301 R. Afshari & S. M. Monzavi (Eds.), *Afshari's Clinical Toxicology and Poisoning Emergency Care*.  
1302 (3rd ed., pp. 221-241). Mashhad, Iran: Mashhad University of Medical Sciences Publication.
- 1303 Ahmadi, M., Hemami, M. R., Kaboli, M., Malekian, M., & Zimmermann, N. E., 2019. Extinction risks of a  
1304 Mediterranean neo-endemism complex of mountain vipers triggered by climate change. *Sci Rep*.  
1305 9, 6332.
- 1306 Akbari, A., Rabiei, H., Hedayat, A., Mohammadpour, N., Zolfagharian, H., & Teimorzadeh, S., 2010.  
1307 Production of effective antivenin to treat cobra snake (*Naja naja oxiana*) envenoming. *Arch Razi*  
1308 *Inst*. 65, 33-37.
- 1309 Al-Sadoon, M. K., Abdel-Moneim, A. E., Bauomy, A. A., & Diab, M. S. M., 2013a. Histochemical and  
1310 Biochemical effects induced by LD50 of *Cerastes cerastes gasperetti* crude venom in mice. *Life*  
1311 *Sci J*. 10, 810-817.
- 1312 Al-Sadoon, M. K., Abdel Moneim, A. E., Diab, M. S. M., & Bauomy, A. A., 2013b. Hepatic and renal tissue  
1313 damages induced by *Cerastes cerastes gasperetti* crude venom. *Life Sci J*. 10, 191-197.
- 1314 Al-Sadoon, M. K., Diab, M. S. M., Bauomy, A. A., & Abdel Moneim, A. E., 2014. *Cerastes cerastes*  
1315 *gasperettii* venom Induced Hematological Alterations and Oxidative Stress in Male Mice. *J Pure*  
1316 *Appl Microbiol*. 8, 693-702.
- 1317 Al-Sadoon, M. K., Diab, M. S. M., Bauomy, A. A., Abdel Moneim, A. E., & Paray, B. A., 2016. The possible  
1318 effects of melatonin in *Cerastes cerastes gasperettii* venom-mediated toxicity and oxidative  
1319 damage in mice. *Curr Sci*. 110, 1505-1512.
- 1320 Al-Sheikhly, O. F., Al-Barazengy, A. N., & Al-Haideri, M. L., 2019. First record of the Iranian Spider Viper  
1321 *Pseudocerastes urarachnoides* Bostanchi, Anderson, Kami & Papenfuss, 2006 (Serpentes:  
1322 Viperidae) in Iraq. *Sauria*. 41, 43-46.
- 1323 Al-Sheikhly, O. F., Haba, M. K., Al-Rikabi, H. O., & Al-Haideri, M. L., 2020. New localities of the Iranian  
1324 Spider-tailed Viper *Pseudocerastes urarachnoides* (Serpentes: Viperidae) in Iraq. *Sauria*. 42, 43-  
1325 46.

- 1326 Alam, J. M., & Qasim, R., 1993. Changes in serum components induced by venoms of marine animals.  
1327 Pak J Pharm Sci. 6, 81-87.
- 1328 Alavi, S. M., & Alavi, L., 2008. Epidemiology of animal bites and stings in Khuzestan, Iran, 1997–2006. J  
1329 Infect Public Health. 1, 51-55.
- 1330 Alcock, A., Finn, F., Maynard, F. P., & McMahon, A. H., 1896. An account of the Reptilia collected by Dr.  
1331 F.P. Maynard, Captain A.H. McMahon, C.I.E., and the members of the Afghan-Baluch Boundary  
1332 Commission of 1896. J Asiat Soc Bengal. 65, 550-566
- 1333 Ali, S. A., Alam, J. M., Stoeva, S., Schutz, J., Abbasi, A., Zaidi, Z. H., & Voelter, W., 1999a. Sea snake  
1334 Hydrophis cyanocinctus venom. I. Purification, characterization and N-terminal sequence of two  
1335 phospholipases A2. Toxicon. 37, 1505-1520.
- 1336 Ali, S. A., Hamid, F., Abbasi, A., Zaidi, Z. H., & Shehnaz, D., 1999b. Pharmacological effects of the leaf-  
1337 nosed viper snake (*Eristocophis macmahoni*) venom and its HPLC fractions. Toxicon. 37, 1095-  
1338 1107.
- 1339 Ali, S. A., Jackson, T. N., Casewell, N. R., Low, D. H., Rossi, S., Baumann, K., . . . Fry, B. G., 2015. Extreme  
1340 venom variation in Middle Eastern vipers: a proteomics comparison of *Eristocophis macmahonii*,  
1341 *Pseudocerastes fieldi* and *Pseudocerastes persicus*. J Proteomics. 116, 106-113.
- 1342 Alinejad, S., Zamani, N., Abdollahi, M., & Mehrpour, O., 2017. A Narrative Review of Acute Adult  
1343 Poisoning in Iran. Iran J Med Sci. 42, 327-346.
- 1344 Alirahimi, E., Kazemi-Lomedasht, F., Shahbazzadeh, D., Habibi-Anbouhi, M., Hosseininejad Chafi, M.,  
1345 Sotoudeh, N., . . . Behdani, M., 2018. Nanobodies as novel therapeutic agents in envenomation.  
1346 Biochim Biophys Acta Gen Subj. 1862, 2955-2965.
- 1347 Almasieh, K., Mirghazanfari, S. M., & Mahmoodi, S., 2019. Biodiversity hotspots for modeled habitat  
1348 patches and corridors of species richness and threatened species of reptiles in central Iran. Eur J  
1349 Wildl Res. 65, 92.
- 1350 Ambartsumian, A. A. (2001). *Thrita and Avicenna: The Origin of Medicine in Central Asia* Paper presented  
1351 at the The 2nd International Ibn Sino (Avicenna) Readings, Tashkent-Bukhara, Uzbekistan.
- 1352 Amininasab, M., Elmi, M. M., Endlich, N., Endlich, K., Parekh, N., Naderi-Manesh, H., . . . Muhle-Goll, C.,  
1353 2004. Functional and structural characterization of a novel member of the natriuretic family of  
1354 peptides from the venom of *Pseudocerastes persicus*. FEBS Lett. 557, 104-108.
- 1355 Amirian, P., Shahveisi, K., Pazhouhi, M., & Jalili, C., 2022. Anti-proliferative and Apoptosis Induction  
1356 effect of Iranian Snake Venom (*Vipera Raddei Kurdistanica*) on Human Breast Cancer (MCF-7)  
1357 and Normal Breast (MCF-10a) Cell Lines. [In Persian]. Sci J Kurdistan Univ Med Sci. 26, 1-10.
- 1358 Amoozegari, Z., Abyaz, S., & Noorbehbahani, M., 2016. Measurement of Hyaluronidase Enzyme Activity  
1359 in Venom of Iranian *Vipera Lebetina*. [In Persian]. Jundishapur Sci Med J. 15, 363-370.
- 1360 Amoozegari, Z., Zare Mirakabadi, A., & Noorbehbahani, M., 2013. Purification of Blood Coagulation  
1361 Factor V Activator from the Venom of Iranian *Vipera Lebetina*. [In Persian]. Jundishapur Sci Med  
1362 J. 12, 21-32.
- 1363 Amoozgari, Z., Cheraghzadeh, M., Noorbehbahani, M., & Lamuchi Deli, N., 2020. Identification of  
1364 Fibrinolytic Activity in Iranian *Vipera Lebetina* Venom. [In Persian]. J Mazandaran Univ Med Sci.  
1365 30, 17-25.
- 1366 Amr, Z. S., Abu Baker, M. A., & Warrell, D. A., 2020. Terrestrial venomous snakes and snakebites in the  
1367 Arab countries of the Middle East. Toxicon. 177, 1-15.
- 1368 Amrollahi Byoki, E., & Zare Mirakabadi, A., 2013. Partial purification and characterization of  
1369 anticoagulant factor from the snake (*echis carinatus*) venom. Iran J Basic Med Sci. 16, 1139-  
1370 1144.
- 1371 Ana Maria, R., 2021. Toxicology and snakes in ptolemaic Egyptian dynasty: The suicide of Cleopatra.  
1372 Toxicol Rep. 8, 676-695.

- 1373 Angaji, S. A., Houshmandi, A., & Zare Mirakabadi, A., 2016. Acute Effects of the Iranian Snake (*Naja Naja*  
1374 *Oxiana*) Venom on Heart. *Biomacromolecular J.* 2, 97-101.
- 1375 Ansari, A., 2020. Habitat evaluation of Levantine viper (*Macrovipera lebetina*. Linnaeus, 1758) in Haftad-  
1376 Gholleh protected area, Markazi province, Iran. *J Wildl Biodiv.* 4, 1-7.
- 1377 Araujo, P. F., Silva, W. M. D., Franca, R. C., & Franca, F. G. R., 2018. A case of envenomation by  
1378 neotropical Opisthoglyphous snake *Thamnodynastes pallidus* (Linnaeus, 1758) (Colubridae:  
1379 Dipsadinae: Tachymenini) in Brazil. *Rev Inst Med Trop Sao Paulo.* 60, e38.
- 1380 Archundia, I. G., de Roodt, A. R., Ramos-Cerrillo, B., Chippaux, J. P., Olguin-Perez, L., Alagon, A., & Stock,  
1381 R. P., 2011. Neutralization of *Vipera* and *Macrovipera* venoms by two experimental polyvalent  
1382 antisera: a study of paraspecificity. *Toxicon.* 57, 1049-1056.
- 1383 Ariaratnam, C. A., Sheriff, M. H., Arambepola, C., Theakston, R. D., & Warrell, D. A., 2009. Syndromic  
1384 approach to treatment of snake bite in Sri Lanka based on results of a prospective national  
1385 hospital-based survey of patients envenomed by identified snakes. *Am J Trop Med Hyg.* 81, 725-  
1386 731.
- 1387 Arnold, N., Robinson, M., & Carranza, S., 2009. A preliminary analysis of phylogenetic relationships and  
1388 biogeography of the dangerously venomous Carpet Vipers, *Echis* (Squamata, Serpentes,  
1389 Viperidae) based on mitochondrial DNA sequences. *Amphibia-Reptilia.* 30, 273-282.
- 1390 Asadi, A., Kaboli, M., Ahmadi, M., Kafash, A., Nazarizadeh, M., Behrooz, R., & Rajabizadeh, M., 2016.  
1391 Prediction for relict population of Mountains Vipres (*Montivipera* spp) in western Iran; an  
1392 ensemble distribution modeling along with climate change detection from past to future. [In  
1393 Persian]. *J Nat Environ.* 69, 303-327.
- 1394 Asadi, A., Montgelard, C., Nazarizadeh, M., Moghaddasi, A., Fatemizadeh, F., Simonov, E., . . . Kaboli, M.,  
1395 2019. Evolutionary history and postglacial colonization of an Asian pit viper (*Gloydius halys*  
1396 *caucasicus*) into Transcaucasia revealed by phylogenetic and phylogeographic analyses. *Sci Rep.*  
1397 9, 1224.
- 1398 Astaraki, P., Basati, G., Abbaszadeh, S., & Mahmoudi, G. A., 2020. A Review of medicinal plants used for  
1399 snakebites and scorpion stings in Iran: A systematic review. *Res J Pharm Technol.* 13, 1565-1569.
- 1400 Babaie, M., Salmanizadeh, H., & Zolfagharian, H., 2013a. Blood coagulation induced by Iranian saw-  
1401 scaled viper (*echis carinatus*) venom: identification, purification and characterization of a  
1402 prothrombin activator. *Iran J Basic Med Sci.* 16, 1145-1150.
- 1403 Babaie, M., Zolfagharian, H., Salmanizadeh, H., Mirakabadi, A. Z., & Alizadeh, H., 2013b. Isolation and  
1404 partial purification of anticoagulant fractions from the venom of the Iranian snake *Echis*  
1405 *carinatus*. *Acta Biochim Pol.* 60, 17-20.
- 1406 Bagherian, A., & Kami, H., 2008. On taxonomic status of the saw-scaled viper genus *Echis* (Viperidae:  
1407 Reptilia) in Iran. [In Persian]. *Iran J Biol.* 21, 501-508.
- 1408 Balali-Mood, M., & Shariat, M. (1999). *Scientific Basis Practical Guide of Envenomation; prevention,*  
1409 *diagnosis and treatment. [In Persian].* Tehran, Iran: Teimourzadeh.
- 1410 Balali Bahadorani, M., & Zare Mirakabadi, A., 2016. Cytopathic Effect of Snake (*Echis Carinatus*) Venom  
1411 on Human Embryonic Kidney Cells. *Asia Pac J Med Toxicol.* 5, 88-93.
- 1412 Banaye Yazdipour, A., Sarbaz, M., Dadpour, B., Moshiri, M., & Kimiafar, K., 2020. Development a national  
1413 minimum data set for poisoning registry in Iran. *Int J Health Plan Manag.* 35, 1453-1467.
- 1414 Banijamali, S. E., Amininasab, M., & Elmi, M. M., 2019. Characterization of a new member of kunitz-type  
1415 protein family from the venom of Persian false-horned viper, *Pseudocerastes persicus*. *Arch*  
1416 *Biochem Biophys.* 662, 1-6.
- 1417 Barati, M., & Davoudi, D., 2017. Evaluation of toxicity and anticancer activity of isolated fraction from  
1418 the venom of Iranian cobra snake on acute lymphoblastic leukemia cells (Jurkat E6. 1). [In  
1419 Persian]. *Cell Tissue J.* 8, 250-260.



- 1420 Barfaraz, A., & Harvey, A. L., 1994. The use of the chick biventer cervicis preparation to assess the  
 1421 protective activity of six international reference antivenoms on the neuromuscular effects of  
 1422 snake venoms in vitro. *Toxicon*. 32, 267-272.
- 1423 Barkagan, Z. S. (1964). *Diagnosis, symptoms and treatment of envenomings by snake venoms and*  
 1424 *arthropods of Central Asia. [In Russian].* (M. D.), Sverdlovsk State Medical Institute, Sverdlovsk,  
 1425 Russia.
- 1426 Bassam, M., 1995. Systemic changes in rats after injection of crude venom from cerastes gasperetti. *J*  
 1427 *Saudi Heart Assoc.* 7, 31-34.
- 1428 Batzri-Izraeli, R., & Bdolah, A., 1982. Isolation and characterization of the main toxic fraction from the  
 1429 venom of the false horned viper (*Pseudocerastes fieldi*). *Toxicon*. 20, 867-875.
- 1430 Bawaskar, H. S., & Bawaskar, P. H., 2019. Snakebite envenoming. *Lancet*. 393.
- 1431 Baxter, E. H., & Gallichio, H. A., 1976. Protection against sea snake envenomation: comparative potency  
 1432 of four antivenenes. *Toxicon*. 14, 347-355.
- 1433 Baza, A., Marrakchi, N., El Ayeb, M., Sanz, L., & Calvete, J. J., 2005. Snake venomomics: comparative  
 1434 analysis of the venom proteomes of the Tunisian snakes *Cerastes cerastes*, *Cerastes vipera* and  
 1435 *Macrovipera lebetina*. *Proteomics*. 5, 4223-4235.
- 1436 Bazi, A., Ghasempouri, S. K., Sahebnaasagh, A., & Saghafi, F., 2019. Bite by the Sheltopusik (*Pseudopus*  
 1437 *apodus*), Locally Called Petilus Snake, to Humans: A Case Report. *Asia Pac J Med Toxicol*. 8, 104-  
 1438 106.
- 1439 Bdolah, A., 1986. Comparison of venoms from two subspecies of the false horned viper (*Pseudocerastes*  
 1440 *persicus*). *Toxicon*. 24, 726-729.
- 1441 Behrooz, R., Kaboli, M., Arnal, V., Nazarizadeh, M., Asadi, A., Salmanian, A., . . . Montgelard, C., 2018.  
 1442 Conservation Below the Species Level: Suitable Evolutionarily Significant Units among Mountain  
 1443 Vipers (the *Montivipera raddei* complex) in Iran. *J Hered.* 109, 416-425.
- 1444 Behrooz, R., Kaboli, M., Nourani, E., Ahmadi, M., Alizadeh Shabani, A., Yousefi, M., . . . Rajabizadeh, M.,  
 1445 2015. Habitat modeling and conservation of the endemic Latifi's Viper (*Montivipera latifii*) in Lar  
 1446 National Park, Northern Iran. *Herpetol Conserv Biol*. 10, 572-582.
- 1447 Besharat, M., Vahdani, P., Abbasi, F., & Korooni Fardkhani, S., 2008. Reporting A Series of 100 Cases of  
 1448 Snake Bites in Loghman Hospital between 2000-2005. [In Persian]. *Res Bull Med Sci*. 13, 315-  
 1449 320.
- 1450 Betts, J., Young, R., Hilton-Taylor, C., Hoffmann, M., Rodriguez, J. P., Stuart, S. N., & Milner-Gulland, E. J.,  
 1451 2020. A framework for evaluating the impact of the IUCN Red List of Threatened Species.  
 1452 *Conserv Biol*. 34, 632-643.
- 1453 Bhat, R. N., 1974. Viperine snake bite poisoning in Jammu. *J Indian Med Assoc.* 63, 383-392.
- 1454 Blaylock, R. S., 2014. The identification and syndromic management of snakebite in South Africa. *S Afr*  
 1455 *Fam Pract.* 47, 48-53.
- 1456 Bok, B., Berroneau, M., Yousefi, M., Nerz, J., Deschandol, F., Berroneau, M., & Tiemann, L., 2017.  
 1457 Sympatry of *Pseudocerastes persicus* and *P. urarachnoides* in the western Zagros Mountains,  
 1458 Iran. *Herpetol Notes*. 10, 323-325.
- 1459 Bostanchi, H., Anderson, S. C., G., K. H., & J., P. T., 2006. A new species of *Pseudocerastes* with elaborate  
 1460 tail ornamentation from western Iran (Squamata: Viperidae). *Proc Calif Acad Sci*. 57, 443-450.
- 1461 Branch, W., 1982. Venomous snakes of southern Africa. 3. Concluding part: Colubridae. *The Snake*. 14, 1-  
 1462 17.
- 1463 Brandehoff, N., Smith, C. F., Buchanan, J. A., Mackessy, S. P., & Bonney, C. F., 2019. First reported case of  
 1464 thrombocytopenia from a *Heterodon nasicus* envenomation. *Toxicon*. 157, 12-17.
- 1465 Broad, A. J., Sutherland, S. K., & Coulter, A. R., 1979. The lethality in mice of dangerous Australian and  
 1466 other snake venom. *Toxicon*. 17, 661-664.

- 1467 Calvete, J. J., Ghezellou, P., Paiva, O., Matainaho, T., Ghassempour, A., Goudarzi, H., . . . Williams, D. J.,  
 1468 2012. Snake venomomics of two poorly known Hydrophiinae: Comparative proteomics of the  
 1469 venoms of terrestrial *Toxicocalamus longissimus* and marine *Hydrophis cyanocinctus*. *J*  
 1470 *Proteomics*. 75, 4091-4101.
- 1471 Calvete, J. J., Pla, D., Els, J., Carranza, S., Damm, M., Hempel, B. F., . . . Encinar, J. R., 2021. Combined  
 1472 Molecular and Elemental Mass Spectrometry Approaches for Absolute Quantification of  
 1473 Proteomes: Application to the Venomomics Characterization of the Two Species of Desert Black  
 1474 Cobras, *Walterinnesia aegyptia* and *Walterinnesia morgani*. *J Proteome Res*. 5, 5064-5078.
- 1475 Carey, J. E., & Wright, E. A., 1960. The toxicity and immunological properties of some sea-snake venoms  
 1476 with particular reference to that of *Enhydrina schistosa*. *Trans R Soc Trop Med Hyg*. 54, 50-67.
- 1477 Carné, A., Fathinia, B., & Rastegar-Pouyani, E., 2020. Molecular phylogeny of the Arabian Horned Viper,  
 1478 *Cerastes gasperettii* (Serpentes: Viperidae) in the Middle East. *Zool Middle East*. 66, 13-20.
- 1479 Casewell, N. R., Harrison, R. A., Wuster, W., & Wagstaff, S. C., 2009. Comparative venom gland  
 1480 transcriptome surveys of the saw-scaled vipers (Viperidae: *Echis*) reveal substantial intra-family  
 1481 gene diversity and novel venom transcripts. *BMC Genomics*. 10, 564.
- 1482 Celen, C., Kececiler, C., Karis, M., Gocmen, B., Yesil-Celiktas, O., & Nalbantsoy, A., 2018. Cytotoxicity of  
 1483 Silica Nanoparticles with Transcaucasian Nose-Horned Viper, *Vipera ammodytes*  
 1484 *transcaucasiana*, Venom on U87MG and SHSY5Y Neuronal Cancer Cells. *Appl Biochem*  
 1485 *Biotechnol*. 186, 350-357.
- 1486 Chan, Y. S., Cheung, R. C., Xia, L., Wong, J. H., Ng, T. B., & Chan, W. Y., 2016. Snake venom toxins: toxicity  
 1487 and medicinal applications. *Appl Microbiol Biotechnol*. 100, 6165-6181.
- 1488 Cherlin, V. A., 1981. The new saw-scaled viper *Echis multisquamatus* sp. nov. from south-western and  
 1489 Middle Asia. [In Russian]. *Proc Zool Inst Acad Sci USSR*. 101, 92-95.
- 1490 Cherlin, V. A., 1990. Taxonomic revision of the snake genus *Echis* (viperidae) II. An analysis of taxonomy  
 1491 and description of new forms. [In Russian]. *Proc Zool Inst Leningrad*. 207, 193-223.
- 1492 Chippaux, J. P., & Goyffon, M., 1998. Venoms, antivenoms and immunotherapy. *Toxicon*. 36, 823-846.
- 1493 Chowdhury, A., Zdenek, C. N., & Fry, B. G., 2022. Diverse and Dynamic Alpha-Neurotoxicity Within  
 1494 Venoms from the Palearctic Viperid Snake Clade of *Daboia*, *Macrovipera*, *Montivipera*, and  
 1495 *Vipera*. *Neurotox Res*.
- 1496 Chowdhury, A., Zdenek, C. N., Lewin, M. R., Carter, R., Jagar, T., Ostanek, E., . . . Fry, B. G., 2021. Venom-  
 1497 Induced Blood Disturbances by Palearctic Viperid Snakes, and Their Relative Neutralization by  
 1498 Antivenoms and Enzyme-Inhibitors. *Front Immunol*. 12, 688802.
- 1499 Chroni, E., Papapetropoulos, S., Argyriou, A. A., & Papapetropoulos, T., 2005. A case of fatal progressive  
 1500 neuropathy. Delayed consequence of multiple bites of a non-venomous snake? *Clin Neurol*  
 1501 *Neurosurg*. 108, 45-47.
- 1502 Corkill, N. L. (1932). *Snakes and Snake Bite in Iraq : A Handbook for Medical Officers*. London, UK  
 1503 Bailliere Tindall and Cox, Royal College of Medicine of Iraq.
- 1504 Corkill, N. L., 1939. Snake Specialists in Iraq. *Iraq*. 6, 45-52.
- 1505 Dadashi Arani, M., & Mastali Parsa, G. R., 2020. Medicine and Health in Ancient Iran, Persian Language  
 1506 and Literature, and the Divan of Hakim Mashreqi Shirazi. [In Persian]. *J Payavard Salamat*. 14,  
 1507 383-393.
- 1508 Dadpour, B., Shafahi, A., Monzavi, S. M., Zavar, A., Afshari, R., & Khoshdel, A. R., 2012. Snakebite  
 1509 prognostic factors: Leading factors of weak therapeutic response following snakebite  
 1510 envenomation. *Asia Pac J Med Toxicol*. 1, 27-33.
- 1511 Darevsky, I. S., 1966. Ecology of rock-viper (*Vipera xanthina raddei* Boettger) in the natural surroundings  
 1512 of Armenia. *Mem Inst Butantan Simp Internac*. 33, 81-83.

- 1513 Darevsky, I. S. (1969). Family of Serpentine snakes (Colubridae) In: M. S. Giliarov, L. A. Zenkevich, & A. G.  
 1514 Bannikov (Eds.), *The Life of Animals, 4 (2): Amphibians and reptiles. [In Russian]* (pp. 351-391).  
 1515 Moscow, Russia: Prosveshenie Moskva.
- 1516 Darracq, M. A., Cantrell, F. L., Klauk, B., & Thornton, S. L., 2015. A chance to cut is not always a chance to  
 1517 cure- fasciotomy in the treatment of rattlesnake envenomation: A retrospective poison center  
 1518 study. *Toxicon*. 101, 23-26.
- 1519 Dashevsky, D., Debono, J., Rokyta, D., Nouwens, A., Josh, P., & Fry, B. G., 2018. Three-Finger Toxin  
 1520 Diversification in the Venoms of Cat-Eye Snakes (Colubridae: Boiga). *J Mol Evol*. 86, 531-545.
- 1521 De Filippi, F. (1865). *Note di un viaggio di Persia nel 1862. [In Italian]*. Milan, Italy: G. Daelli e C. Editori.
- 1522 Dehghani, R. (2010). *Environmental Toxicology. [In Persian]* (1st ed.). Kashan, Iran: Kashan University of  
 1523 Medical Sciences Publications.
- 1524 Dehghani, R., Ahaki Varzaneh, A., Varzandeh, M., Akbari, M., & Jahani, A., 2022. Venomous animal bites  
 1525 and stings in Lordegan city, Chaharmahal Bakhtiari province of Iran in 2019–2020. *J Entomol Res*.  
 1526 46, 694-698.
- 1527 Dehghani, R., Dadpour, B., & Mehrpour, O., 2014a. Epidemiological Profile of Snakebite in Iran, 2009-  
 1528 2010 Based on Information of Ministry of Health and Medical Education. *Int J Med Toxicol*  
 1529 *Forensic Med*. 4, 33-41.
- 1530 Dehghani, R., Fathi, B., Shahi, M. P., & Jazayeri, M., 2014b. Ten years of snakebites in Iran. *Toxicon*. 90,  
 1531 291-298.
- 1532 Dehghani, R., Kassiri, H., & Dehghani, M., 2020. A brief review on biting/stinging of animals and its risk of  
 1533 infection. *Arch Clin Infect Dis*. 15, e97499.
- 1534 Dehghani, R., Mehrpour, O., Shahi, M. P., Jazayeri, M., Karrari, P., Keyler, D., & Zamani, N., 2014c.  
 1535 Epidemiology of venomous and semi-venomous snakebites (Ophidia: Viperidae, Colubridae) in  
 1536 the Kashan city of the Isfahan province in Central Iran. *J Res Med Sci*. 19, 33-40.
- 1537 Dehghani, R., Rabani, D., Panjeh Shahi, M., Jazayeri, M., & Sabahi Bidgoli, M., 2012. Incidence of snake  
 1538 bites in kashan, iran during an eight year period (2004-2011). *Arch Trauma Res*. 1, 67-71.
- 1539 Dehghani, R., Rastegar Pouyani, N., Dadpour, B., Keyler, D., Panjehshahi, M., Jazayeri, M., . . . Habibi  
 1540 Tamijani, A., 2016a. A survey on Non-Venomous Snakes in Kashan (Central Iran). *J Biol Today*  
 1541 *World*. 5, 65-75.
- 1542 Dehghani, R., Sharif, A., Assadi, M. A., Haddad Kashani, H., & Sharif, M. R., 2016b. Fungal flora in the  
 1543 mouth of venomous and non-venomous snakes. *Comp Clin Pathol*. 25, 1207-1211.
- 1544 Dehghani, R., Sharif, A., Madani, M., Kashani, H. H., & Sharif, M. R., 2016c. Factors Influencing Animal  
 1545 Bites in Iran: A Descriptive Study. *Osong Public Health Res Perspect*. 7, 273-277.
- 1546 Dehghani, R., Sharif, M. R., Moniri, R., Sharif, A., & Haddad Kashani, H., 2015. The identification of  
 1547 bacterial flora in oral cavity of snakes. *Comp Clin Pathol*. 25, 279-283.
- 1548 del Marmol, G. M., Mozaffari, O., & Gállego, J., 2016. *Pseudocerastes urarachnoides*: the ambush  
 1549 specialist. *Bol Asoc Herpetol Esp*. 27, 36-42.
- 1550 Derakhshani, A., Silvestris, N., Hajiasgharzadeh, K., Mahmoudzadeh, S., Fereidouni, M., Paradiso, A. V., . .  
 1551 . Baradaran, B., 2020. Expression and characterization of a novel recombinant cytotoxin II from  
 1552 *Naja naja oxiana* venom: A potential treatment for breast cancer. *Int J Biol Macromol*. 162,  
 1553 1283-1292.
- 1554 Dhananjaya, B. L., Menon, J. C., Joseph, J. K., Raveendran, D. K., & Oommen, O. V. (2015). Snake Venom  
 1555 Detection Kit (SVDK): Update on Current Aspects and Challenges. In: P. Gopalakrishnakone, A.  
 1556 Faiz, R. Fernando, C. Gnanathanan, A. Habib, & Y. C.C. (Eds.), *Clinical Toxinology in Asia Pacific*  
 1557 *and Africa* (pp. 379-400). Netherlands, Dordrecht: Springer.
- 1558 Di Nicola, M. R., Pontara, A., Kass, G. E. N., Kramer, N. I., Avella, I., Pampena, R., . . . Paolino, G., 2021.  
 1559 Vipers of Major clinical relevance in Europe: Taxonomy, venom composition, toxicology and  
 1560 clinical management of human bites. *Toxicology*. 453, 152724.

- 1561 Dorooshi, G., Javid, Z. N., Meamar, R., Farjadegan, Z., Nasri, M., & Eizadi-Mood, N., 2021. Evaluation of  
 1562 The effects of Anti-Inflammatory Drugs on Local and Systemic manifestations of snakebite: A  
 1563 cross-sectional study. *J Venom Res.* 11, 21-25.
- 1564 Ebrahim, K., Shirazi, F. H., Mirakabadi, A. Z., & Vatanpour, H., 2015. Cobra venom cytotoxins; apoptotic  
 1565 or necrotic agents? *Toxicon.* 108, 134-140.
- 1566 Ebrahim, K., Vatanpour, H., Zare, A., Shirazi, F. H., & Nakhjavani, M., 2016. Anticancer Activity of a  
 1567 Caspian Cobra (*Naja naja oxiana*) snake Venom in Human Cancer Cell Lines Via Induction of  
 1568 Apoptosis. *Iran J Pharm Res.* 15, 101-112.
- 1569 Ebrahimi, V., Hamdami, E., Khademian, M. H., Moemenbellah-Fard, M. D., & Vazirianzadeh, B., 2018.  
 1570 Epidemiologic prediction of snake bites in tropical south Iran: Using seasonal time series  
 1571 methods. *Clin Epidemiol Glob Health.* 6, 208-215.
- 1572 Efendiev, I. N. (2021). Modern approaches to the provision of specialized medical aid for Gyrza bites  
 1573 and other viper family snakebites. [In Russian]. In: V. A. Manukovskiy, V. E. Parfenov, I. A.  
 1574 Voznyuk, & I. M. Barsukova (Eds.), *Dzhanelidzevskie Readings* (pp. 185-187). Saint Petersburg,  
 1575 Russia: Dzhanelidze Research Institute of Emergency Medicine.
- 1576 Elfiky, A. A., Girgis, E. F., Zid, M. M., & Mohamed, Y. E., 2022. Cross neutralization of some kinds of vipers  
 1577 and snake venoms from Africa and Middle East using VACSERA polyvalent viper antisera. *J Egypt  
 1578 Soc Parasitol.* 52, 363-370.
- 1579 Elkabbaj, D., Hassani, K., & El Jaoudi, R., 2012. Acute renal failure following the Saharan horned viper  
 1580 (*Cerastes cerastes*) bite. *Arab J Nephrol Transplant.* 5, 159-161.
- 1581 Elmi, M. M., Amininasab, M., Hondo, T., Kikuchi, J., Kuroda, Y., Naderi-Manesh, H., & Sarbolouki, M. N.,  
 1582 2006. Structural and functional characterization of a mutant of *Pseudocerastes persicus*  
 1583 natriuretic peptide. *Protein Pept Lett.* 13, 295-300.
- 1584 Eskafi, A. H., Bagheri, K. P., Behdani, M., Yamabhai, M., Shahbazzadeh, D., & Kazemi-Lomedasht, F.,  
 1585 2021. Development and characterization of human single chain antibody against Iranian  
 1586 *Macrovipera lebetina* snake venom. *Toxicon.* 197, 106-113.
- 1587 Eslamian, L., Mobaiyen, H., Bayat-Makoo, Z., Piri, R., Benisi, R., & Naghavi-Behzad, M., 2016. Snake bite  
 1588 in Northwest Iran: A retrospective study. *J Anal Res Clin Med.* 4, 133-138.
- 1589 Esmaili Jahromi, H., Zare Mirakabadi, A., & Kamalzadeh, M., 2016. Evaluation of Iranian Snake  
 1590 '*Macrovipera lebetina*' Venom Cytotoxicity in Kidney Cell Line HEK-293. *Asia Pac J Med Toxicol.*  
 1591 5, 49-54.
- 1592 Esmaili, A., Kamyab, M., Fatemikia, H., Ahmadzadeh, H., Movahed, A., Kim, E., . . . Seyedian, R., 2021.  
 1593 Experimental Evaluation of Mouse Hind Paw Edema Induced by Iranian *Naja oxiana* Venom.  
 1594 *Arch Razi Inst.* 76, 139-147.
- 1595 Ettling, J., Aghasyan, A., & Aghasyan, L., 2012. Envenomation by an Armenian Viper, *Montivipera raddei*  
 1596 (Boettger 1890): A Case History. *Russ J Herpetol.* 19, 203-206.
- 1597 Fakhmanesh, Z., Rastegar Pouyani, E., & Kami, H. G., 2014. The Study of Genetic Variation in Different  
 1598 Populations of the Zigzag Mountain Viper (*Montivipera albicornuta*) in Its Distribution Range by  
 1599 Using Mitochondrial Gene Sequencing. [In Persian]. *J Anim Biol.* 7, 67-74.
- 1600 Fallahi, N., Shahbazzadeh, D., Maleki, F., Aghdasi, M., Tabatabaie, F., & Khanaliha, K., 2020. The In Vitro  
 1601 Study of Anti-leishmanial Effect of *Naja naja oxiana* Snake Venom on *Leishmania major*. *Infect  
 1602 Disord Drug Targets.* 20, 913-919.
- 1603 Farstad, D., Thomas, T., Chow, T., Bush, S., & Stiegler, P., 1997. Mojave rattlesnake envenomation in  
 1604 southern California: a review of suspected cases. *Wilderness Environ Med.* 8, 89-93.
- 1605 Farzad, R., Gholami, A., Hayati Roodbari, N., & Shahbazzadeh, D., 2020. The anti-rabies activity of  
 1606 Caspian cobra venom. *Toxicon.* 186, 175-181.
- 1607 Farzan, M., Karami, M., & Kaseb, M. H., 2003. A case report of Volkmann's ischemic contracture in  
 1608 extensor muscle of forearm following snakebite. [In Persian]. *Sci J Forensic Med.* 9, 143-146.

- 1609 Farzaneh, E., Fouladi, N., Shafaei, Y., Mirzamohammadi, Z., Naslseraji, F., & Mehrpour, O., 2017.  
 1610 Epidemiological study of snakebites in Ardabil Province (Iran). *Electron Physician*. 9, 3986-3990.
- 1611 Farzanpay, R. (1990). *Ophiology. [In Persian]*. Iran, Tehran: Iran University Press
- 1612 Fatehi-Hassanabad, Z., & Fatehi, M., 2004. Characterisation of some pharmacological effects of the  
 1613 venom from *Vipera lebetina*. *Toxicon*. 43, 385-391.
- 1614 Fathi, B., Yonuesi, F., & Salami, F., 2022. Acute Venom Toxicity Determinations for Five Iranian Vipers  
 1615 and a scorpion. *Iran J Toxicol*. 16, 73-82.
- 1616 Fathinia, B., Anderson, S. C., Rastegar-Pouyani, N., Jahani, H., & Mohamadi, H., 2009. Notes on the  
 1617 natural history of *Pseudocerastes urarachnoides* (Squamata: Viperidae). *Russ J Herpetol*. 16,  
 1618 134-138.
- 1619 Fathinia, B., & Rastegar-Pouyani, N., 2010. On the species of *Pseudocerastes* (Ophidia: Viperidae) in Iran.  
 1620 *Russ J Herpetol*. 17, 275-279.
- 1621 Fathinia, B., Rastegar-Pouyani, N., & Rastegar-Pouyani, E., 2018. Molecular phylogeny and historical  
 1622 biogeography of genera *Eristicophis* and *Pseudocerastes* (Ophidia, Viperidae). *Zool Scr*. 47, 673-  
 1623 685.
- 1624 Fathinia, B., Rastegar-Pouyani, N., Rastegar-Pouyani, E., Todehdehghan, F., & Mansouri, M., 2016.  
 1625 Annual activity pattern of *Pseudocerastes urarachnoides* BOSTANCHI, ANDERSON, KAMI &  
 1626 PAPENFUSS, 2006, with notes on its natural history (Squamata: Serpentes: Viperidae).  
 1627 *Herpetozoa*. 29, 135-142.
- 1628 Fathinia, B., Rastegar-Pouyani, N., Rastegar-Pouyani, E., Toodeh-Dehghan, F., & Rajabzadeh, M., 2014.  
 1629 Molecular systematics of the genus *Pseudocerastes* (Ophidia: Viperidae) based on the  
 1630 mitochondrial cytochrome  $\beta$  gene. *Turk J Zool*. 38, 575-581.
- 1631 Fathinia, B., Rastegar Pouyani, N., & Rajabzadeh, M., 2011. The snake fauna of Ilam Province,  
 1632 southwestern Iran. *Iran J Anim Biosyst*. 6, 9-23.
- 1633 Fathinia, B., Rödder, D., Rastegar-Pouyani, N., Rastegar-Pouyani, E., Hosseinzadeh, M. S., & Kazemi, S.  
 1634 M., 2020. The past, current and future habitat range of the Spider-tailed Viper, *Pseudocerastes*  
 1635 *urarachnoides* (Serpentes: Viperidae) in western Iran and eastern Iraq as revealed by habitat  
 1636 modelling. *Zool Middle East*. 66, 197-205.
- 1637 Figueroa, A., McKelvy, A. D., Grismer, L. L., Bell, C. D., & Lailvaux, S. P., 2016. A Species-Level Phylogeny  
 1638 of Extant Snakes with Description of a New Colubrid Subfamily and Genus. *PLoS One*. 11,  
 1639 e0161070.
- 1640 Firouz, E. (2005). *The Complete Fauna of Iran*. New York, USA: I.B. Tauris.
- 1641 Francis, B., Bdolah, A., & Kaiser, II. 1995. Amino acid sequences of a heterodimeric neurotoxin from the  
 1642 venom of the false horned viper (*Pseudocerastes fieldi*). *Toxicon*. 33, 863-874.
- 1643 Freitas, I., Ursenbacher, S., Mebert, K., Zinenko, O., Schweiger, S., Wüster, W., . . . Fahd, S., 2020.  
 1644 Evaluating taxonomic inflation: towards evidence-based species delimitation in Eurasian vipers  
 1645 (Serpentes: Viperinae). *Amphibia-Reptilia*. 41, 285-311.
- 1646 Fry, B. G., Wuster, W., Ryan Ramjan, S. F., Jackson, T., Martelli, P., & Kini, R. M., 2003. Analysis of  
 1647 Colubroidea snake venoms by liquid chromatography with mass spectrometry: evolutionary and  
 1648 toxinological implications. *Rapid Commun Mass Spectrom*. 17, 2047-2062.
- 1649 Fuchs, J., Gessner, T., Kupferschmidt, H., & Weiler, S., 2022. Exotic venomous snakebites in Switzerland  
 1650 reported to the National Poisons Information Centre over 22 years. *Swiss Med Wkly*. 152,  
 1651 w30117.
- 1652 Garcia-Arredondo, A., Martinez, M., Calderon, A., Saldivar, A., & Soria, R., 2019. Preclinical Assessment  
 1653 of a New Polyvalent Antivenom (Inoserp Europe) against Several Species of the Subfamily  
 1654 Viperinae. *Toxins (Basel)*. 11, 149.
- 1655 Garcia-Lima, E., & Laure, C. J., 1987. A study of bacterial contamination of rattlesnake venom. *Rev Soc*  
 1656 *Bras Med Trop*. 20, 19-21.

- 1657 Gasanov, S. E., Dagda, R. K., & Rael, E. D., 2014. Snake Venom Cytotoxins, Phospholipase A2s, and  
 1658 Zn(2+)-dependent Metalloproteinases: Mechanisms of Action and Pharmacological Relevance. *J*  
 1659 *Clin Toxicol.* 4, 1000181.
- 1660 Gasanov, S. E., Shrivastava, I. H., Israilov, F. S., Kim, A. A., Rylova, K. A., Zhang, B., & Dagda, R. K., 2015.  
 1661 *Naja naja oxiana* Cobra Venom Cytotoxins CTI and CTII Disrupt Mitochondrial Membrane  
 1662 Integrity: Implications for Basic Three-Fingered Cytotoxins. *PLoS One.* 10, e0129248.
- 1663 Ghelichy Salakh, A., Kami, H., & Rajabzadeh, M., 2020. Modeling the species distribution of Caucasian  
 1664 pit viper (*Gloydius halys caucasicus*)(Viperidae: Crotalinae) under the influence of climate  
 1665 change. *Caspian J Environ Sci.* 18, 217-226.
- 1666 Ghelichy Salakh, A., Kami, H. G., & Rajabzadeh, K., 2019. Distribution modeling of Caucasian pit viper,  
 1667 *Gloydius halys caucasicus* in Iran (Ophidia: Viperidae). [In Persian]. *J Anim Environ.* 11, 139-146.
- 1668 Ghezellou, P., Albuquerque, W., Garikapati, V., Casewell, N. R., Kazemi, S. M., Ghassempour, A., &  
 1669 Spengler, B., 2021. Integrating Top-Down and Bottom-Up Mass Spectrometric Strategies for  
 1670 Proteomic Profiling of Iranian Saw-Scaled Viper, *Echis carinatus sochureki*, Venom. *J Proteome*  
 1671 *Res.* 20, 895-908.
- 1672 Ghezellou, P., Dillenberger, M., Kazemi, S. M., Jestrzanski, D., Hellmann, B., & Spengler, B., 2022.  
 1673 Comparative Venom Proteomics of Iranian, *Macrovipera lebetina cernovi*, and Cypriot,  
 1674 *Macrovipera lebetina lebetina*, Giant Vipers. *Toxins (Basel).* 14, 716.
- 1675 Ghezellou, P., Garikapati, V., Kazemi, S. M., Strupat, K., Ghassempour, A., & Spengler, B., 2019. A  
 1676 perspective view of top-down proteomics in snake venom research. *Rapid Commun Mass*  
 1677 *Spectrom.* 33 Suppl 1, 20-27.
- 1678 Gholamifard, A., 2011. Endemism in the reptile fauna of Iran. *Iran J Anim Biosyst.* 7, 13-29.
- 1679 Gholamifard, A., & Esmaeili, H. R., 2010. First record and range extension of Field's horned viper,  
 1680 *Pseudocerastes fieldi* Schmidt, 1930 (Squamata: Viperidae), from Fars province, southern Iran.  
 1681 *Turk J Zool.* 34, 551-552.
- 1682 Gholamifard, A., & Rastegar-Pouyani, N. (2012). *Systematics and Distribution of Walterinnesia morgani*  
 1683 *(Mocquard, 1905) (Elapidae) in Iran*. Paper presented at the 5th Asian Herpetological  
 1684 Conference, Chengdu, China.
- 1685 Gholamifard, A., Rastegar Pouayni, N., & Esmaeili, H. R., 2012. Annotated checklist of reptiles of Fars  
 1686 Province, southern Iran. *Iran J Anim Biosyst.* 8, 155-167.
- 1687 Ghorbanpur, M., Zare Mirakabadi, A., Zokaee, F., & Zolfagarrian, H., 2010. Identification and partial  
 1688 purification of an anticoagulant factor from the venom of the Iranian snake *Agkistrodon halys*. *J*  
 1689 *Venom Anim Toxins Incl Trop Dis.* 16, 96-106.
- 1690 Ghorbanpur, M., Zare Mirakabadi, A., Zokaee, F., Zolfagarrian, H., & Rabiei, H., 2009. Purification and  
 1691 partial characterization of a coagulant serine protease from the venom of the Iranian snake  
 1692 *Agkistrodon halys*. *J Venom Anim Toxins Incl Trop Dis.* 15, 411-423.
- 1693 Ghulikyan, L. A., Mohamadvarzi, M., Ghukasyan, G. V., Kishmiryan, A. V., Zaqaryan, N. A., Kirakosyan, G.  
 1694 R., & Ayvazyan, N. M., 2016. Molecular events associated with *Vipera latifi* venom effect on  
 1695 condition of human red blood cells. *Proc Yerevan State Univ Chem Biol.* 240, 43-50.
- 1696 Gillett, A. K., Flint, M., & Mills, P. C., 2014. An antemortem guide for the assessment of stranded  
 1697 Australian sea snakes (Hydrophiinae). *J Zoo Wildl Med.* 45, 755-765.
- 1698 Gitter, S., Moroz-Perlmutter, C., Boss, J. H., Livni, E., Rechnic, J., Goldblum, N., & De Vries, A., 1962.  
 1699 Studies on the snake venoms of the near east: *Walterinnesia aegyptia* and *Pseudocerastes*  
 1700 *fieldii*. *Am J Trop Med Hyg.* 11, 861-868.
- 1701 Gold, B. S., Dart, R. C., & Barish, R. A., 2002. Bites of venomous snakes. *N Engl J Med.* 347, 347-356.
- 1702 Gonzales, D., 1978. Contribution to the clinical and epidemiological aspects of snake bites in Spain.  
 1703 *Period Biol.* 80, 135-139.

- 1704 Greene, S., Cheng, D., Vilke, G. M., & Winkler, G., 2021. How Should Native Crotalid Envenomation Be  
1705 Managed in the Emergency Department? *J Emerg Med.* 61, 41-48.
- 1706 Guibé, J., 1957. Reptiles from Iran collected by Mr. Francis Petter. Description of a new Viperidae:  
1707 *Pseudocerastes latirostris*, n. sp [In French]. *Bull Mus Natl Hist.* 29, 136-143.
- 1708 Gutierrez, J. M., 2018. Antivenoms: Life-saving drugs for envenomings by animal bites and stings.  
1709 *Toxicon.* 150, 11-12.
- 1710 Gutierrez, J. M., Calvete, J. J., Habib, A. G., Harrison, R. A., Williams, D. J., & Warrell, D. A., 2017.  
1711 Snakebite envenoming. *Nat Rev Dis Primers.* 3, 17063.
- 1712 Hafezi, G., Rahmani, A. H., Soleymani, M., & Nazari, P., 2018. An Epidemiologic and Clinical Study of  
1713 Snake Bites during a Five-Year Period in Karoon, Iran. *Asia Pac J Med Toxicol.* 7, 13-16.
- 1714 Hajjalani, F., Elmi, T., Mohamadi, M., Sadeghi, S., Shahbazzadeh, D., Ghaffarifar, F., . . . Zamani, Z., 2020.  
1715 Analysis of the active fraction of Iranian *Naja naja oxiana* snake venom on the metabolite  
1716 profiles of the malaria parasite by (1)HNMR in vitro. *Iran J Basic Med Sci.* 23, 534-543.
- 1717 Hamza, L., Gargioli, C., Castelli, S., Rufini, S., & Laraba-Djebari, F., 2010. Purification and characterization  
1718 of a fibrinogenolytic and hemorrhagic metalloproteinase isolated from *Vipera lebetina* venom.  
1719 *Biochimie.* 92, 797-805.
- 1720 Harvey, A. L., Barfaraz, A., Thomson, E., Faiz, A., Preston, S., & Harris, J. B., 1994. Screening of snake  
1721 venoms for neurotoxic and myotoxic effects using simple in vitro preparations from rodents and  
1722 chicks. *Toxicon.* 32, 257-265.
- 1723 Hassanian-Moghaddam, H., Monzavi, S. M., Shirazi, F. M., Warrell, D. A., & Mehrpour, O., 2022. First  
1724 report of a confirmed case of *Montivipera latifii* (Latifi's viper) envenoming and a literature  
1725 review of envenoming by *Montivipera* species. *Toxicon.* 207, 48-51.
- 1726 Heiner, J. D., Beberta, V. S., Varney, S. M., Bothwell, J. D., & Cronin, A. J., 2013. Clinical Effects and  
1727 Antivenom Use for Snake Bite Victims Treated at Three US Hospitals in Afghanistan. *Wilderness*  
1728 *Environ Med.* 24, 412-416.
- 1729 Hempel, B. F., Damm, M., Gocmen, B., Karis, M., Oguz, M. A., Nalbantsoy, A., & Sussmuth, R. D., 2018.  
1730 Comparative Venomics of the *Vipera ammodytes transcaucasiana* and *Vipera ammodytes*  
1731 *montandoni* from Turkey Provides Insights into Kinship. *Toxins (Basel).* 10, 23.
- 1732 Heydari Sereshk, Z., & Riyahi Bakhtiari, A., 2014. Distribution patterns of PAHs in different tissues of  
1733 annulated sea snake (*Hydrophis cyanocinctus*) and short sea snake (*Lapemis curtus*) from the  
1734 Hara Protected Area on the North Coast of the Persian Gulf, Iran. *Ecotoxicol Environ Saf.* 109,  
1735 116-123.
- 1736 Höggren, M., Nilson, G., Andrén, C., Orlov, N. L., & Tuniyev, B. S., 1993. Vipers of the Caucasus: natural  
1737 history and systematic review. *Herpetol Nat Hist.* 1, 11-19.
- 1738 Hosseinian Yousefkhani, S. S., Yousefi, M., Khani, A., & Rsategar-Pouyani, E., 2014. Snake fauna of  
1739 Shirahmad wildlife refuge and Parvand protected area, Khorasan Razavi province, Iran. *Herpetol*  
1740 *Notes.* 7, 75-82.
- 1741 Hosseinzadeh, M. S., Aliabadian, M., Rastegar-Pouyani, E., & Rastegar-Pouyani, N., 2014. The roles of  
1742 environmental factors on reptile richness in Iran. *Amphibia-Reptilia.* 35, 215-225.
- 1743 Ibrahim, A. M., ElSefi, T. T., Ghanem, M., Fayed, A. M., & Shaban, N. A., 2017. A Horned Viper Bite Victim  
1744 with PRES. *Case Rep Neurol Med.* 2017, 1835796.
- 1745 IFDA. (2021, Jan 4). Iran Essential Medicine List. 2nd ed. Tehran, Iran: Iranian Food & Drug  
1746 Administration. Retrieved from: <https://www.fda.gov.ir/getattachment/c1d15ec6-a2b8-4804-9c33-739e28d12e75>
- 1747  
1748 Igci, N., & Demiralp, D. O., 2012. A preliminary investigation into the venom proteome of *Macrovipera*  
1749 *lebetina obtusa* (Dwigubsky, 1832) from Southeastern Anatolia by MALDI-TOF mass  
1750 spectrometry and comparison of venom protein profiles with *Macrovipera lebetina lebetina*  
1751 (Linnaeus, 1758) from Cyprus by 2D-PAGE. *Arch Toxicol.* 86, 441-451.

- 1752 Ineich, I., Girard, F., & Weinstein, S. A., 2020. Local envenoming by the Schokari sand racer, *Psammophis*  
 1753 *schokari* Forskal, 1775 (Serpentes, Psammophiidae) and a brief review of reported bites by sand  
 1754 racers (*Psammophis* spp.). *Toxicon*. 185, 72-75.
- 1755 Isbister, G. K., Brown, S. G., Page, C. B., McCoubrie, D. L., Greene, S. L., & Buckley, N. A., 2013. Snakebite  
 1756 in Australia: a practical approach to diagnosis and treatment. *Med J Aust*. 199, 763-768.
- 1757 Ishunin, G. I., 1950. Case of envenoming by a non-venomous snake. [In Russian]. *Izv Akad Nauk Uzb SSR*.  
 1758 6, 93-95.
- 1759 Jalali, A., Savari, M., Dehdardargahi, S., & Azarpanah, A., 2012. The pattern of poisoning in southwestern  
 1760 region of Iran: envenoming as the major cause. *Jundishapur J Nat Pharm Prod*. 7, 100-105.
- 1761 Javani Jouni, F., Zafari, J., Shams, E., Abdolmaleki, P., & Rastegari, A. A., 2022. Evaluation of Anti-Cancer  
 1762 Effects of Caspian Cobra (*Naja naja oxiana*) Snake Venom in Comparison with Doxorubicin in  
 1763 HeLa Cancer Cell Line and Normal HFF Fibroblast. [In Persian]. *J Ilam Univ Med Sci*. 29, 20-27.
- 1764 Jayne, W. A., 1919. The Medical Gods of Ancient Iran. *Ann Med Hist*. 2, 8-13.
- 1765 Jimenez-Cazalla, F. (2012). *Malpolon insignitus* (Geoffroy Saint-Hilaire, 1827). In: Martínez, G., León, R.,  
 1766 Jiménez-Robles, O., González De la Vega, J. P., Gabari, V., Rebollo, B., Sánchez-Tójar, A.,  
 1767 Fernández-Cardenete, J. R., Gállego, J. (Eds.). *Moroccoherps. Amphibians and Reptiles of*  
 1768 *Morocco and Western Sahara*. Retrieved from:  
 1769 [http://www.moroccoherps.com/en/ficha/Malpolon\\_insignitus/](http://www.moroccoherps.com/en/ficha/Malpolon_insignitus/)
- 1770 Joger, U. (1984). *The venomous snakes of the Near and Middle East*. Wiesbaden, Germany: Reichert  
 1771 Verlag.
- 1772 Johnston, C. I., Ryan, N. M., Page, C. B., Buckley, N. A., Brown, S. G., O'Leary, M. A., & Isbister, G. K.,  
 1773 2017. The Australian Snakebite Project, 2005-2015 (ASP-20). *Med J Aust*. 207, 119-125.
- 1774 Jowkar, H., Ostrowski, S., Tahbaz, M., & Zahler, P., 2016. The Conservation of Biodiversity in Iran:  
 1775 Threats, Challenges and Hopes. *Iran Stud*. 49, 1065-1077.
- 1776 Junqueira-de-Azevedo, I. L., Campos, P. F., Ching, A. T., & Mackessy, S. P., 2016. Colubrid Venom  
 1777 Composition: An -Omics Perspective. *Toxins (Basel)*. 8, 230.
- 1778 Kadkhodazadeh, M., Rajabibazl, M., Motedayen, M., Shahidi, S., Veisi Malekshahi, Z., Rahimpour, A., &  
 1779 Yarahmadi, M., 2020. Isolation of Polyclonal Single-Chain Fragment Variable (scFv) Antibodies  
 1780 Against Venomous Snakes of Iran and Evaluation of Their Capability in Neutralizing the Venom.  
 1781 *Iran J Pharm Res*. 19, 288-296.
- 1782 Kakanj, M., Ghazi-Khansari, M., Zare Mirakabadi, A., Daraei, B., & Vatanpour, H., 2015. Cytotoxic Effect  
 1783 of Iranian *Vipera lebetina* Snake Venom on HUVEC Cells. *Iran J Pharm Res*. 14, 109-114.
- 1784 Kamyab, M., Kim, E., Hoseiny, S. M., & Seyedian, R., 2017. Enzymatic Analysis of Iranian *Echis carinatus*  
 1785 Venom Using Zymography. *Iran J Pharm Res*. 16, 1155-1160.
- 1786 Karabuva, S., Vrkic, I., Brizic, I., Ivic, I., & Luksic, B., 2016. Venomous snakebites in children in southern  
 1787 Croatia. *Toxicon*. 112, 8-15.
- 1788 Kassiri, H., Khodkar, I., Kazemi, S., Kasiri, N., & Lotfi, M., 2019. Epidemiological analysis of snakebite  
 1789 victims in southwestern Iran. *J Acute Dis*. 8, 260-264.
- 1790 Kasturiratne, A., Wickremasinghe, A. R., de Silva, N., Gunawardena, N. K., Pathmeswaran, A.,  
 1791 Premaratna, R., . . . de Silva, H. J., 2008. The global burden of snakebite: a literature analysis and  
 1792 modelling based on regional estimates of envenoming and deaths. *PLoS Med*. 5, e218.
- 1793 Kaviani Pooya, H., 2010. Medicine and Evolution of Treatment in Ancient Iran. [In Persian]. *J Med Hist*. 2,  
 1794 67-98.
- 1795 Kazemi-Lomedasht, F., Yamabhai, M., Sabatier, J. M., Behdani, M., Zareinejad, M. R., & Shahbazzadeh,  
 1796 D., 2019. Development of a human scFv antibody targeting the lethal Iranian cobra (*Naja oxiana*)  
 1797 snake venom. *Toxicon*. 171, 78-85.



- 1798 Kazemi, E., Kaboli, M., & Khorasani, N., 2021a. Genetic diversity of *Naja oxiana* (Eichwald, 1831)  
 1799 populations in Iran using cytochrome b mitochondrial marker. [In Persian]. *J Anim Environ.* 13,  
 1800 197-206.
- 1801 Kazemi, E., Nazarizadeh, M., Fatemizadeh, F., Khani, A., & Kaboli, M., 2021b. The phylogeny,  
 1802 phylogeography, and diversification history of the westernmost Asian cobra (Serpentes:  
 1803 Elapidae: *Naja oxiana*) in the Trans-Caspian region. *Ecol Evol.* 11, 2024-2039.
- 1804 Kazemi Shishavan, M., & Maleki, R., 2018. Comparative Study of Symbol: Iranian Contemporary  
 1805 Architecture and Seljuk (Case Study:Tombes) *Int J Archit Urban Dev.* 8, 33-50.
- 1806 Kazemi, S. M., Al-Sabi, A., Long, C., Shoulkamy, M. I., & Abd El-Aziz, T. M., 2021c. Case Report: Recent  
 1807 Case Reports of Levant Blunt-Nosed Viper *Macrovipera lebetina obtusa* Snakebites in Iran. *Am J*  
 1808 *Trop Med Hyg.* 104, 1870-1876.
- 1809 Kazemi, S. M., Jahan-Mahin, M. H., Mohammadian-Kalat, T., Hosseinzadeh, M. S., & Weinstein, S. A.,  
 1810 2023a. Local envenoming by the coinsnake or Asian racer, *Hemorrhoids nummifer* and mountain  
 1811 racer or leopard snake, *Hemorrhoids ravergeri* (Serpentes: Colubridae, Colubrinae) in Iran: A  
 1812 reminder of the importance of species identification in the medical management of snakebites.  
 1813 *Toxicon.* 226, 107070.
- 1814 Kazemi, S. M., Jahan-Mahin, M. H., Zangi, B., Khozani, R. S., & Warrell, D. A., 2023b. A case of  
 1815 envenoming by a Persian false-horned viper *Pseudocerastes persicus* (Duméril, Bibron &  
 1816 Duméril, 1854) (Serpentes: Viperidae) in Southeastern Iran. *Toxicon.* 223, 107009.
- 1817 Kelly, C. M. R., Barker, N. P., Villet, M. H., & Broadley, D. G., 2009. Phylogeny, biogeography and  
 1818 classification of the snake superfamily Elapoidea: a rapid radiation in the late Eocene. *Cladistics.*  
 1819 25, 38-63.
- 1820 Khadem-Rezaiyan, M., Moallem, S. R., & Afshari, R., 2018. Epidemiology of Snake, Spider and Scorpion  
 1821 Envenomation in Mashhad, Khorasan Razavi, Iran (2004-2011). *Iran J Toxicol.* 12, 27-31.
- 1822 Khan, S. U., & Al-Saleh, S. S., 2015. Biochemical characterization of a factor X activator protein purified  
 1823 from *Walterinnesia aegyptia* venom. *Blood Coagul Fibrinolysis.* 26, 772-777.
- 1824 Khani, S., Kami, H., & Rajabizadeh, M., 2017. Geographic variation of *Gloydius halys caucasicus*  
 1825 (Serpentes: Viperidae) in Iran. *Zool Middle East.* 63, 303-310.
- 1826 Khosravani, M., Mohebbi Nodez, S. M., Rafatpanah, A., Mosalla, S., & Fekri, S., 2018. The first study of  
 1827 snake and scorpion envenomation in Qeshm Island, South of Iran. *J Entomol Zool Stud.* 6, 982-  
 1828 987.
- 1829 Khosrojerdi, H., & Amini, M., 2013. Acute and delayed stress symptoms following snakebite. *Asia Pac J*  
 1830 *Med Toxicol.* 2, 140-144.
- 1831 Kirakosyan, G., Mohamadvarzi, M., Ghulikyan, L., Zaqaryan, N., Kishmiryan, A., & Ayyvazyan, N., 2016.  
 1832 Morphological and functional alteration of erythrocyte ghosts and giant unilamellar vesicles  
 1833 caused by *Vipera latifi* venom. *Comp Biochem Physiol C Toxicol Pharmacol.* 190, 48-53.
- 1834 Kochar, D. K., Tanwar, P. D., Norris, R. L., Sabir, M., Nayak, K. C., Agrawal, T. D., . . . Simpson, I. D., 2007.  
 1835 Rediscovery of severe saw-scaled viper (*Echis sochureki*) envenoming in the Thar desert region  
 1836 of Rajasthan, India. *Wilderness Environ Med.* 18, 75-85.
- 1837 Kochva, E. (1990). Venomous snakes of Israel. In: P. Gopalkrishnakone & L. M. Chou (Eds.), *Snakes of*  
 1838 *Medical Importance (Asia-Pacific region)* (pp. 311-321). Singapore, Singapore: Venom and Toxin  
 1839 Group, National University of Singapore.
- 1840 Kocourek, I., 1990. Beware of Coluber snakes! [In Croatian]. *ŽIVA (Journal of Czechoslovakian Academy*  
 1841 *of Sciences).* 38, 130.
- 1842 Kuch, U., & Mebs, D., 2002. Envenomations by Colubrid Snakes in Africa, Europe, and the Middle East. *J*  
 1843 *Toxicol Toxin Rev.* 21, 159-179.
- 1844 Kudriavtsev, S. V., 1983. Verified case of poisoning with the venom of the Central Asian cobra (*Naja*  
 1845 *oxiana* Eichw., 1831). [In Russian]. *Ter Arkh.* 55, 113-114.

- 1846 Kukushkin, O., Iskenderov, T., Bunyatova, S., & Zinenko, O., 2012. Additions to the distribution of *Vipera*  
 1847 *eriwanensis* (Serpentes: Viperidae) in Transcaucasia, with comments on the identity of vipers in  
 1848 northeastern Azerbaijan. *Herpetol Notes*. 5, 423-427.
- 1849 Kularatne, S. A., 2002. Common krait (*Bungarus caeruleus*) bite in Anuradhapura, Sri Lanka: a  
 1850 prospective clinical study, 1996-98. *Postgrad Med J*. 78, 276-280.
- 1851 Kumlutas, Y., Ilgaz, C., & Candan, K., 2015. Westernmost record of *Montivipera wagneri* (NILSON &  
 1852 ANDREN, 1984). *Herpetozoa*. 28, 98-101.
- 1853 Kurtovic, T., Lang Balija, M., Ayvazyan, N., & Halassy, B., 2014. Paraspecificity of *Vipera a. ammodytes*-  
 1854 specific antivenom towards *Montivipera raddei* and *Macrovipera lebetina obtusa* venoms.  
 1855 *Toxicon*. 78, 103-112.
- 1856 Latifi, M., 1984. Variation in yield and lethality of venoms from Iranian snakes. *Toxicon*. 22, 373-380.
- 1857 Latifi, M. (1985). *Snakes of Iran. [In Persian]*. Tehran, Iran: Iranian Department of Environment.
- 1858 Latifi, M. (1991). *Snakes of Iran (English translated version)*. Oxford, Ohio: Society for the Study of  
 1859 Amphibians and Reptiles.
- 1860 Latifi, M., R., H. A., & Eliazan, M., 1966. The Poisonous Snakes of Iran. *Mem Inst Butantan Simp Internac.*  
 1861 33, 735-744.
- 1862 Latifi, M., & Tabatabai, M., 1989. Studies on *Echis carinatus* venoms and antivenoms of different  
 1863 countries. *Arch Razi Inst*. 40, 97-105.
- 1864 Lauer, C., Zickgraf, T. L., & Weisse, M. E., 2011. Case report of probable desert black snake  
 1865 envenomation in 22-year-old male causing profound weakness and respiratory distress.  
 1866 *Wilderness Environ Med*. 22, 246-249.
- 1867 Lavonas, E. J., Ruha, A. M., Banner, W., Bebartha, V., Bernstein, J. N., Bush, S. P., . . . Hospital, A., 2011.  
 1868 Unified treatment algorithm for the management of crotaline snakebite in the United States:  
 1869 results of an evidence-informed consensus workshop. *BMC Emerg Med*. 11, 2.
- 1870 Lewis, R. L., & Gutmann, L., 2004. Snake venoms and the neuromuscular junction. *Semin Neurol*. 24,  
 1871 175-179.
- 1872 Liapis, K., Charitaki, E., & Psaroulaki, A., 2019. Case Report: Spherocytic Hemolytic Anemia after  
 1873 Envenomation by Long-Nosed Viper (*Vipera ammodytes*). *Am J Trop Med Hyg*. 101, 1442-1445.
- 1874 Lifshitz, M., Maimon, N., & Livnat, S., 2003. *Walterinnesia aegyptia* envenomation in a 22-year-old  
 1875 female: a case report. *Toxicon*. 41, 535-537.
- 1876 Lillywhite, H. B., Sheehy, C. M., 3rd, Brischoux, F., & Grech, A., 2014. Pelagic sea snakes dehydrate at sea.  
 1877 *Proc Biol Sci*. 281, 20140119.
- 1878 Logonder, U., Krizaj, I., Rowan, E. G., & Harris, J. B., 2008. Neurotoxicity of ammodytoxin a in the  
 1879 envenoming bites of *Vipera ammodytes ammodytes*. *J Neuropathol Exp Neurol*. 67, 1011-1019.
- 1880 Lomonte, B., Pla, D., Sasa, M., Tsai, W. C., Solorzano, A., Urena-Diaz, J. M., . . . Calvete, J. J., 2014. Two  
 1881 color morphs of the pelagic yellow-bellied sea snake, *Pelamis platura*, from different locations of  
 1882 Costa Rica: snake venomomics, toxicity, and neutralization by antivenom. *J Proteomics*. 103, 137-  
 1883 152.
- 1884 Lumsden, N. G., Fry, B. G., Manjunatha Kini, R., & Hodgson, W. C., 2004. In vitro neuromuscular activity  
 1885 of 'colubrid' venoms: clinical and evolutionary implications. *Toxicon*. 43, 819-827.
- 1886 Mackessy, S. P., 2002. Biochemistry and pharmacology of colubrid snake venoms. *J Toxicol Toxin Rev*.  
 1887 21, 43-83.
- 1888 Madani, R., Razavi, S. M., & Golchinfar, F., 2018. Determination of thelethal dose (LD50) and the  
 1889 effective dose (ED50) of Iranian horned viper venom. [In Persian]. *Vet Res Biol Prod*. 31, 70-76.
- 1890 Malekara, E., Pazhouhi, M., Rashidi, I., & Jalili, C., 2020. Anti-proliferative and cytotoxic effect of Iranian  
 1891 snake (*Vipera raddei kurdistanica*) venom on human breast cancer cells via reactive oxygen  
 1892 species-mediated apoptosis. *Res Pharm Sci*. 15, 76-86.

- 1893 Malekoutian, M., Karamiani, R., & Rastegar-Pouyani, N., 2018. Study of Snake Fauna of Kangavar County,  
1894 Kermanshah Province. [In Persian]. J Environ Sci Technol. 20, 257-264.
- 1895 Malik, G. M., 1995. Snake bites in adults from the Asir region of southern Saudi Arabia. Am J Trop Med  
1896 Hyg. 52, 314-317.
- 1897 Mamonov, G., 1977. Case report of envenomation by the mountain racer *Coluber ravergieri* in USSR. The  
1898 Snake. 9, 27-28.
- 1899 Marinov, I., Atanasov, V. N., Stankova, E., Duhalov, D., Petrova, S., & Hubenova, A., 2010. Severe  
1900 coagulopathy after *Vipera ammodytes ammodytes* snakebite in Bulgaria: a case report. Toxicon.  
1901 56, 1066-1069.
- 1902 Mashhadi, I., Kavousi, Z., Peymani, P., Salman Zadeh Ramhormozi, S., & Keshavarz, K., 2017. Economic  
1903 Burden of Scorpion Sting and Snake Bite from a Social Perspective in Iran. Shiraz E Med J. 18,  
1904 e57573.
- 1905 Massey, D. J., Calvete, J. J., Sanchez, E. E., Sanz, L., Richards, K., Curtis, R., & Boesen, K., 2012. Venom  
1906 variability and envenoming severity outcomes of the *Crotalus scutulatus scutulatus* (Mojave  
1907 rattlesnake) from Southern Arizona. J Proteomics. 75, 2576-2587.
- 1908 McDiarmid, R. W., Campbell, J. A., & Touré, T. A. (1999). *Snake species of the world : a taxonomic and*  
1909 *geographic reference*. Washington, DC: Herpetologists' League.
- 1910 Mebert, K., Göçmen, B., İçci, N., Karış, M., Oğuz, M. A., Yıldız, M. Z., . . . Ursenbacher, S., 2020. Mountain  
1911 Vipers in Central-Eastern Turkey: Huge Range Extensions for Four Taxa Reshape Decades of  
1912 Misleading Perspectives. Herpetol Conserv Biol. 15, 169-187.
- 1913 Mehdizadeh Kashani, T., Vatanpour, H., Zolfagharian, H., Hooshdar Tehrani, H., Heydari, M. H., &  
1914 Kobarfard, F., 2012. Partial Fractionation of Venoms from Two Iranian Vipers, *Echis carinatus*  
1915 and *Cerastes persicus* Fieldi and Evaluation of Their Antiplatelet Activity. Iran J Pharm Res. 11,  
1916 1183-1189.
- 1917 Mehrpour, O., Akbari, A., Nakhaee, S., Esmaeli, A., Mousavi Mirzaei, S. M., Ataei, H., & Amirabadizadeh,  
1918 A., 2018. A case report of a patient with visual hallucinations following snakebite. J Surg Trauma.  
1919 6, 73-76.
- 1920 Mehta, S. R., & Sashindran, V. K., 2002. Clinical Features and Management of Snake Bite. Med J Armed  
1921 Forces India. 58, 247-249.
- 1922 Meissner, A., Hausmann, B., Linn, C., Piepgras, P., Monig, H., Wronski, R., & Bruhn, H. D., 1989.  
1923 Defibrination syndrome after snake bites. [In German]. Dtsch Med Wochenschr. 114, 1484-  
1924 1487.
- 1925 Mertens, R., 1965. The not well-known "sidewinders" of the Asian secret adders. [In German]. Natur und  
1926 Museum Frankfurt a. M., 95, 346-352.
- 1927 Minton, S. A., 1966. A contribution to the herpetology of West Pakistan. Bull Am Mus Nat Hist. 134, 27-  
1928 184.
- 1929 Minton, S. A., 1990. Venomous bites by nonvenomous snakes: an annotated bibliography of colubrid  
1930 envenomation. J Wilderness Med. 1, 119-127.
- 1931 Minton, S. A., Jr., 1967. Paraspecific protection by elapid and sea snake antivenins. Toxicon. 5, 47-55.
- 1932 Mirtschin, P., Rasmussen, A., & Weinstein, S. (2018). *Australia's Dangerous Snakes: Identification,*  
1933 *Biology and Envenoming* (1st ed.). Melbourne, Australia: CSIRO Publishing.
- 1934 Mittel'man, L. S., 1966. Action of venom of the central Asian cobra (*Naja oxiana* eich.) on the blood-  
1935 coagulating system. [In Russian]. Biull Eksp Biol Med. 62, 69-71.
- 1936 Modahl, C. M., & Mackessy, S. P., 2019. Venoms of Rear-Fanged Snakes: New Proteins and Novel  
1937 Activities. Front Ecol Evol. 7, 279.
- 1938 Modahl, C. M., Saviola, A. J., & Mackessy, S. P. (2016). Venoms of Colubrids. In *Venom Genomics and*  
1939 *Proteomics* (pp. 51-79). Dordrecht, Netherlands: Springer.

- 1940 Mohammad Alizadeh, A., Hassanian-Moghaddam, H., Zamani, N., Rahimi, M., Mashayekhian, M.,  
 1941 Hashemi Domeneh, B., . . . Ostadi, A., 2016. The Protocol of Choice for Treatment of Snake Bite.  
 1942 Adv Med. 2016, 7579069.
- 1943 Mohebbi, G., Seyedian, R., & Nabipour, I., 2016. The toxinology of sea snakes: A systematic review. [In  
 1944 Persian]. Iran South Med J. 19, 662-703.
- 1945 Mondal, R. N., Chowdhury, F. R., Rani, M., Mohammad, N., Islam, M. M., Haque, M. A., & Faiz, M. A.,  
 1946 2012. Pre-Hospital and Hospital Management Practices and Circumstances behind Venomous  
 1947 Snakebite in Northwestern Part of Bangladesh. Asia Pac J Med Toxicol. 1, 18-21.
- 1948 Monzavi, S. M., Afshari, R., Khoshdel, A. R., Mahmoudi, M., Salarian, A. A., Samieimanesh, F., . . .  
 1949 Mihandoust, A., 2019a. Analysis of effectiveness of Iranian snake antivenom on Viper venom  
 1950 induced effects including analysis of immunologic biomarkers in the Echis carinatus sochureki  
 1951 envenomed victims. Toxicon. 158, 38-46.
- 1952 Monzavi, S. M., Afshari, R., Khoshdel, A. R., Salarian, A. A., Khosrojerdi, H., & Mihandoust, A., 2019b.  
 1953 Interspecies Variations in Clinical Envenoming Effects of Viper Snakes Evolutionized in a  
 1954 Common Habitat: A Comparative Study on Echis carinatus sochureki and Macrovipera lebetina  
 1955 obtusa Victims in Iran. Asia Pac J Med Toxicol. 8, 107-114.
- 1956 Monzavi, S. M., Dadpour, B., & Afshari, R., 2014. Snakebite management in Iran: Devising a protocol. J  
 1957 Res Med Sci. 19, 153-163.
- 1958 Monzavi, S. M., Salarian, A. A., Khoshdel, A. R., Dadpour, B., & Afshari, R., 2015. Effectiveness of a clinical  
 1959 protocol implemented to standardize snakebite management in Iran: initial evaluation.  
 1960 Wilderness Environ Med. 26, 115-123.
- 1961 Moradi, N., Rastegar-Pouyani, N., & Rastegar-Pouyani, E., 2014. Geographic variation in the morphology  
 1962 of Macrovipera lebetina (Linnaeus, 1758) (Ophidia: Viperidae) in Iran. Acta Herpetol. 9, 187-202.
- 1963 Moradi, N., Shafiei, S., & Sehhatisabet, M. E., 2013. The snake fauna of Khabr National Park, southeast of  
 1964 Iran. Iran J Anim Biosyst. 9, 41-55.
- 1965 Moradi, S. H., Rastegar Pouyani, E., Hosseinian, S., & Zargan, J., 2021. Evaluation ecological niche  
 1966 between Platyceps rhodorachis and P. karelini (Serpentes: Colubridae) in Iran. Iran J Anim  
 1967 Biosyst. 17, 147-155.
- 1968 Moradiasl, E., Adham, D., Mirzanejadasl, H., Eghbali, H., Solimanzadeh, H., Rafinejad, J., . . . Akbarzadeh,  
 1969 T., 2018. Spatial Analysis of Snakebites in Ardabil Province Using GIS during 2011-2015. [In  
 1970 Persian]. J Safe Prom Injury Prev. 6, 81-86.
- 1971 Moridikia, A., Zargan, J., Sobati, H., Goodarzi, H. R., & Hajinourmohamadi, A., 2018. Anticancer and  
 1972 antibacterial effects of Iranian viper (Vipera latifii) venom; an in-vitro study. J Cell Physiol. 233,  
 1973 6790-6797.
- 1974 Moshtaghie, M., Kaboli, M., & Salehi, M., 2018. Investigating the morphological changes of Hemorrhoids  
 1975 ravigieri (Reptilia: Ophidia: Colubridae) in Iran. [In Persian]. J Anim Environ. 10, 87-96.
- 1976 Motedayen, M. H., Nikbakht Brujeni, G., Rasaee, M. J., Zare Mirakabadi, A., Khorasani, A., Eizadi, H., . . .  
 1977 Esmailzad, M., 2018. Production of a Human Recombinant Polyclonal Fab Antivenom against  
 1978 Iranian Viper Echis carinatus. Arch Razi Inst. 73, 287-294.
- 1979 Mozaffari, O., Kamali, K., & Fahimi, H. (2016). *The Atlas of Reptiles of Iran. [In Persian]*. Tehran, Iran:  
 1980 Iranian Department of Environment.
- 1981 Müller, J., 2017. A review of the distribution of Vipera ammodytes transcaucasiana Boulenger, 1913  
 1982 (Serpentes: Viperidae) in Turkey. Biharean Biol. 11, 23-26.
- 1983 Nabipour, I. (2012). *The venomous animals of the Persian Gulf. [In Persian]*. Bushehr, Iran: Bushehr  
 1984 University of Medical Sciences Press.
- 1985 Nabipour, I., Khoshdel, A. R., Golaghaei, A. R., Tashakori Beheshti, A., & Afshari, R., 2015. Clinico-  
 1986 epidemiologic Study on Marine Envenomations and Injuries in South Iran, Persian Gulf Coasts.  
 1987 Asia Pac J Med Toxicol. 4, 112-115.

- 1988 Naik, B. S., 2017. "Dry bite" in venomous snakes: A review. *Toxicon*. 133, 63-67.
- 1989 Najmabadi, M. (1992). *History of Medicine in Iran. [In Persian]*. Tehran, Iran: University of Tehran Press.
- 1990 Nalbantsoy, A., İgci, N., Gocmen, B., & Mebert, K., 2016. Cytotoxic potential of Wagner's Viper,  
1991 *Montivipera wagneri*, venom. *North-West J Zool*. 12, 286-291.
- 1992 Nasiripour, A., Ranjbar, B., Naderimanesh, H., Mehrnezhad, F., Soufian, S., Sadeghi, G., & Kolahian, S.,  
1993 2008. Structural-Functional Studies of Peptides Derived from a Long-Chain Snake Neurotoxin  
1994 *Naja Naja Oxiana*. [In Persian]. *Physiol Pharmacol*. 12, 209-220.
- 1995 Nasrabadi, R., Rastegar-Pouyani, E., Hosseinian Yousefkhani, S., & Khani, A., 2016. A checklist of  
1996 herpetofauna from Sabzevar, Northeastern Iran. *Iran J Anim Biosyst*. 12, 255-259.
- 1997 Nasri Nasrabadi, N., Mohammadpour Dounighi, N., Ahmadinejad, M., Rabiei, H., Tabar zad, M., Najafi,  
1998 M., & Vatanpour, H., 2022. Isolation of the Anticoagulant and Procoagulant Fractions of the  
1999 Venom of Iranian Endemic *Echis carinatus*. *Iran J Pharm Res*. 21, e127240.
- 2000 Navidpour, S., Salemi, A., & Zare Mirakabadi, A., 2019. First Case Report of an Unusual *Echis* genus  
2001 (*Squamata: Ophidia: Viperidae*) Body Pattern Design in Iran. *Arch Razi Inst*. 74, 197-202.
- 2002 Nayernouri, T., 2015. A Brief History of Ancient Iranian Medicine. *Arch Iran Med*. 18, 549-551.
- 2003 Nazari, A., Samianifard, M., Rabie, H., & Mirakabadi, A. Z., 2020. Recombinant antibodies against Iranian  
2004 cobra venom as a new emerging therapy by phage display technology. *J Venom Anim Toxins Incl*  
2005 *Trop Dis*. 26, e20190099.
- 2006 Nejadrahim, R., Sahranavard, M., Aminizadeh, A., & Delirrad, M., 2019. Snake Envenomation in North-  
2007 West Iran: A Three-Year Clinical Study. *Int J Med Toxicol Forensic Med*. 9, 31-38.
- 2008 Nikolić, S., Antić, M., Pavić, A., Ajtić, R., & Pavić, S., 2021. Analysis of the venomous snakebite patients  
2009 treated in the Užice General Hospital (Western Serbia) between 2006 and 2018. *Srp Arh Celok*  
2010 *Lek*. 149, 189-195.
- 2011 Nilson, G., & Andrén, C., 1984. Systematics of the *Vipera xanthina* complex (Reptilia: Viperidae). II. An  
2012 overlooked viper within the xanthina species-group in Iran. *Bonn Zool Beitr*. 35, 175.
- 2013 Nilson, G., & Rastegar-Pouyani, N., 2007. *Walterinnesia aegyptia* Lataste, 1887 (Ophidia: Elapidae) and  
2014 the status of *Naja morgani* Mocquard 1905. *Russ J Herpetol*. 14, 7-14.
- 2015 Nilson, G., & Rastegar-Pouyani, N., 2013. The occurrence of *Telescopus nigriceps* (Ahl, 1924) in western  
2016 Iran, with comments on the Genus *Telescopus* (Serpentes: Colubridae). *Zool Middle East*. 59,  
2017 131-135.
- 2018 Nilson, G., Tuniyev, B., Andrén, C., & Orlov, N., 1999. Vipers of Caucasus: taxonomic considerations.  
2019 *Kaupia*. 8, 103-106.
- 2020 Nodooshan, M. M., Sobati, H., Malekara, E., Goodarzi, H. R., Ebrahimi, F., Normohamadi, A., & Zargan, J.,  
2021 2021. Crude venom of *Pseudocerastes persicus* snake: From the antibacterial to anticancer  
2022 effects. *Rom J Mil Med*. 124.
- 2023 Oghabian, Z., Ebrahimi, F., Farhadpour, S., Shojaeepour, S., & Dehghani, R., 2022. Clinical Manifestations  
2024 of Snakebite Patients Referred to Afzalipour Hospital in Kerman - Southeastern Iran. *Asia Pac J*  
2025 *Med Toxicol*. 11, 146-151.
- 2026 Oghalaie, A., Kazemi-Lomedasht, F., Zareinejad, M. R., & Shahbazzadeh, D., 2017. Antiadhesive and  
2027 cytotoxic effect of Iranian *Vipera lebetina* snake venom on lung epithelial cancer cells. *J Family*  
2028 *Med Prim Care*. 6, 780-783.
- 2029 Oh, A. M. F., Tan, C. H., Tan, K. Y., Quraishi, N. H., & Tan, N. H., 2019. Venom proteome of *Bungarus*  
2030 *sindanus* (Sind krait) from Pakistan and in vivo cross-neutralization of toxicity using an Indian  
2031 polyvalent antivenom. *J Proteomics*. 193, 243-254.
- 2032 Op den Brouw, B., Coimbra, F. C. P., Bourke, L. A., Huynh, T. M., Vlecken, D. H. W., Ghezellou, P., . . . Fry,  
2033 B. G., 2021a. Extensive Variation in the Activities of *Pseudocerastes* and *Eristicophis* Viper  
2034 Venoms Suggests Divergent Envenoming Strategies Are Used for Prey Capture. *Toxins (Basel)*.  
2035 13, 112.

- 2036 Op den Brouw, B., Ghezellou, P., Casewell, N. R., Ali, S. A., Fathinia, B., Fry, B. G., . . . Ikonopoulou, M.  
 2037 P., 2021b. Pharmacological Characterisation of Pseudocerastes and Eristicophis Viper Venoms  
 2038 Reveal Anticancer (Melanoma) Properties and a Potentially Novel Mode of Fibrinogenolysis. *Int J*  
 2039 *Mol Sci.* 22, 6896.
- 2040 Oraie, H., 2020. Genetic evidence for occurrence of *Macrovipera razii* (Squamata, Viperidae) in the  
 2041 central Zagros region, Iran. *Herpetozoa.* 33, 27.
- 2042 Oraie, H., Rastegar-Pouyani, E., Khosravani, A., Moradi, N., Akbari, A., Sehhatiasabet, M. E., . . . Joger, U.,  
 2043 2018. Molecular and morphological analyses have revealed a new species of blunt-nosed viper  
 2044 of the genus *Macrovipera* in Iran. *Salamandra.* 54, 233-248.
- 2045 Papenfuss, T., Shafiei Bafti, S., & Nilson, G. (2021). *Eristicophis macmahoni*. *The IUCN Red List of*  
 2046 *Threatened Species 2021: e.T164709A1070000*. Retrieved from
- 2047 Patikorn, C., Blessmann, J., Nwe, M. T., Tiglao, P. J. G., Vasaruchapong, T., Maharani, T., . . .  
 2048 Chaikunapruk, N., 2022. Estimating economic and disease burden of snakebite in ASEAN  
 2049 countries using a decision analytic model. *PLoS Negl Trop Dis.* 16, e0010775.
- 2050 Patra, A., Chanda, A., & Mukherjee, A. K., 2019. Quantitative proteomic analysis of venom from  
 2051 Southern India common krait (*Bungarus caeruleus*) and identification of poorly immunogenic  
 2052 toxins by immune-profiling against commercial antivenom. *Expert Rev Proteomics.* 16, 457-469.
- 2053 Perry, G., 1988. Mild toxic effects resulting from the bites of Jan's desert racer, *Coluber rhodorachis*, and  
 2054 Moila's snake, *Malpolon moilensis* (Ophidia: Colubridae). *Toxicon.* 26, 523-524.
- 2055 Pillai, L. V., Ambike, D., Husainy, S., Khaire, A., Captain, A., & Kuch, U., 2012. Severe Neurotoxic  
 2056 Envenoming and Cardiac Complications after the Bite of a 'Sind Krait' (*Bungarus cf. sindanus*) in  
 2057 Maharashtra, India. *Trop Med Health.* 40, 103-108.
- 2058 Pla, D., Quesada-Bernat, S., Rodriguez, Y., Sanchez, A., Vargas, M., Villalta, M., . . . Calvete, J. J., 2020.  
 2059 Dagestan blunt-nosed viper, *Macrovipera lebetina obtusa* (Dwigubsky, 1832), venom. Venomics,  
 2060 antivenomics, and neutralization assays of the lethal and toxic venom activities by anti-  
 2061 *Macrovipera lebetina turanica* and anti-*Vipera berus berus* antivenoms. *Toxicon X.* 6, 100035.
- 2062 Pommier, P., & de Haro, L., 2007. Envenomation by Montpellier snake (*Malpolon monspessulanus*) with  
 2063 cranial nerve disturbances. *Toxicon.* 50, 868-869.
- 2064 Pook, C. E., Joger, U., Stumpel, N., & Wuster, W., 2009. When continents collide: phylogeny, historical  
 2065 biogeography and systematics of the medically important viper genus *Echis* (Squamata:  
 2066 *Serpentes: Viperidae*). *Mol Phylogenet Evol.* 53, 792-807.
- 2067 Pymm, R. (2017). *Serpent Stones: Myth and Medical Application*. In: C. J. Duffin, C. Gardner-Thorpe, & R.  
 2068 T. J. Moody (Eds.), *Geology and Medicine: Historical Connections* (pp. 163-180). Bath, UK: The  
 2069 Geological Society Publishing House.
- 2070 Pyron, R. A., Burbrink, F. T., & Wiens, J. J., 2013. A phylogeny and revised classification of Squamata,  
 2071 including 4161 species of lizards and snakes. *BMC Evol Biol.* 13, 93.
- 2072 Rahmani, A. H., Hazrati, B., & Alidadi, H., 2022. Evaluation of the frequency of shaldon's catheter  
 2073 complications in the hemodialysis patients in Ahvaz Razi hospital. *Asia Pac J Med Toxicol.* 11, 58-  
 2074 61.
- 2075 Rahmani, A. H., Jalali, A., Alemzadeh-Ansari, M. H., Tafazoli, M., & Rahim, F., 2014. Dosage comparison  
 2076 of snake anti-venom coagulopathy. *Iran J Pharm Res.* 13, 283-289.
- 2077 Rajabi, M., Dadpour, B., Rahimi, P., & Moshiri, M., 2022. Rapid progressive course of naja naja oxiana-  
 2078 bitten patient. *J Kerman Univ Med Sci.* 29, 79-83.
- 2079 Rajabizadeh, M. (2013). *Biodiversity of the snakes in northern and western mountains of Iran, with*  
 2080 *special emphasis on biodiversity in colubroids (Doctoral dissertation)*. Ghent University, Ghent,  
 2081 Belgium.
- 2082 Rajabizadeh, M. (2018). *Snakes of Iran. [In Persian]*. Tehran, Iran: Iranshensai Publishing.

- 2083 Rajabizadeh, M., Nilson, G., & Kami, H. G., 2011a. A new species of mountain viper (Ophidia: Viperidae)  
 2084 from the Central Zagros Mountains, Iran. *Russ J Herpetol.* 18, 235-240.
- 2085 Rajabizadeh, M., Nilson, G., Kami, H. G., & Naderi, A. R., 2011b. Distribution of the subgenus  
 2086 *Acridophaga* Reuss, 1927 (Serpentes: Viperidae) in Iran. *Iran J Anim Biosyst.* 7, 83-87.
- 2087 Rajabizadeh, M., & Rezghi, M., 2021. A comparative study on image-based snake identification using  
 2088 machine learning. *Sci Rep.* 11, 19142.
- 2089 Rajabizadeh, M., Yazdanpanah, A., & Ursenbacher, S., 2012. Preliminary analysis of dorsal pattern  
 2090 variation and sexual dimorphism in *Montivipera latifii* (Mertens, Darevsky and Klemmer, 1967)  
 2091 (Ophidia: Viperidae). *Acta Herpetol.* 7, 13-21.
- 2092 Ramezani, M., Kami, H., & Ahmadpanah, N., 2011. Faunistic studies on snakes of West Golestan state.  
 2093 *Proc Soc Behav Sci.* 19, 811-817.
- 2094 Rasmi, A., 2016. Contribution of Persian culture to origination of medicine symbol. [In Persian]. *Med Hist*  
 2095 *J.* 4, 33-67.
- 2096 Rasouli, M. R., Saadat, S., Haddadi, M., Gooya, M. M., Afsari, M., & Rahimi-Movaghar, V., 2011.  
 2097 Epidemiology of injuries and poisonings in emergency departments in Iran. *Public Health.* 125,  
 2098 727-733.
- 2099 Rasoulinasab, F., Rasoulinasab, M., Shahbazzadeh, D., Asadi, A., & Kaboli, M., 2020. Comparison of  
 2100 venom from wild and long-term captive *Gloydius caucasicus* and the neutralization capacity of  
 2101 antivenom produced in rabbits immunized with captive venom. *Heliyon.* 6, e05717.
- 2102 Rastegar-Pouyani, E., Oraie, H., Khosravani, A., Kaboli, M., Mobaraki, A., Yousefi, M., . . . Wink, M., 2014.  
 2103 A re-evaluation of taxonomic status of *Montivipera* (Squamata: Viperidae) from Iran using a DNA  
 2104 barcoding approach. *Biochem Syst Ecol.* 57, 350-356.
- 2105 Rastegar-Pouyani, N., Gholamifard, A., Karamiani, R., Bahmani, Z., Mobaraki, A., Abtin, E., . . . Sayyadi, F.,  
 2106 2015. Sustainable Management of the Herpetofauna of the Iranian Plateau and Coastal Iran.  
 2107 *Amphib Reptile Conserv.* 9, 1-15.
- 2108 Rastegar-Pouyani, N., Kami, H. G., Rajabzadeh, H. R., Shafiei, S., & Anderson, S. C., 2008. Annotated  
 2109 Checklist of Amphibians and Reptiles of Iran. *Iran J Anim Biosyst.* 4, 7-30.
- 2110 Razok, A., Shams, A., & Yousaf, Z., 2020. *Cerastes cerastes* snakebite complicated by coagulopathy and  
 2111 cardiotoxicity with electrocardiographic changes. *Toxicon.* 188, 1-4.
- 2112 Reading, C. J., Luiselli, L. M., Akani, G. C., Bonnet, X., Amori, G., Ballouard, J. M., . . . Rugiero, L., 2010. Are  
 2113 snake populations in widespread decline? *Biol Lett.* 6, 777-780.
- 2114 Reid, H. A., 1956. Sea-snake bite research. *Trans R Soc Trop Med Hyg.* 50, 517-542.
- 2115 Reid, H. A., 1961. Myoglobinuria and sea-snake-bite poisoning. *Br Med J.* 1, 1284-1289.
- 2116 Rezaei-Orimi, J., Amrollahi-Sharifabadi, M., Aghabeiglooei, Z., Nasiri, E., & Mozaffarpur, S. A., 2022.  
 2117 Rhazes's methodology in the science of toxicology. *Arch Toxicol.* [Online ahead of print].
- 2118 Rezaei-Orimi, J., Nasiri, E., Moallemi, M., & Padashi, S., 2019. A Review on the Diagnosis and  
 2119 Management of Bites in the Canon of Medicine of Avicenna. [In Persian]. *J Mazandaran Univ*  
 2120 *Med Sci.* 29, 175-188.
- 2121 Rezaie-Atagholipour, M., Ghezellou, P., Hesni, M. A., Dakhteh, S. M., Ahmadian, H., & Vidal, N., 2016.  
 2122 Sea snakes (Elapidae, Hydrophiinae) in their westernmost extent: an updated and illustrated  
 2123 checklist and key to the species in the Persian Gulf and Gulf of Oman. *Zookeys.* 129-164.
- 2124 Rezaie-Atagholipour, M., Riyahi-Bakhtiari, A., Rajabizadeh, M., & Ghezellou, P., 2012a. Status of the  
 2125 Annulated Sea Snake, *Hydrophis cyanocinctus*, in the Hara Protected Area of the Persian Gulf:  
 2126 (Reptilia: Elaphidae: Hydrophiinae). *Zool Middle East.* 57, 53-60.
- 2127 Rezaie-Atagholipour, M., Riyahi-Bakhtiari, A., Sajjadi, M., Yap, C. K., Ghaffari, S., Ebrahimi-Sirizi, Z., &  
 2128 Ghezellou, P., 2012b. Metal concentrations in selected tissues and main prey species of the  
 2129 annulated sea snake (*Hydrophis cyanocinctus*) in the Hara Protected Area, northeastern coast of  
 2130 the Persian Gulf, Iran. *Mar Pollut Bull.* 64, 416-421.

- 2131 Riley, B. D., Pizon, A. F., & Ruha, A. (2011). Snakes and other reptiles. In: L. S. Nelson, N. A. Lewin, M. A.  
 2132 Howland, R. S. Hoffman, L. R. Goldfrank, & N. E. Flomenbaum (Eds.), *Goldfrank's Toxicologic*  
 2133 *Emergencies*. (pp. 1601-1610). New York, USA: McGraw-Hill.
- 2134 Rosenberg, H. I., Bdolah, A., & Kochva, E., 1985. Lethal factors and enzymes in the secretion from  
 2135 Duvernoy's gland of three colubrid snakes. *J Exp Zool.* 233, 5-14.
- 2136 Rosenberg, H. I., Kinamon, S., Kochva, E., & Bdolah, A., 1992. The secretion of Duvernoy's gland of  
 2137 Malpolon monspessulanus induces haemorrhage in the lungs of mice. *Toxicon.* 30, 920-924.
- 2138 RVSRI. (2021). Razi™ Pentavalent snake antivenom immunoglobulin prescribing information. Tehran,  
 2139 Iran: Razi Vaccine and Serum Research Institute (RVSRI). Retrieved from:  
 2140 [https://english.rvsri.ac.ir/portal/home/?WEBSITE/240651/240900/240909/Pentavalent-snake-](https://english.rvsri.ac.ir/portal/home/?WEBSITE/240651/240900/240909/Pentavalent-snake-antivenom-immunoglobulin)  
 2141 [antivenom-immunoglobulin](https://english.rvsri.ac.ir/portal/home/?WEBSITE/240651/240900/240909/Pentavalent-snake-antivenom-immunoglobulin)
- 2142 Saameie, M. (2020, Mar 27, 2020). Venom. [In Persian]. Tehran, Iran: The Great Islamic Encyclopaedia.  
 2143 Retrieved from: <https://cgie.org.ir/fa/article/257535>
- 2144 Sadeghi, M., Barazandeh, M., Zakariaei, Z., Davoodi, L., Tabaripour, R., Fakhar, M., & Zakariaei, A., 2021.  
 2145 Massive cutaneous complications due to snakebite: A case report and literature review. *Clin*  
 2146 *Case Rep.* 9, e04129.
- 2147 Safaei-Mahroo, B., Ghaffari, H., Fahimi, H., Broomand, S., Yazdani, M., Najafi-Majd, E., . . . Nasrabadi,  
 2148 R., 2015. The herpetofauna of Iran: checklist of taxonomy, distribution and conservation status.  
 2149 *Asia Herpetol Res.* 6, 257-290.
- 2150 Safaei-Mahroo, B., Ghaffari, H., Salmabadi, S., Kamangar, A., Almasi, S., Kazemi, S. M., & Ghafoor, A.,  
 2151 2016. Eastern Montpellier Snake (*Malpolon insignitus fuscus*) Ophiophagy Behavior from Zagros  
 2152 Mountains. *Russ J Herpetol.* 24, 69-72.
- 2153 Sagheb, M. M., Sharifian, M., Moini, M., & Salehi, O., 2011a. Acute renal failure and acute necrotizing  
 2154 pancreatitis after *Echis carinatus sochureki* bite, report of a rare complication from southern  
 2155 Iran. *Prague Med Rep.* 112, 67-71.
- 2156 Sagheb, M. M., Sharifian, M., Moini, M., & Salehi, O., 2011b. Clinical features of snake bite in southern  
 2157 Iran. *Trop Doct.* 41, 236-237.
- 2158 Salmanzadeh, H., Babaie, M., & Zolfagharian, H., 2013. In vivo evaluation of homeostatic effects of *Echis*  
 2159 *carinatus* snake venom in Iran. *J Venom Anim Toxins Incl Trop Dis.* 19, 3.
- 2160 Salmanzadeh Zehkesh, S., & Mohammadpour Donighi, N., 2021. Synthesis of sodium alginate  
 2161 nanoparticles containing *Agkistrodon halys* snake venom and evaluation of biological activity  
 2162 and survival of colon cancer cells (SW-480). [In Persian]. *Res Karyotic Cell Tissue.* 2, 35-42.
- 2163 Samianifard, M., Nazari, A., Tahoori, F., & Mohammadpour Dounighi, N., 2021. Proteome Analysis of Toxic  
 2164 Fractions of Iranian Cobra (*Naja naja Oxiana*) Snake Venom Using Two-Dimensional  
 2165 Electrophoresis and Mass Spectrometry. *Arch Razi Inst.* 76, 127-138.
- 2166 Sanders, K. L., Lee, M. S., Mumpuni, Bertozzi, T., & Rasmussen, A. R., 2013. Multilocus phylogeny and  
 2167 recent rapid radiation of the viviparous sea snakes (Elapidae: Hydrophiinae). *Mol Phylogenet*  
 2168 *Evol.* 66, 575-591.
- 2169 Sanz, L., Ayzazyan, N., & Calvete, J. J., 2008. Snake venomomics of the Armenian mountain vipers  
 2170 *Macrovipera lebetina obtusa* and *Vipera raddei*. *J Proteomics.* 71, 198-209.
- 2171 Saviola, A. J., Peichoto, M. E., & Mackessy, S. P., 2014. Rear-fanged snake venoms: an untapped source  
 2172 of novel compounds and potential drug leads. *Toxin Rev.* 33, 185-201.
- 2173 Schaetti, B., Kucharzewski, C., Masroor, R., & Rastegar Pouyani, E., 2012. *Platyceps karelini* (Brandt,  
 2174 1838) from Iran to Pakistan and revalidation of *Coluber chesneii* Martin, 1838 (Reptilia:  
 2175 Squamata: Colubrinae). *Revue Suisse de Zoologie.* 119, 441-483.
- 2176 Schneemann, M., Cathomas, R., Laidlaw, S. T., El Nahas, A. M., Theakston, R. D., & Warrell, D. A., 2004.  
 2177 Life-threatening envenoming by the Saharan horned viper (*Cerastes cerastes*) causing micro-








- 2178           angiopathic haemolysis, coagulopathy and acute renal failure: clinical cases and review. QJM.  
2179           97, 717-727.
- 2180 Schöttler, W. H. A., 1938. The venoms of *Vipera latastei* and *V. lebetina*. [In German]. Z Hyg Infektionskr.  
2181           120, 408-434.
- 2182 Schweiger, M., 1991. *Coluber ravergieri* Ménétries, 1832-an unusual aggressive Snake. [In German].  
2183           Herpetofauna. 13, 70.
- 2184 Shadnia, S., Esmaily, H., Sasanian, G., Pajoumand, A., Hassanian-Moghaddam, H., & Abdollahi, M., 2007.  
2185           Pattern of acute poisoning in Tehran-Iran in 2003. Hum Exp Toxicol. 26, 753-756.
- 2186 Shahbazi, B., Najafabadi, Z. S., Goudarzi, H., Sajadi, M., Tahoori, F., & Bagheri, M., 2019. Cytotoxic effects  
2187           of *Pseudocerastes persicus* venom and its HPLC fractions on lung cancer cells. J Venom Anim  
2188           Toxins Incl Trop Dis. 25, e20190009.
- 2189 Shahi, M., Jaberhashemi, S. A., Hosseinzadeh, M. S., & Kazemi, S. M., 2022. A new Record of Persian  
2190           Krait *Bungarus persicus* Abtin, Nilson, Mobaraki, Hosseini, Dehgannejhad 2014 (Serpentes:  
2191           Elapidae: Bungarinae) from Hormozgan Province, Southern Iran. Ecopersia. 10, 173-177.
- 2192 Shahidi Bonjar, L., 2014. Design of a new therapy to treat snake envenomation. Drug Des Devel Ther. 8,  
2193           819-825.
- 2194 Shanaki Bavarsad, M., Amoozegari, Z., & Noorbehbahani, M., 2009. Phospholipase A2 Activity in Crude  
2195           Venom and Fractions Separated from Iranian *Vipera Lebetina* Venom. [In Persian]. Jundishapur  
2196           Sci Med J. 8, 355-360.
- 2197 Sharifi, I., Tabatabaie, F., Nikpour, S., Mostafavi, M., Tavakoli Oliabee, R., Sharifi, F., . . . Shahbazzadeh, D.,  
2198           2021. The Effect of *Naja naja oxiana* Snake Venom Against *Leishmania tropica* Confirmed by  
2199           Advanced Assays. Acta Parasitol. 66, 475-486.
- 2200 Shaw, C. J., 1925. Notes on the effect of the bite of McMahons viper (*E macmahonii*). J Bombay Nat Hist  
2201           Soc. 30, 485-486.
- 2202 Shaykhi Ilanloo, S., Khani, A., Kafash, A., & Rastegar Pouyani, E., 2015. Reptile fauna of the Khajeh  
2203           protected area, with assessing its similarities with physiogeographical area of the Iranian Lizards.  
2204           [In Persian]. J Taxon Biosyst. 7, 13-22.
- 2205 Shi, J., Yang, D., Zhang, W., & Ding, L., 2016. Distribution and infraspecies taxonomy of *Gloydus halys-*  
2206           *Gloydus intermedius* complex in China (Serpentes: Crotalinae). Chin J Zool. 51, 777-798.
- 2207 Shockley, C. H., 1949. Herpetological notes for Ras Jiunri, Baluchistan. Herpetologica. 5, 121-123.
- 2208 Shoorabi, M., Nazarizadeh Dehkordi, M., Kaboli, M., & Rastegar Pouyani, E., 2017. Phylogenetic  
2209           Relationships, Genetic Structure and Differentiation of the Caspian Cobra (*Naja oxiana* Eichwald  
2210           1831) snake in Iran Using D-Loop Mitochondrial DNA Marker. [In Persian]. Mod Genet J. 12, 253-  
2211           263.
- 2212 Sinaei, N., Zare Mirakabadi, A., Jafari, E., Najafi, A., Behnam, B., & Karami-Mohajeri, S., 2022. Induction  
2213           of Apoptosis in Glioblastoma Cell Line (U87-MG) by Caspian Cobra (*Naja naja oxiana*) Snake  
2214           Venom. Proc Natl Acad Sci India Sect B Biol Sci. 92, 269-274.
- 2215 Sindaco, R., Venchi, A., & Grieco, C. (2013). *The Reptiles of the Western Palearctic. Volume 2: Annotated*  
2216           *Checklist and Distributional Atlas of the Snakes of Europe, North Africa, Middle East and Central*  
2217           *Asia, with an Update to Volume 1.* Latina, Italy: Edizioni Belvedere.
- 2218 Sitprija, V., 2006. Snakebite nephropathy. Nephrology (Carlton). 11, 442-448.
- 2219 Soleimanfallah, D., Hojati, V., Shajiee, H., Sharafi, S., Babaei Savasari, R., & Khani, S., 2018. A Study on  
2220           Reptile fauna of Sefid Kouh-Aresk No-Hunting Area in Semnan Province. [In Persian]. J Anim  
2221           Environ. 10, 97-106.
- 2222 Soleimani, G., Shafighi Shahri, E., Shahraki, N., Godarzi, F., Soleimanzadeh Mousavi, S. H., & Tavakolikia,  
2223           Z., 2021. Clinical and Laboratory Findings and Prognosis of Snake and Scorpion Bites in Children  
2224           under 18 Years of Age in Southern Iran in 2018-19. Int J Pediatr. 9, 12795-12804.


- 2225 Spawls, S., & Branch, W. (1995). *Dangerous Snakes of Africa: Natural History - Species Directory -*  
 2226 *Venoms and Snakebite*. Fort Myers, FL: Ralph Curtis Publishing.
- 2227 Stümpel, N., & Joger, U., 2009. Recent advances in phylogeny and taxonomy of Near and Middle Eastern  
 2228 Vipers—an update. *Zookeys*. 31, 179-191.
- 2229 Stümpel, N., Rajabizadeh, M., Avci, A., Wüster, W., & Joger, U., 2016. Phylogeny and diversification of  
 2230 mountain vipers (*Montivipera*, Nilson et al., 2001) triggered by multiple Plio–Pleistocene refugia  
 2231 and high-mountain topography in the Near and Middle East. *Mol Phylogenet Evol.* 101, 336-351.
- 2232 Sultanov, M. N., 1966. Clinical course and treatment of *Tarbophis fallax iberus* bite. [In Russian]. *Med*  
 2233 *Parazitol (Mosk)*. 35, 570-572.
- 2234 Sultanov, M. N., 1983. Experience with the treatment of poisonous snake bites. [In Russian]. *Klin Med*  
 2235 *(Mosk)*. 61, 105-109.
- 2236 Sunagar, K., Jackson, T. N., Undheim, E. A., Ali, S. A., Antunes, A., & Fry, B. G., 2013. Three-fingered  
 2237 RAVERS: Rapid Accumulation of Variations in Exposed Residues of snake venom toxins. *Toxins*  
 2238 *(Basel)*. 5, 2172-2208.
- 2239 Sunagar, K., Khochare, S., Senji Laxme, R. R., Attarde, S., Dam, P., Suranse, V., . . . Captain, A., 2021. A  
 2240 Wolf in Another Wolf's Clothing: Post-Genomic Regulation Dictates Venom Profiles of Medically-  
 2241 Important Cryptic Kraits in India. *Toxins (Basel)*. 13.
- 2242 Suraweera, W., Warrell, D., Whitaker, R., Menon, G., Rodrigues, R., Fu, S. H., . . . Jha, P., 2020. Trends in  
 2243 snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study. *Elife*.  
 2244 9.
- 2245 Taheri, S., 2015. The Inversion of a Symbol Concept. [In Persian]. *J Fine Art Vis Art*. 20, 25-34.
- 2246 Taherian, M., Yaghoobi, H., & Bandehpour, M., 2016. Evaluation of the Coagulant Effect of Zanjani and  
 2247 Latifi Viper Snake Venom Endemic in Iran. *Trends Pept Protein Sci*. 1, 27-30.
- 2248 Talebi Mehrdar, M., 2020. Two Proteins From Snake Venom Have Potent Antibacterial Effects Against  
 2249 *Bacillus Anthracis* and *Streptococcus Pneumoniae*. *Iran J Toxicol*. 14, 139-144.
- 2250 Talebi Mehrdar, M., Madani, R., Hajihosseini, R., & Moradi Bidhendi, S., 2017. Antibacterial Activity of  
 2251 Isolated Immunodominant Proteins of *Naja Naja (Oxiana)* Venom. *Iran J Pharm Res*. 16, 297-305.
- 2252 Talebzadeh-Farooji, M., Amininasab, M., Elmi, M. M., Naderi-Manesh, H., & Sarbolouki, M. N., 2004.  
 2253 Solution structure of long neurotoxin NTX-1 from the venom of *Naja naja oxiana* by 2D-NMR  
 2254 spectroscopy. *Eur J Biochem*. 271, 4950-4957.
- 2255 Talyzin, F. F. (1963). *Snakes. [In Russian]*. Retrieved from Moscow, Russia:
- 2256 Tamiya, N., & Puffer, H., 1974. Lethality of sea snake venoms. *Toxicon*. 12, 85-87.
- 2257 Tan, C. H., Tan, K. Y., Lim, S. E., & Tan, N. H., 2015. Venomics of the beaked sea snake, *Hydrophis*  
 2258 *schistosus*: A minimalist toxin arsenal and its cross-neutralization by heterologous antivenoms. *J*  
 2259 *Proteomics*. 126, 121-130.
- 2260 Tan, C. H., Tan, K. Y., Ng, T. S., Sim, S. M., & Tan, N. H., 2018. Venom Proteome of Spine-Bellied Sea  
 2261 Snake (*Hydrophis curtus*) from Penang, Malaysia: Toxicity Correlation, Immunoprofiling and  
 2262 Cross-Neutralization by Sea Snake Antivenom. *Toxins (Basel)*. 11, 3.
- 2263 Theakston, R. D., Phillips, R. E., Warrell, D. A., Galagedera, Y., Abeysekera, D. T., Dissanayaka, P., . . .  
 2264 Aloysius, D. J., 1990. Envenoming by the common krait (*Bungarus caeruleus*) and Sri Lankan  
 2265 cobra (*Naja naja naja*): efficacy and complications of therapy with Haffkine antivenom. *Trans R*  
 2266 *Soc Trop Med Hyg*. 84, 301-308.
- 2267 Theakston, R. D., & Warrell, D. A., 1991. Antivenoms: a list of hyperimmune sera currently available for  
 2268 the treatment of envenoming by bites and stings. *Toxicon*. 29, 1419-1470.
- 2269 Todehdehghan, F., Salemi, A., & Fathinia, B., 2019. Identification key for Echis snakes (Serpents:  
 2270 Viperidae) of the East, South East, and South West of Iran. *J Entomol Zool Stud*. 7, 1180-1185.
- 2271 Tok, C. V., & Kumluts, Y., 1996. On *Vipera ammodytes transcaucasiana* (Viperidae) from Perşembe, Black  
 2272 Sea region of Turkey. *Zool Middle East*. 13, 47-50.


- 2273 Tsai, M. C., Lee, C. Y., & Bdolah, A., 1983. Mode of neuromuscular blocking action of a toxic  
 2274 phospholipase A2 from *Pseudocerastes fieldi* (Field's horned viper) snake venom. *Toxicon*. 21,  
 2275 527-534.
- 2276 Tu, A. T., 1974. Sea snake investigation in the Gulf of Thailand. *J Herpetol*. 8, 201-210.
- 2277 Tuniyev, B., Nilson, G., Agasyan, A., Orlov, N. L., & Tuniyev, S. (2009a). *Vipera eriwanensis*. *The IUCN Red*  
 2278 *List of Threatened Species 2009: e.T164679A114547682*. Retrieved from  
 2279 <https://www.iucnredlist.org/species/164679/114547682>
- 2280 Tuniyev, B., Nilson, G., Kasaka, Y., Avci, A., Agasyan, A., Orlov, N. L., & Tuniyev, S. (2009b). *Vipera*  
 2281 *transcaucasiana*. *The IUCN Red List of Threatened Species 2009: e.T164708A114549008*.  
 2282 Retrieved from <https://www.iucnredlist.org/species/164708/114549008>
- 2283 Tushiev, A., 1963. On the issue of clinics and treatment in bites by venomous snakes. [In Russian].  
 2284 *Zdravookhr Turkmenistana*. 7, 32-34
- 2285 Valenta, J., Stach, Z., & Svitek, M., 2010. Acute pancreatitis after viperid snake cerastes cerastes  
 2286 envenoming: a case report. *Prague Med Rep*. 111, 69-75.
- 2287 Van den Enden, E., & Bottieau, E., 2005. Envenoming by the viperid snake *Eristicophis macmahonii*.  
 2288 *Toxicon*. 46, 918-920.
- 2289 Wallach, V., Williams, K. L., & Boundy, J. (2017). *Snakes of the World*. Boca Raton, FL: CRC Press
- 2290 Warrell, D. A. (1994). Sea Snake Bites in the Asia-Pacific Region. In: P. Gopalakrishnakone (Ed.), *Sea*  
 2291 *Snake Toxicology* (pp. 1-36). Singapore: Singapore University Press.
- 2292 Warrell, D. A. (1995). Clinical Toxicology of Snakebite in Africa and The Middle East / Arabian Peninsula.  
 2293 In: J. Meier & J. White (Eds.), *Handbook of Clinical Toxicology of Animal Venoms and Poisons* (pp.  
 2294 433-492). Boca Raton, USA: CRC Press
- 2295 Warrell, D. A., 2010. Snake bite. *Lancet*. 375, 77-88.
- 2296 Warrell, D. A. (2016). *Guidelines for the management of snake-bites* (2nd ed.). New Delhi; India: WHO  
 2297 Press.
- 2298 Weinstein, S. A., Griffin, R., & Ismail, A. K., 2014. Non-front-fanged colubroid ("colubrid") snakebites:  
 2299 three cases of local envenoming by the mangrove or ringed cat-eyed snake (*Boiga dendrophila*;  
 2300 *Colubridae*, *Colubrinae*), the Western beaked snake (*Rhamphiophis oxyrhynchus*;  
 2301 *Lamprophiidae*, *Psammophinae*) and the rain forest cat-eyed snake (*Leptodeira frenata*;  
 2302 *Dipsadidae*). *Clin Toxicol (Phila)*. 52, 277-282.
- 2303 Weinstein, S. A., & Minton, S. A., 1984. Lethal potencies and immunoelectrophoretic profiles of venoms  
 2304 and *Vipera bornmulleri* and *Vipera latifii*. *Toxicon*. 22, 625-629.
- 2305 Weinstein, S. A., Warrell, D. A., & Keyler, D. E. (2023a). Medically significant bites by non-front-fanged  
 2306 snakes (NFFCs). In *"Venomous" Bites from "Non-Venomous Snakes"* (2nd ed., pp. 155-594).  
 2307 Cambridge, MA: Elsevier.
- 2308 Weinstein, S. A., Warrell, D. A., & Keyler, D. E. (2023b). *"Venomous" Bites from "Non-Venomous Snakes"*  
 2309 (2nd Ed.). Cambridge, MA Elsevier
- 2310 Weinstein, S. A., White, J., Keyler, D. E., & Warrell, D. A., 2013. Non-front-fanged colubroid snakes: a  
 2311 current evidence-based analysis of medical significance. *Toxicon*. 69, 103-113.
- 2312 White, J., 2005. Snake venoms and coagulopathy. *Toxicon*. 45, 951-967.
- 2313 World Health Organization. (2021). Antivenom and Manufacturers. Snakebite Information and Data  
 2314 Platform. Retrieved from: [https://www.who.int/teams/control-of-neglected-tropical-](https://www.who.int/teams/control-of-neglected-tropical-diseases/snakebite-envenoming/snakebite-information-and-data-platform/overview#tab=tab_1)  
 2315 [diseases/snakebite-envenoming/snakebite-information-and-data-platform/overview#tab=tab\\_1](https://www.who.int/teams/control-of-neglected-tropical-diseases/snakebite-envenoming/snakebite-information-and-data-platform/overview#tab=tab_1)
- 2316 Xie, B., Dashevsky, D., Rokyta, D., Ghezellou, P., Fathinia, B., Shi, Q., . . . Fry, B. G., 2022. Dynamic genetic  
 2317 differentiation drives the widespread structural and functional convergent evolution of snake  
 2318 venom proteinaceous toxins. *BMC Biol*. 20, 4.

- 2319 Yaghmour, F., Els, J., Maio, E., Whittington-Jones, B., Samara, F., El Sayed, Y., . . . Mupandawana, M.,  
 2320 2022. Oil spill causes mass mortality of sea snakes in the Gulf of Oman. *Sci Total Environ.* 825,  
 2321 154072.
- 2322 Yayon, A., Sikular, E., & Keynan, A., 1988. Desert black snake bites. [In Hebrew]. *Harefuah.* 115, 269-270.
- 2323 Yousefi, M., Ahmadi, M., Nourani, E., Behrooz, R., Rajabizadeh, M., Geniez, P., & Kaboli, M., 2015.  
 2324 Upward Altitudinal Shifts in Habitat Suitability of Mountain Vipers since the Last Glacial  
 2325 Maximum. *PLoS One.* 10, e0138087.
- 2326 Yousefi, M., Kafash, A., Khani, A., & Nabati, N., 2020. Applying species distribution models in public  
 2327 health research by predicting snakebite risk using venomous snakes' habitat suitability as an  
 2328 indicating factor. *Sci Rep.* 10, 18073.
- 2329 Yousefi, M., Kafash, A., Valizadegan, N., Sheykhi Ilanloo, S., Rajabizadeh, M., Malekoutikhah, S., . . .  
 2330 Ashrafi, S., 2019. Climate Change is a Major Problem for Biodiversity Conservation: A Systematic  
 2331 Review of Recent Studies in Iran. *Contemp Probl Ecol.* 12, 394-403.
- 2332 Zaeri, S., Aghaei, Z., Mashayekhi, N. R., Salemi, A., & Seyedian, R. J., 2021a. Pharmacological  
 2333 characterization of the iranian *Cerastes cerastes gasperettii* (Reptilia: Ophidia: Viperidae)  
 2334 venom. *J Emerg Pract Trauma.* 7, 123-126.
- 2335 Zaeri, S., Fatemikia, H., Kamyab, M., Esmaili, A., Kim, E., Mohammadpour Dounighi, N., . . . Seyedian, R.,  
 2336 2021b. Hemodynamic Changes Provoked through Intravascular Injection of the *Echis carinatus*  
 2337 Venom in Rats. *Arch Razi Inst.* 76, 599-607.
- 2338 Zaher, H., Murphy, R. W., Arredondo, J. C., Graboski, R., Machado-Filho, P. R., Mahlow, K., . . . Graziotin,  
 2339 F. G., 2019. Large-scale molecular phylogeny, morphology, divergence-time estimation, and the  
 2340 fossil record of advanced caenophidian snakes (Squamata: Serpentes). *PLoS One.* 14, e0216148.
- 2341 Zamani, N., Modir-Fallah Rad, L., Soltaninejad, K., & Shadnia, S., 2016. A retrospective study on  
 2342 snakebite victims in a tertiary referral center. *Iran J Toxicol.* 10, 47-50.
- 2343 Zare Mirakabadi, A., & Horrieh, P., 2020. The toxicity induction in human dermal fibroblasts (HDF) cells  
 2344 by saliva of *Echis carinatus sochureki*. [In Persian]. *Res Karyotic Cell Tissue.* 1, 1-8.
- 2345 Zare Mirakabadi, A., & Teymurzadeh, S. (2009). *Venomous Snakes of Iran; Prevention, First Aid and*  
 2346 *Treatment. [In Persian].* Tehran, Iran: Teimourzadeh Publication.
- 2347 Zargan, J., Mirzaei Nodushan, M., Sobati, H., Haji Noormohammadi, A., Goodarzi, H. R., & Ebrahimi, F.,  
 2348 2022. In-Vitro Evaluation of Anticancer and Antibacterial Properties of *Pseudocerastes Persicus*  
 2349 Snake Venom Fractions. [In Persian]. *Jundishapur Sci Med J.* 21, 122-137.
- 2350 Zinenko, O., Stumpel, N., Mazanaeva, L., Bakiev, A., Shiryaev, K., Pavlov, A., . . . Joger, U., 2015.  
 2351 Mitochondrial phylogeny shows multiple independent ecological transitions and northern  
 2352 dispersion despite of Pleistocene glaciations in meadow and steppe vipers (*Vipera ursinii* and  
 2353 *Vipera renardi*). *Mol Phylogenet Evol.* 84, 85-100.
- 2354 Zolfagharian, H., & Dounighi, N. M., 2015. Study on development of *Vipera lebetina* snake anti-venom in  
 2355 chicken egg yolk for passive immunization. *Hum Vaccin Immunother.* 11, 2734-2739.
- 2356









Journal Pre-proof





Journal Pre-proof



## HIGHLIGHTS

1. A comprehensive review on medically important snakes in Iran regarding geographical distribution, taxonomy, venom composition
2. A focus on environmental value of Iran's medically important snakes
3. A critical appraisal of clinical effects of medically important snakes in Iran
4. A detailed evaluation of clinical management of snakebite envenoming in Iran

Journal Pre-proof

**Ethical Statement**

No experimentation on human or animal subjects was involved in this study.

Journal Pre-proof

**Declaration of interests**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Journal Pre-proof